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ABSTRACT
Prostacyclin and its stable analogues are used to treat pulmonary arterial 
hypertension (PAH), a disease associated with abnormal smooth muscle cell 
(SMC) proliferation. These analogues are thought to mediate the ir anti­
proliferative effects through prostacyclin (IP) receptors linked to cyclic AMP 
(cAMP) generation, though other targets may be involved including 
peroxisome proliferator activated receptors (PPARs), transcription factors 
known to regulate cell growth. Thus the aim was to assess the role o f the IP 
receptor and PPARy in mediating the anti-proliferative effects of prostacyclin 
analogues in HEK-293 cells stably expressing the IP receptor (HEK-293-IP) 
and in SMCs derived from normal and hypertensive lungs.
In proliferation assays, the growth rate of HEK-293-IP cells was significantly 
decreased compared to cells expressing the empty vector. Furthermore, 
treprostinil and carbacyclin, and non receptor-dependent cAMP-elevating 
agents only inhibited proliferation in HEK-293-IP cells, suggesting the 
physical presence of the IP receptor is crucial in mediating the effects of 
both analogues and agents working downstream of the receptor. Protein 
kinase A and to a lesser extent, PPARy appear to be involved since 
antagonists o f these two pathways partially reversed the anti-proliferative 
effects of treprostin il. Using a dual luciferase reporter gene assay, I 
demonstrated tha t analogues could activate PPARy via a novel IP receptor- 
dependent, cAMP-independent mechanism, likely to involve 
phosphorylation.
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In separate studies, pulmonary SMC derived from young idiopathic PAH 
patients replicated at a faster rate compared to control cells. RT-PCR and 
immnuostaining showed tha t PAH cells expressed fewer IP receptors, 
although treprostinil still inhibited SMC proliferation, albeit through a 
mechanism largely involving PPARy but not the IP receptor or cAMP. This 
contrasted to normal pulmonary SMC, where treprostinil inhibited 
proliferation via the IP receptor, cAMP and PPARy. In conclusion, the IP 
receptor appears to play an im portant role in regulating cell growth and 
mediating the effects of prostacyclin analogues in normal but not in 
pulmonary hypertensive SMC.
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1. Introduction
1.1 Pulm onary Hypertension
The pulmonary circulation is a low resistance and low pressure system that 
allows blood into the lung microcirculation to promote gas exchange. 
Pulmonary hypertension is a serious chronic disorder of the pulmonary 
circulation. I t  is a progressive and often fatal haemodynamic abnormality 
characterised by a raised pulm onary-artery pressure (PAP). Although PAP in 
normal individuals varies with age, from early childhood to the fifth  decade 
o f life, its upper lim it (mean PAP) is approximately 20 mm Hg (Mandegar et 
a/., 2004). In pulmonary hypertension however, PAP is raised significantly 
above this level and is clinically defined as a mean PAP of more than 25 mm 
Hg at rest rising to more than 30 mm Hg during exercise (Rubin, 1993).
PAP is a product of cardiac output (CO) and pulmonary vascular resistance 
(PVR). Elevated PVR has a harmful effect on the heart as the right ventricle 
is submitted to an increased work load necessary to overcome the 
downstream resistance. This eventually leads to right-ventricu lar 
hypertrophy and failure, a common cause of death in patients with 
pulmonary hypertension.
1.1.1 Classification o f pulmonary hypertension
Pulmonary hypertension arises from a number of disease conditions. 
Associated or secondary hypertension (SPH) denotes the disease when it is 
in association with other cardiac or systemic disorders (Simonneau e t al., 
2004). Idiopathic (sporadic) pulmonary arterial hypertension (IPAH) defines 
the disease in which pulmonary arteriopathy is the primary cause. IPAH was 
firs t discovered over 100 years ago in patients with right heart failure whose
18
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necropsy showed no obvious reasons for pulmonary arteriosclerosis and was 
termed syphilitic pulmonary arteritis. In 1951 Dresdale and his colleagues 
coined the term  'prim ary pulmonary hypertension' (PPH) (Dresdale e t a/., 
1951). However, at the 3rd world conference on Pulmonary Hypertension in 
2003, the term  PPH was replaced with IPAH and was distinguished from 
familial PAH (FPAH) which is essentially the same disease, only supported 
by a genetic basis (Simonneau e ta /., 2004).
Mutations in the type II  bone morphogenetic protein receptor (BMPR-II) 
gene, a member of the transform ing growth factor p (TGF-p) receptor 
superfamily, have been linked to cases of FPAH (Deng et a/., 2000) and the 
same genetic abnormality accounts for approximately 30% of cases of 
sporadic pulmonary hypertension. I t  displays autosomal dominant 
inheritance and genetic anticipation (Loyd et a/., 1995; Loyd e t a/., 1984). 
TGF-p itself can strongly inhibits smooth muscle cell proliferation (McCaffrey 
e t a/., 1997) as well as promoting cell differentiation (Adam et a/., 2000) 
although its effects are dependent on cell type and experimental setting. 
Similarly, type I I  bone morphogenetic protein (BMP-II) also inhibits vascular 
smooth muscle cell proliferation after balloon in jury (Nakaoka et a/., 1997). 
However, smooth muscle cells isolated from the pulmonary arteries of 
patients w ith IPAH exhibited no anti-proliferative response to the BMPR-II 
ligands, BMP-2, BMP-4 and BMP-7, compared with cells from control patients 
or patients with SPH whose proliferation was inhibited by these agents 
(Morrell e t a/., 2001). Genetic defects in BMPR-II do not explain all cases of 
FPAH or sporadic cases of IPAH, suggesting that other genes may be 
involved in the aetiology of the disease. Mutations in the gene tha t codes for 
activin receptor-like kinase (ALK 1), another TGF-p cell surface receptor,
19
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appear to be responsible for the rare occurrence of pulmonary arterial 
hypertension in patients with hereditary hemorrhagic telangiectasia 
(Trembath e ta l., 2001).
Serotonin has long been recognised as a potent naturally occurring 
vasoconstrictor and has been implicated in the pathogenesis of PAH. 
Outbreaks of PAH have been associated with use of fenfluram ine-derivate 
anorexigens, appetite suppressant drugs which prevent serotonin uptake by 
platelets (reviewed in de Caestecker, 2006). A genetic link between 
anorexigenic drugs and PAH has been established following the observation 
tha t only a m inority of patients who ingest these agents actually develop the 
pathology. A polymorphism in the promoter region of the human serotonin 
transporter (5-HTT) gene alters its transcriptional activity hence the level of 
its expression is predetermined based on its genotype. The polymorphism 
involves two alleles: the L and the S allele. The L allele has a 2- to 3-fold 
higher level of 5-HTT gene transcription compared to the S allele. I t  is 
believed tha t 60 -70%  of IPAH patients possess the L/L genotype, while L/L 
genotype is present in only 20-30%  of the control population of Caucasian 
subjects, indicating that L/L genotype may confer genetic susceptibility to 
IPAH (Eddahibi e t a!., 2001). This concept has recently been challenged as 
recent extensive analyses have failed to confirm a link between IPAH and 
the L/L genotype (Machado et al., 2006; Willers et al., 2006). Despite this, 
in vitro  and in vivo experimental data support the hypothesis tha t increased 
5-HTT expression, regardless of genotype, plays a role in the pathogenesis 
o f PH (reviewed in de Caestecker, 2006)
20
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Pulmonary arterial hypertension has also been divided into four distinct 
functional classes (I-IV ) by the New York Heart Association (Table 1.1). This 
method of classification defines the severity of the disease, class I being the 
least severe and class IV being the most severe.
Class Description
Class 1 PAH without a resulting limitation of physical activity. 
Ordinary physical activity does not induce dyspnea or 
fatigue, chest pain, or near syncope.
Class II PAH resulting in a slight limitation of physical activity. 
The patient is comfortable at rest, but ordinary physical 
activity causes undue dyspnea or fatigue, chest pain or 
near syncope.
Class III PAH resulting in a marked limitation of physical activity. 
The patient is comfortable at rest, but less than ordinary 
activity causes undue dyspnea or fatigue, chest pain or 
near syncope.
Class IV PAH resulting in an inability to carry out any physical 
activity without symptoms. The patient has signs of right 
heart failure. Dyspnea, fatigue or both may be present 
even at rest, and discomfort is increased by any physical 
activity
Table 1.1 New York Heart Association (NYHA) functional classification of 
pulmonary arterial hypertension (PAH). Classification modified from the NYHA 
classification of patients with cardiac disease. Adapted from the executive 
summary of the World Symposium on Primary Pulmonary Hypertension in Evian,
France, in 1998.
Physiologically, PAH describes an intrinsic disease of the pulmonary vascular 
smooth muscle and endothelial cells due to abnormalities at cellular and 
molecular level (Rubin, 1997), such as mutations of cell surface receptors, 
dysfunctional ion channels and abnormal membrane transporters (reviewed 
in Mandegar et al., 2004). The obliterative abnormality blocks the blood 
from flowing through small pulmonary vessels leading to chronic and 
sustained pulmonary hypertension. This occurs in both idiopathic and familial 
PAH as well as in disorders tha t produce obliterative pulmonary artery
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disease as a complication of systemic processes, including collagen vascular 
disease or HIV infection.
1.1 .2  Pathophysiology o f IPAH
There are three main factors tha t combine to produce increased vascular 
resistance in obliterative pulmonary hypertension: vasoconstriction, vascular 
wall remodelling and thrombosis in situ (reviewed in Rubin, 1997). All three 
factors contribute to the narrowing of the lumen of small and medium sized 
arteries, a general histological finding in IPAH, in association with intimal 
and medial hypertrophy, concentric laminar intimal fibrosis, fibrinoid 
degeneration and formation of plexiform lesions (Wagenvoort, 1980; 
Bjornsson and Edwards, 1985; Pietra et al., 1989). Figure 1.1 summarises 
the three factors and the ir causes.
1.1.2.1 In  situ thrombosis
Endothelial cell dysfunction, and its interaction with growth factors and 
platelets, is thought to be partially responsible for thrombus formation as it 
promotes a pro-coagulant environment within the vascular bed. In fact 
patients with IPAH have been shown to have enhanced pro-coagulant 
activity due to increased levels of plasma fibrinopeptide-A and prolonged 
half-life o f fibrinogen (Eisenberg et al., 1990). Moreover, it has been 
reported tha t there is diminished fibrinolytic activity and increased levels of 
plasminogen activator inhibitor in 70% of patients with IPAH (Welsh e t al., 
1996). In addition high levels of urinary metabolites of thromboxane A2, a 
marker of platelet activation, have also been reported in these patients 
(Christman et al., 1992). Platelet activation and aggregation may lead to
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thrombus formation and be a significant factor in stimulating 
vasoconstriction and cellular proliferation by releasing vasoactive and 
mitogenic substances.
Platelets, fibroblasts, endothelial cells and thrombus formation are all 
involved in pulmonary vascular remodelling. It is becoming increasingly clear 
however, that vasoconstriction and even more significantly pulmonary artery 
smooth muscle cell (PASMC) proliferation lead to the vascular remodelling 
processes that characterise severe pulmonary hypertension.
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Figure 1.1 Diagram illustrating the three main factors contributing to the development of 
sustained elevation of pulmonary vascular resistance (PVR) and artery pressure (PAP) in 
pulmonary arterial hypertension (PAH). (Em) membrane potential, (SMC) pulmonary artery 
smooth muscle cells, (EC) pulmonary arterial endothelial cells. Adapted from Mandegar et 
al, 2004.
1 .1 .2 .2  Pulm onary a rte ry  vasoconstriction
Smooth muscle constriction is elicited by a rise in cytosolic free Ca2+ 
concentration ([Ca2+]cyt). The contractile proteins, actin and myosin, contract 
PASMC in a Ca2+-dependent manner. The degree of pulmonary 
vasoconstriction depends on both the level of [Ca2+]cyt and the sensitivity of
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the contractile apparatus to [Ca2+]cyt (reviewed in Mandegar et a!., 2004). 
Control of [Ca2+]cyt levels in PASMC is achieved principally, though not 
exclusively, in two distinct ways. The firs t is via trans-sarcolemmal influx of 
Ca2+ through Ca2+ permeable channels or exit of Ca2+ through membrane 
Ca2+-Mg2+ ATPase pumps. The second is the mobilisation of Ca2+ from the 
sarcoplasmic reticulum (SR) through Ca2+ release channels or sequestration 
of Ca2+ back into the SR by Ca2+-Mg2+ ATPase pumps (SERCA) (Berridge, 
1993; Blaustein, 1988). There are two types of SR Ca2+ channels, which are 
named for their affin ity for either the plant alkaloid ryanodine or the 
phospholipid metabolite inositol (l,4 ,5 )-trisphosphate  (IP3).
In PASMC [Ca2+]cyt can therefore be increased by Ca2+ release from the 
intracellular stores and through Ca2+ influx through Ca2+ channels. A number 
of Ca2+ channels are responsible for Ca2+ entry through the plasma 
membrane and the excitation-contraction coupling process is thus dependent 
on the function of these channels. These include voltage-dependent Ca2+ 
channels (VDCC) regulated by changes in membrane potential (Em), receptor 
operated Ca2+ channels (ROC) activated by agonists binding to specific 
membrane receptors and store operated Ca2+ channels (SOC) activated by 
depletion of Ca2+ from intracellular stores (Nelson et al., 1990; Thorneloe 
and Nelson, 2005). As well as passing Ca2+, ROCs and SOCs are non- 
selective cation channels which when opened cause membrane 
depolarisation (Thorneloe and Nelson, 2005).
In addition, the activity of K+ channels indirectly regulates the extent of Ca2+ 
influx through the VDCC by altering the Em. For example, in smooth muscle, 
opening of potassium channels causes membrane hyperpolarisation thereby
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reducing Ca2+ entry through VDCC and promoting relaxation. Down- 
regulated or dysfunctional K+ channels can also lead to sustained membrane 
depolarisation and contribute to maintain elevated [Ca2+]cyt levels found in 
pulmonary hypertensive cells, contributing to both vasoconstriction and cell 
proliferation (Remillard and Yuan, 2005). Indeed Yuan and colleagues (Yuan 
et at., 1998) have shown that there was a lower voltage-gated K+ (Kv) 
channel expression and decreased K+ channel activity in PASMC from a small 
number of IPAH patients. More recently, enhanced expression of transient 
receptor potential (TRP) channel genes that encode channels responsible for 
non voltage-dependent Ca2+ entry were much higher in PASMC from IPAH 
patients than in those from normotensive or secondary pulmonary 
hypertension patients (Yu et a!., 2004). Sustained elevation of [Ca2+]cyt 
induces a chronic state of vasoconstriction and is thus likely to contribute to 
smooth muscle cell hypertrophy and vascular remodelling.
1.1 .2 .3  Pulmonary arteria l wall remodelling
In a normal state, the thickness and tissue mass of the pulmonary arterial 
walls are maintained at an optimum level by a balance between proliferation 
and apoptosis of PASMC, fibroblasts and pulmonary arterial endothelial cells 
(PAEC). In IPAH, however this balance is disrupted in favour of proliferation, 
leading to a thickening of the pulmonary arterial wall and a narrowing of the 
vessel lumen. The latter is eventually obliterated which leads to increased 
PVR. Vascular remodelling defines the structural changes tha t lead to 
hypertrophy and/or luminal occlusion. Loss of pulmonary vascular 
compliance and increased PVR due to vascular remodelling results in
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pronounced pulmonary hypertension and is the principal pathological finding 
in IPAH (Rubin, 1997).
The molecular mechanisms underlying pulmonary artery remodelling are 
very complex but changes in Ca2+ homeostasis are likely to play a major 
role. Elevated [Ca2+]cyt drives quiescent cells into the cell cycle where they 
undergo mitosis promoting cellular proliferation (Landsberg and Yuan,
2004). In addition it has been shown that resting [Ca2+]cyt is significantly 
elevated in proliferating PASMC compared to growth-arrested cells, 
highlighting the fact that increased Ca2+ influx is required for cell 
proliferation as well as for smooth muscle contraction (Golovina et al., 2001; 
Platoshyn et al., 2000).
The balance of vasoconstrictor and mitogenic agents with vasodilator and 
anti-m itogenic agents is crucial in maintaining normal vascular function. In 
IPAH this balance is shifted more towards over production of 
vasoconstrictors such as endothelin (ET-1) and thromboxane (TXA2) at the 
expense of vasodilators and anti-m itogenic factors such as prostacyclin 
(PGI2) and nitric oxide (NO) (Christman et al., 1992; Tuder et al., 1999). 
Matrix metalloproteinases (MMPs) are also thought to have a role in the 
development of PAH. The gelatinases MMP-2 and MMP-9, which degrade 
collagen and elastin and regulate extracellular matrix deposition, have been 
shown to contribute to smooth muscle cell migration and proliferation 
(Frisdal et al., 2001; Vieillard-Baron et al., 2003). Activation of these 
metalloproteinases increases tenascin-C expression, a protein which 
promotes proliferation and suppresses apoptosis in PASMC (Cowan et al., 
1999). Furthermore MMP-2 has been found to be up-regulated in PASMC
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from IPAH patients (Lepetit et al., 2005) and is thought to regulate vascular 
tone and structure by cleaving vasoactive peptides (Martinez et al., 2004).
1.1 .2 .4 Role o f endothelium derived factors and
phosphodiesterases in vascular wall remodelling 
Endothelin
ET-1, produced by endothelial cells as well as smooth muscle cells (Kanse et 
al., 1991), is an efficient survival and anti-apoptotic agent as well as being a 
potent potent vasoconstrictor peptide (Yanagisawa et al., 1988). In addition 
it has mitogenic effects, promoting both inflammation and smooth muscle 
cell proliferation and has been found to play a role in vascular remodelling 
(Kirchengast and Munter, 1998; Davie et al., 2002). Clinical and animal 
studies have implicated increased ET-1 production in the pathogenesis of 
primary and secondary pulmonary hypertension (Komai et al., 1993; 
Noguchi et al., 1997; Giaid, 1998). Indeed, endothelin antagonists appear 
effective in reversing the development of experimental pulmonary 
hypertension and are of proven benefit in the treatm ent of IPAH (Weinberger 
et al., 2001; Attina et al., 2005). The effects of ET-1 are mediated by the 
endothelin-A (ETA) and endothelin-B (ETB) receptors. In the cardiovascular 
system, ETA receptors are found in smooth muscle cells and cardiac 
myocytes, whereas ETB receptors are localized on both endothelial and 
smooth muscle cells (reviewed in Galie et al., 2004). Human PASMC express 
both receptors and signalling through either type may prevent apoptosis 
(Davie et al., 2002). The binding of ET-1 to ETA and ETB receptors in SMC 
activates phospholipase C (PLC), which leads to an increase of inositol 
triphosphate (IP3) and intracellular Ca2+ leading to long-lasting
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vasoconstriction. The increase of intracellular Ca2+ also stimulates protein 
kinase C, which mediates the mitogenic action of ET-1 (reviewed in Galie et 
al., 2004). By contrast, activation of ETB receptors in endothelial cells 
stimulates the release of NO and prostacyclin (Hirata e ta /., 1993), prevents 
apoptosis (Shichiri et a/., 1997) and mediates the pulmonary clearance of 
circulating ET-1 (Dupuis et a/., 1996). I t  has been demonstrated that both 
ETa and ETB receptors are up-regulated in the vasculature of experimental 
models of both systemic (Wu e t a/., 2000) and pulmonary hypertension (Li 
e ta /., 1994; Soma e ta /., 1999).
Throm boxane
Thromboxane A2 (TXA2) is produced primarily by platelets but also by the 
endothelium. I t  is a potent vasoconstrictor and smooth muscle mitogen. It  is 
an arachidonic acid metabolite of the cyclo-oxygenase pathway which acts 
as an agonist for platelet aggregation and is likely to contribute to vascular 
remodelling and histopathologic changes associated with IPAH. In fact 
patients with IPAH have been found to have elevated levels of urinary 11- 
dehydro-TBX2, a urinary metabolite of TXA2 (Christman e ta /., 1992), as well 
as elevated synthesis of TXA2 (Robbins e ta /., 2001).
N itric  ox ide
NO is a potent endogenous vasodilator that directly relaxes vascular smooth 
muscle through stimulation of soluble guanylate cyclase and increased 
production of intracellular cyclic guanosine monophosphate (cGMP). I t  is 
produced from the terminal guanidine-nitrogen of L-arginine and oxygen in 
the endothelium by endothelial NO synthase (eNOS). I t  had been suggested
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originally that the expression of eNOS is reduced in the lungs of patients 
with PAH (Giaid and Saleh, 1995) but this finding has not been confirmed in 
more recent investigations (Tuder et al., 1999). However, there is evidence 
showing that whole body NO production, exhaled NO and urinary NO 
metabolites are all decreased in patients with PAH (Demoncheaux et al., 
2005; Girgis et al., 2005). Current literature suggests that reduced bio­
availability of NO in PAH is not principally the result of impaired eNOS 
expression but rather caused by complex pathways involving reduced L- 
arginine availability and increased NO degradation (Hoeper and Rubin, 
2006).
Phosphodiesterases
There are 11 phosphodiesterase (PDE) isoform families responsible for the 
hydrolysis of cyclic nucleotides (Maurice e ta /., 2003). cGMP, the intracellular 
second messenger of NO has gained substantial consideration as a possible 
target in the treatm ent of pulmonary vascular disease. PDE5, one of the 
PDEs responsible for the breakdown of cGMP, is abundantly expressed in 
PASMC (Murray et al., 2002) and PDE5 inhibitors have been shown to have 
pulmonary vasodilatory effects in both experimental and human PAH (Zhao 
et al., 2001; Aldashev et al., 2005). In addition these inhibitors have 
antiproliferative effects on PASMC (Corbin et al, 2005; Wharton et al.,
2005). The inhibition of other PDE isozymes which breakdown cyclic AMP 
(cAMP), such as PDE1, PDE3 and PDE4, also suppresses proliferation and 
promotes apoptosis of PASMC, thus may have a role in pulmonary vascular 
remodelling and smooth muscle cell proliferation (Phillips et al., 2005; 
Growcott et al., 2006).
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Prostacyclin
Prostacyclin (PGI2), discovered by Sir John Vane and colleagues in 1976 
(Moncada et al., 1976), is the main prostanoid in the mammalian 
vasculature, and its production is greater in pulmonary than in systemic 
arteries (Shaul et al., 1991). I t  is derived from arachidonic acid, which is 
converted by cyclo-oxygenase, primarily cyclo-oxygenase-2 (COX-2) into 
prostaglandin H (PGH2) which in turn is eventually metabolised into PGI2 by 
prostacyclin synthase (PGIS) (Fig. 1.2). PGH2 is also the precursor of other 
prostanoids such as PGE2( PGF2( PGD2and TXA2.
Arachidonic Acid
COOH PGH
OH
PGIS
PGI
OH
Figure 1.2. Synthesis of prostacyclin (PGb). Arachidonic acid is converted into 
prostaglandin H2 (PGH2) by cyclo-oxygenase-2 (COX-2). Prostacyclin synthase (PGIS), in 
turn, metabolises PGH2 into PGI2 .
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Several lines of evidence suggest that the major biological activities of PGI2 
are mediated by PGI2 (IP) receptors coupled via the stimulatory G protein, 
Gs to adenylyl cyclase (Narumiya et al., 1999). Prostacyclin, and its stable 
analogues induce inhibition of proliferation of vascular smooth muscle cells 
by stimulating the production of cyclic AMP (cAMP) (Wharton et al., 2000; 
Clapp et al., 2002) whereas relaxation appears to result from both cyclic 
AMP dependent and independent pathways (Turcato and Clapp, 1999; Orie 
et al., 2006). In IPAH patients there is a decrease in prostacyclin production 
(Christman et al., 1992) which may be the result of a lower expression of 
PGIS observed in the small arteries of such patients (Tuder et al., 1999). 
Furthermore over-expression of PGIS in rats has been shown to inhibit 
proliferation and migration of smooth muscle cells in rat balloon-injured 
carotid arteries (Harada et al., 1999). Prostacyclin and its stable analogues 
will be discussed in greater detail later.
1.1 .3  Current treatm ent o f IPAH
As yet lung transplantation is the only curative treatm ent for this disorder. 
Anticoagulants, such as heparin and warfarin, have been shown to be 
beneficial but the ir efficacy seems to be biased towards patients that display 
throm botic lesions (Gaine and Rubin, 1998). They are given in combination 
with other therapies such as calcium-channel blockers (Ogata et at., 1993). 
Long term therapy with calcium-channel blockers has achieved sustained 
haemodynamic improvement and survival in a m inority of IPAH patients. I t  
results in a substantial reduction in mean pulmonary artery pressure and 
pulmonary vascular resistance (Rich et al., 1992). However, less than 10% 
of cases fall into this "responder" category (Runo and Loyd, 2003). In
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addition some patients on calcium-channel blockers experience systemic 
hypotension, oxygen de-saturation or a decline in cardiac output and are 
unlikely to benefit from this vasodilatory therapy; in fact it may even cause 
further clinical deterioration (Gaine and Rubin, 1998). Another drawback to 
this therapy is that abrupt discontinuation results in rebound pulmonary 
hypertension which may be fatal (Gaine and Rubin, 1998). Apart from 
transplantation, anti-coagulation and calcium channel blockers, the 
development of most treatm ents for IPAH has focused on readdressing the 
balance between vasodilators and vasoconstrictors in the pulmonary 
vasculature.
1.1.3.1 PGI2 and stable analogues
Prostacyclin in the form of epoprostenol (Flolan) has been the most widely 
studied drug in PAH. I t  improves haemodynamics and exercise tolerance and 
prolongs survival in IPAH patients who do not respond to vasodilator testing 
at cardiac catheterisation (Higenbottam et al., 1993; Barst et al., 1996; 
Barst et a/., 1994). Cohort analysis of patients with IPAH who were receiving 
continuous intravenous epoprostenol showed clinical benefit for patients in 
NYHA functional class I I I  and IV (McLaughlin et al., 2002; Sitbon et al., 
2002). The beneficial effects of prostacyclin may relate to the ir ability to 
inhibit smooth muscle cell proliferation (Wharton et al., 2000; Clapp et al., 
2002), to decrease production of ET-1 (Prins et at., 1994; Woods et al., 
2000) and increase its clearance in patients (Langleben et at., 1999) and 
improve pressure-flow response to exercise (Castelain et at., 2002). 
Epoprostenol has a short half-life in plasma (3 minutes) and is inactivated at 
low pH. Therefore its administration requires continuous intravenous infusion
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with the use of a portable infusion pump connected to a permanent 
tunnelled catheter inserted into a subclavian vein (Barst et a l., 1996). 
Having an in-dwelling line may lead to complications such as exit-site 
infections and bleeding as well as sepsis. The dose of epoprostenol needs to 
be increased as the disease progresses to prevent symptom recurrence. It  is 
not clear why this is so, but may be due to increased production of 
endogenous counter-mediators such as TXA2 or to IP receptor 
desensitisation or down-regulation (Nilius et al., 2000). Stable PGI2 
analogues with increased bioavailability have therefore been developed as 
an alternative to epoprostenol to try  and circumvent some of these 
problems.
Schering's first compound Iloprost (Ventavis) has at least the same binding 
capacity to the IP receptor as PGI2 but it is more stable and has a much 
more extended duration of action in vivo (Skuballa et al., 1985). I t  has been 
approved for treating IPAH in Europe and is administered either 
intravenously or via an inhaler. Because of its relatively short duration of 
action compared to other analogues (plasma half-life of 15-30 mins), it must 
be inhaled as many as 6 to 12 times a day. The results of short-term  studies 
and trials have been encouraging and this agent has the added advantage of 
relatively few systemic side effects (Olschewski et al., 2002; Hoeper et al., 
2000). However the long term efficacy of inhaled iloprost and the effects of 
repeated inhalation remain to be established.
Beraprost sodium (Beraprost) is the only orally-available PGI2 analogue; it 
has a half-life of 35-40 mins and is currently licensed for use in Japan. 
There have been two random clinical trials of Beraprost performed to date
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(both in patients in NYHA class I I  and I I I ) .  The firs t tria l showed a significant 
improvement in the 6 minute walking distance test over 12 weeks in IPAH 
patients (but none in patients with PAH and associated conditions) although 
surprisingly there were no significant haemodynamic changes (Galie et al., 
2002). The second study, conducted over 12 months, showed tha t the 
significant improvement in walking distance seen at 3 and 6 months was lost 
at 9 months and thereafter (Barst et a l., 2003). There were no significant 
haemodynamic or survival benefits over placebo control patients at 12 
months. While beraprost is not very efficacious over a prolonged period, it 
may prove beneficial as a component of combination therapy (Howard and 
Morrell, 2005).
Treprostinil (Treprostinil Sodium, Remodulin; UT-15) is a stable PGI2 
analogue, has a relatively long half life (~34-86 minutes) and can be 
administered as a continuous subcutaneous infusion. Treprostinil has been 
an approved therapy in the United States since 2002, and more recently in 
Europe. Patients undergoing treprostinil treatm ent frequently complain of 
severe pain at the site of infusion, a major hurdle for the widespread use of 
treprostinil. In November 2004 however, the FDA approved the intravenous 
use for those not able to tolerate subcutaneous infusion because of site or 
leg pain. Recent studies also show that there is a possibility of a successful 
switch from intravenous epoprostenol to intravenous treprostinil (Gomberg- 
Maitland e t al., 2005). In trials, treprostinil has given positive results in 
patients with class II-IV  pulmonary arterial hypertension by improving 
indexes of dyspnea, signs and symptoms of pulmonary hypertension and 
haemodynamic measures (reviewed in McLaughlin et al., 2002; Rubin, 
2002).
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In addition to having different half-lives, PGI2 analogues have different 
affinities towards a wide range of prostanoid receptors including 
prostaglandin E2 (EP) receptors (Kiriyama et al., 1997; Clapp et al., 1998; 
Abramovitz e t al., 2000). Figure 1.3 illustrates the chemical structure of PGI2 
and its analogues with their respective half-lives and their known receptor 
selectivities. The importance of receptor selectivity is yet to be fully 
established. There is little data upon which to judge whether or not the IP 
receptor is solely responsible for the beneficial clinical effects of PGI2 or 
whether some effects may be mediated by the other receptors for which 
these compounds have affin ity for.
Iloprost binds to the IP receptor with approximately the same affin ity as it 
binds to EPi and EP3 receptors (Abramovitz et al., 2000). Cicaprost has a 
long in vivo half-life of over an hour and is described as the most selective 
IP receptor agonist exhibiting high binding affinity to the IP receptor ( K j  
~10-20 nM). However, in species other than mouse, cicaprost has significant 
agonist activity at the EP4 receptor (Narumiya et al., 1999; Abramovitz et 
al., 2000). In contrast, carbacyclin (Carbaprostacyclin, cPGI2) has a 
relatively poor receptor selectivity having equal affin ity for IP, EPi and EP3 
receptors, but does have the added feature of being membrane permeable. 
Treprostinil appears to be one of the most potent analogues in terms of 
inhibition of cell proliferation (Clapp et al., 2002) but there is little  data on 
receptor selectivity. Cicaprost and carbacyclin, although not approved 
therapies for PAH, have proved to be good tools in the laboratory due to 
the ir relative IP receptor selectivity and membrane-permeability 
respectively.
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COOH
Figure 1.3. Structure of prostacyclin (PGI2) and its stable analogues. Half-life (U12) in vivo 
is shown in blue. Receptor selectivity is shown in red. (IP) PGI2 receptor, (EP1-4 ) 
prostaglandin E receptors, (FP) prostaglandin F receptor. (Kiriyama et al, 1997; 
Abramovitz et al. 2000).
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1.1 .3 .2  Endothelin-receptor antagonists
Bosentan (Tracleer) is an orally active dual (ETAand ETB) endothelin receptor 
antagonist. In studies involving NYHA class I I I  PAH patients, bosentan 
significantly improved PAP, CO and PVR (Channick et at., 2001; 
Apostolopoulou e ta /., 2005; Apostolopoulou e ta /., 2006). There is currently 
a debate about whether specific ETA receptor antagonists may offer better 
clinical results, given that these would target only the vasoconstrictive and 
mitogenic pathway of ET-1. However, data on head to head comparisons are 
still lacking. Bosentan was approved for treatm ent of PAH in both North 
America and Europe in 2001 and 2002 respectively as is sitaxsentan (thelin), 
an ETA antagonist approved for treatm ent in the US since July 2005.
1.1 .3 .3  PDE5 inhibitors
Sildenafil, a PDE5 antagonist, is renowned for its effects on penile erectile 
dysfunction (Boolell et al., 1996). I t  has, however, recently been approved 
for use in PAH in both the USA and Europe. I t  has been shown to improve 
functional class and haemodynamics as well as other clinical endpoints in a 
tria l involving 279 patients with PAH in functional classes I-IV  (Galie et al., 
2005).
1.1 .3 .4  Potential future therapies for IPAH  
Nitric Oxide
Since IPAH is associated with a defect in the production of NO, this agent 
has been proposed as a potential therapy (Giaid and Saleh, 1995). Short­
term  inhalation of NO has substantial pulmonary specific vasodilator effects
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in humans (Giaid and Saleh, 1995) and there are isolated studies suggesting 
tha t treatm ent with L-arginine, the substrate for NOS, reduces PAP and 
increases exercise tolerance in patients with IPAH (Nagaya et al., 2001). 
However long-term NO inhalation therapy has been shown to benefit only a 
small number of patients. Furthermore, its administration can cause 
haemodynamic deterioration and the generation of toxic by-products, 
making it unsuitable for home use (Hasuda e ta /., 2000).
Vasoactive In testinal Peptide
Vasoactive intestinal peptide is a member of the superfamily tha t secretes 
glucagon-growth hormone releasing factor. I t  too acts as a potent 
vasodilator and inhibits smooth muscle cell proliferation and platelet 
activation. In an encouraging study involving 8 patients with IPAH, inhaled 
vasoactive intestinal peptide produced a significant functional and 
haemodynamic improvement (Petkov e ta /., 2003).
Selective Serotonin-reuptake inhibitors
Serotonin appears to have a role in the pathogenesis of various types of 
human and experimental forms of PAH. Therefore it has been proposed that 
specific treatm ents utilising selective serotonin reuptake inhibitors, such as 
fluoxetine, may provide protection against PAH (Eddahibi et al., 2002; 
Marcos et al., 2003). These agents are yet to be tested in PAH patients.
Combination therapy
The combined use of drugs with different mechanisms of action is the most 
likely emerging option for treatm ent of PAH. Most experts agree that a
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combination of prostanoids, endothelin and PDE inhibitors will result in a 
better clinical outcome than each of the treatments alone. Some in vitro  
evidence comes from studies showing that combinations of PGI2 analogues 
with PDE3 or PDE4 inhibitors results in a significant additive or synergistic 
elevation in cAMP and ensuing anti-m itogenic effects (Phillips et ai.f 2005; 
Growcott et a l 2006). There are only a few clinical studies and case series 
assessing combination therapy but the data presented are encouraging. 
Administering bosentan to patients receiving prostanoid treatm ent 
(intravenous or inhaled) improves exercise capacity and echocardiographic 
parameters of right heart function (Seyfarth et ai., 2005). In addition, a 
study by Hoeper and colleagues (Hoeper et a i 2005), where PAH patients 
were treated with endothelin receptor antagonists, PDE5 inhibitors and 
prostanoids, demonstrated tha t such a combination approach significantly 
improved 1, 2 and 3 year survival rates compared to historical control 
groups treated with iloprost or beraprost alone.
Numerous other new compounds have been evaluated as potential 
treatm ent for PAH in experimental studies or small case series. Drugs used 
for other diseases such as statins, Rho-kinase inhibitors and imatinib 
mesylate, for example, have also been shown to be able to control the 
pathological vascular remodelling of PAH (reviewed in Ito  e ta /., 2007).
An open-label observational study on 16 PAH patients has shown that 
administration of simvastatin improves the 6-minute walk performance and 
haemodynamics w ithout severe complications (Kao, 2005). A Rho-kinase 
inhibitor, Fasudil, when given intravenously to 9 patients with severe PH
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exhibited a significant acute reduction in the pulmonary vascular resistance 
(Fukumoto et al., 2005).
Platelet derived growth factor (PDGF) is involved in the proliferation of 
PASMC and PDGF receptors are upregulated in an animal model of PAH 
(Balasubramaniam et al., 2003). Im atin ib mesylate is a selective PDGF 
receptor antagonist shown to be able to reverse established severe PAH and 
prolong survival in two animal models of PAH (Schermuly et al., 2005). 
Since this compound is tolerable and clinically used for the treatm ent of 
certain malignancies the result of this drug may be easily transferable to 
PAH therapies. Interestingly a case study reported that the oral 
administration of this drug improved exercise capacity, haemodynamics and 
functional class in a patient who was refractory to combination therapy (oral 
bosentan, inhaled iloprost and sildenafil) (Ghofrani et al., 2005). Larger 
controlled tria ls are needed to identify the long-term benefits and anti­
remodelling effects of these potential future treatments.
In summary, there have been many recent advances in our understanding of 
the pathobiology of pulmonary vascular disease and new medicines have 
been introduced into clinical practice. Surprisingly, however, the mechanism 
o f action of prostacyclin and its analogues, to date the most effective 
treatm ent given to patients with IPAH, remains poorly understood.
1.2 The prostacyclin receptor
1.2.1 Expression and distribution
The IP receptor (Figure 1.4) is a membrane bound G-protein coupled- 
receptor (GPCR) belonging to the family of the prostanoid receptors
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(Narumiya et al., 1999). The human IP gene was first cloned from 
megakaryocyte and lung cDNA libraries and spans approximately 7kb, 
consisting of three exons and two introns. The gene maps to chromosome 
band 19ql3.3 and encodes a protein of 386 amino acids folding into seven 
trans-membrane domains (reviewed in Smyth and Fitzgerald, 2002).
Figure 1.4. Diagram representing the IP receptor. This G protein coupled receptor (GPCR) 
consists of 386 amino acids forming seven trans-membrane domains. The C terminus is 
located in the cytoplasm and the N terminus is located extra-cellularly. Adapted from 
Cayman Chemicals.
membrane
cytoplasm
The IP receptor is expressed in a number of tissues including kidney, liver, 
lung, heart and aorta (Boie et al., 1994; Nakagawa et al., 1994). In the 
vasculature it is mainly localised in platelets and vascular smooth muscle 
cells (Oliva and Nicosia, 1987). I t  appears to be confined to the arterial side 
of the circulation, even in the pulmonary vasculature (Oida et al., 1995)
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consistent with the notion tha t venous smooth muscle cells contain primarily 
EP type rather than IP receptors (Coleman et al., 1994). Nevertheless, both 
isolated human pulmonary arteries and veins exhibit the same sensitivities 
to the relaxant effect of cicaprost (Walch et al., 1999). IP receptors are 
present in fibroblasts too where they appear to mediate the anti-m igratory 
effects of PGI2 analogues (Kohyama et al., 2002). In addition, the IP 
receptor is expressed in the atrium  and ventricle of the heart indicating a 
possible role for PGI2 in cardiac tissue (reviewed in Smyth and Fitzgerald, 
2002).
1.2 .2  IP  receptor knockout and transgene studies
The generation of IP receptor knockout mice made it possible to elucidate 
the importance of this receptor in vivo (Murata et al., 1997). These mice 
were viable and reproductive, had a normal basal blood pressure and heart 
rate and had no increased occurrence of vascular disorders. On the other 
hand, PGIS knockout mice, which lack PGI2 production, were hypertensive 
and exhibited renal and aortic abnormalities including arterial sclerosis 
(Yokoyama e t al., 2002). In the latter study there was however, a parallel 
increase in the biosynthesis o f other eicosanoids such as PGE2 and TXA2 
probably as a result of a move to other synthetic pathways which could 
account for the different phenotype observed between PGIS and IP receptor 
knockout mice.
The ability of PGI2 and its analogues to inhibit cell proliferation appears to 
rely on IP receptor activation. In VSMC from IP knockout mice, cicaprost had 
no anti-proliferative or cAMP elevating effects (Fujino et al., 2002; Kothapalli 
et al., 2003). Moreover, IP deficient mice lacked a hypotensive response to
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cicaprost as well as being more susceptible to thrombus formation after 
endothelial damage was evoked (Murata et al., 1997). In addition, these 
mice developed a greater degree of cardiac hypertrophy (Hara et a!., 2005), 
pulmonary hypertension and pulmonary vascular remodelling after chronic 
exposure to hypobaric hypoxia than did wild type mice (Hoshikawa et al.,
2001 ).
1.2 .3  IP  receptor signal transduction
The IP receptor is a "re laxant" prostanoid receptor together with the 
prostaglandin D receptor (DP) and the two prostaglandin E receptors EP2 and 
EP4 (Coleman et al., 1994). Receptors activate intracellular signalling 
cascades by coupling to heterotrimeric G proteins. The IP receptor primarily 
activates adenylyl cyclase (AC) via the stimulatory G protein, Gs (Namba et 
al., 1994), hence agonist binding to the receptor results in an increase in 
cAMP.
The main target for cAMP in mammalian cells is to activate protein kinase A 
(PKA, cAMP-dependent protein kinase). PKA is regulated by two catalytic (C) 
and two regulatory (R) subunits. Cyclic AMP binds to the R dimer and this 
leads to the dissociation of the R dimer from the C dimer. The dissociation of 
the C subunits activates them and results in the phosphorylation of the PKA 
phosphorylation consensus sequence X-Arg-Arg-X-Ser-X on target proteins 
(reviewed in Koyama et al., 2001). In addition cAMP has also been shown to 
act in a PKA-independent manner by directly activating guanine nucleotide 
exchange factors (cAMP-GEFs) such as Epac-1 and -2 which promote the 
formation of GTP bound, active, Rap 1, a small Ras-like G protein involved in
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cellular proliferation, and Rap 2 (Kawasaki et al., 1998; de Rooij et al., 
2000).
Similar to other GPCRs, the IP receptor may couple to more than one G 
protein. In expression systems, as well as coupling to Gs, the IP receptor has 
also been shown to couple to Gq. This in turn activates PLC leading to IP3 
turnover and mobilisation of intracellular Ca2+ (reviewed in Smyth and 
Fitzgerald, 2002). Some have also reported coupling to the inhibitory G 
protein, G, (Lawler et al., 2001). There is controversy over whether the 
receptor couples dependently or independently of Gs/Gq and whether it 
couples to Gj at all (Wise and Jones, 2000).
Differential coupling of the IP receptor to multiple signalling pathways can 
be regulated by C-terminal modification. Isoprenylation and glycosylation of 
the C-terminal are both thought to be required for efficient coupling o f the 
IP receptor to both Gs and Gq (Hayes et al., 1999; Miggin et al., 2002; 
Smyth et al., 1998). In addition, the IP receptor possesses multiple cysteine 
residues in the C-terminal that are capable of being palmitoylated. Differing 
patterns of palmitoylation have been demonstrated to be required for 
coupling to Gs- versus Gq-mediated signal transduction pathways (Miggin et 
al., 2003).
1.2.3.1 Mechanisms o f IP  receptor-mediated vasoreiaxing 
effects o f PGI2 analogues
PGI2 and its stable analogues promote vasorelaxation in a wide variety of 
vascular beds (Siegel et al., 1989) including guinea-pig aorta (Clapp et al., 
1998; Turcato and Clapp, 1999), rat tail artery (Schubert et al., 1997; Orie
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et al., 2006) and human pulmonary artery and vein (Walch et al., 1999). I t  
is readily assumed that the IP receptor and subsequent elevation o f cAMP 
mediates the major biological activities of PGI2 and its analogues, since 
these agents readily increase cAMP in many different smooth muscle cell 
types (Vegesna and Diamond, 1986; Turcato and Clapp, 1999; Clapp et al.,
2002) and relaxation is commonly potentiated by agents preventing the 
breakdown of cAMP (Holzmann et al., 1980; Tanaka et al., 2004}. One of 
the final cellular events associated with PGI2-induced vasorelaxation is 
membrane hyperpolarisation of smooth muscle cells resulting from 
activation of plasma membrane K+ channels (Siegel et at., 1989; Tanaka et 
at., 2004). Depending on the vascular bed, the main channels involved are 
the ATP sensitive K+ ( K At p )  channel, the large conductance Ca2+ activated K+ 
(MaxiK) channel or the inward rectifier K+ channel (Tanaka e t al., 2004; 
Orie et al., 2006). The form er two channels appear to be im portant in 
mediating part of the dilatory effects of iloprost in the pulmonary 
vasculature (Dumas et al., 1997). Originally, K+ channel activation was 
thought to be driven exclusively through a cAMP-dependent mechanism 
(Schubert et al., 1997) although there is growing evidence for the 
involvement of cAMP independent mechanisms (Turcato and Clapp, 1999; 
Orie et al., 2006) possibly through direct Gs protein coupling to the channel 
(Tanaka eta/ . ,  2004)
1.2 .3 .2  Mechanisms o f IP  receptor-mediated anti-proliferative
effects o f PGI2 analogues
Vascular smooth muscle cells are usually quiescent in vivo but in pulmonary 
vascular disease they undergo proliferation. PGI2 and its stable analogues
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inhibit smooth muscle cell proliferation and DNA synthesis by blocking the 
progress from the Gi phase into the S phase of the cell cycle (Wharton et 
al., 2000; Kothapalli e t a l., 2003). Cyclic AMP-elevation appears to be the 
main signalling mechanism by which the receptor mediates inhibition of 
proliferation in a variety of cell types: 2',5'-dideoxyadenosine (DDA), an 
adenylyl cyclase inhibitor, attenuated both the acute stimulation of cAMP 
production as well as the inhibition of smooth muscle cell proliferation 
induced by iloprost, cicaprost and treprostinil (Wharton et al., 2000; Clapp 
et al., 2002; Phillips et al., 2005). Different PGI2 analogues inhibit 
proliferation with different potencies. Treprostinil appears to be the most 
potent analogue in human PASMC with an IC50 of 4.2nM (Clapp et al., 2002). 
Specificity to the IP receptor does not appear to confer increased potency, in 
fact cicaprost, the most IP specific analogue to date, has a less potent anti­
proliferative effect than either treprostinil or iloprost (Clapp et al., 2002).
I t  has been shown very recently that this IP receptor dependent increase in 
cAMP activates PKA (Phillips et al., 2005). What is acting directly 
downstream of PKA remains to be elucidated. I t  is well known tha t cAMP 
inhibits SMC proliferation in vitro  (Assender et al., 1992; Indolfi et al., 1997) 
and reduces the formation of neointimal lesions after arterial in jury in vivo 
(Indolfi et al., 1997). I t  does so primarily by being able to inhibit both the 
extracellular-signal regulated kinase (ERK) and the phosphoinositide-3 
kinase (PI3K) mitogenic pathways (reviewed in Bornfeldt and Krebs, 1999; 
Koyama et al., 2001).
The ERK signalling pathway mediates mitogenic responses induced by a 
variety of growth factor receptors in many cell types including SMCs
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(Servant et al., 1996; Nelson et al., 1998). Activation of this cascade leads 
to the activation of the small GTP-binding protein Ras and then sequential 
phosphorylation events lead to activation of the protein kinases, Raf, 
mitogen-activated protein (MAP) kinase kinase (also known as MAPKK or 
MEK) and ERK (also known as MAPK). cAMP, via PKA, inhibits activation of 
the ERK pathway in many cell types including arterial SMC (Graves et al., 
1993) however the exact mechanism is still unclear and may involve more 
than one target (reviewed in Bornfeldt and Krebs, 1999). Several studies 
suggest that the inhibition may be at the point of Raf given the ability of PKA 
to phosphorylate both Raf-1 and B-Raf isoforms (Wu et al., 1993; Peraldi et 
al., 1995). Again, the precise mechanism is uncertain but a reduction in the 
binding affin ity between the PKA-phosphorylated Raf and Ras appears to be 
the most described mechanism (reviewed in Bornfeldt and Krebs, 1999).
PI3K comprises a family of agonist-stimulated lipid signalling enzymes that 
initiate signalling cascades by generating three distinct membrane lipids, the 
polyphosphoinositides PtdIns-3-P, PtdIns-3,4-P2, and PtdIns-3,4,5-P3 
(reviewed in Toker, 2000). There are three classes of PI3Ks, each 
responsible for generating one of the three polyphosphoinositides. Class I 
PI3Ks are activated in many cell types in response to growth factor or 
hormone stimulation, such as platelet derived growth factor (PDGF) and 
insulin, and are crucial for cell proliferation and several other cellular 
processes (Toker, 2000). A number of protein kinases are activated 
downstream of PI3K, including protein kinase B (PKB, Akt), p21-activated 
kinase, protein kinase C£, and the mammalian target of rapamycin (mTOR) 
which is inhibited by elevation of cAMP levels (Toker, 2000; Scott and 
Lawrence, 1998). In addition to blocking the PI3K pathway, cAMP has been
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shown to up-regulate levels o f p27kipl in SMC (Fukumoto et al., 1999; 
Kronemann et al., 1999). Up-regulation of this cyclin dependent kinase 
inhibitor (CDKI) causes cell cycle arrest by inhibiting the activity of cyclin 
dependent kinases (CDK) 2 and 4 (Fukumoto et al., 1999). Interestingly, 
Stewart and colleagues show tha t cicaprost also regulates p27kipl levels and 
tha t this is causally related to its antiproliferative effect (Stewart e t al., 
2004).
Gi phase progression is controlled by a sequential activation of cyclins and 
CDKs, specifically cyclin D l-cdk4 /6  and cyclin E-cdk2. These regulate cell 
cycle progression by phosphorylating pocket proteins such as pRb, which 
releases sequestered E2F and in turn activates cyclin genes such as cyclin A 
(Takahashi et al., 2000). This occurs possibly through interaction with the 
cell cycle-dependent element (CDE) and the cell cycle gene homology region 
(CHR) on the cyclin A promoter (Zwicker et al., 1995; Liu e t al., 1998). The 
net result is progression into the S phase of the cell cycle. I t  has been shown 
tha t cicaprost blocks proliferation at the Gi to S phase o f the cell cycle, 
partly as a result of inhibiting activation of the cyclin A prom oter and 
induction of cyclin A (Kothapalli e t al., 2003). In addition it has also been 
shown to block the activation of cyclin E-cdk2 (Kothapalli e ta /., 2003).
Moreover, the cyclin A promoter contains a cAMP response element (CRE) 
(TGACGTCA), a site necessary for the efficient activation of this cyclin 
(Desdouets et al., 1995). The CRE binding protein (CREB) family of 
transcription factors, which includes CREB, ATF1 and CRE modulator 
(CREM), can be activated by phosphorylation by several kinases in response 
to cAMP, calcium, stress and mitogenic stimuli. PKA is mainly responsible for
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phosphorylating CREB at S erl33  (Mayr and Montminy, 2001). 
Phosphorylation of CREB promotes recruitment of the transcriptional co­
activator CREB binding protein (CBP) and p300 (Chrivia e ta /., 1993; Arias et 
a/., 1994), two highly related histone acetyltransferases (HATs). CBP/p300 
then interacts with polymerase I I  complexes to mediate transcription. 
Transcription appears to peak 30 minutes after the increase in cAMP (Mayr 
and Montminy, 2001). Cicaprost has been shown to inhibit the binding of 
CREB and phospho-CREB to the CRE element in the cyclin A promoter 
(Kothapalli e t a/., 2003). I t  is still unclear how cicaprost can mediate this 
inhibition of CREB binding given that it is well established that IP couples to 
Gsto increase cAMP levels. Kothapalli and colleagues suggest a possible role 
for Gj signalling as they have shown that pertussis toxin reverses the effects 
of cicaprost on cyclin E-cdk2 and CRE occupancy, an effect that prevents 
cicaprost from inhibiting cell proliferation.
I t  is possible tha t activation of CREB through IP receptor signalling may have 
effects other than those observed on cyclin A transcription. CREB has been 
shown to cooperate with BMP-stimulated Smad signalling (Ionescu et al., 
2004) and also appears to be involved with the peroxisome proliferator- 
activated receptors (PPARs), a family of transcription factors involved in cell 
metabolism, differentiation and growth which can be activated by some PGI2 
analogues (Forman et al,, 1997). CITED2, a CBP/p300- interacting protein, 
has been shown to be a PPARa co-regulator (Tien et at., 2004) and PPARy- 
co-activator 1 (PGC-1) contains a CRE motif, even though PPARy itself does 
not possess one (Conkright et al., 2003). I t  is thought that CREB regulates 
this gene through an indirect mechanism.
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Figure 1.5 Simplified summary of the interactions of cAMP with the ERK/MAPK and PI3K 
signalling pathways and the mechanism of inhibition of cell proliferation. GFR, growth factor 
receptors. Please see text for other abbreviations
1 .3  PPARs
Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription 
factors which regulate target gene expression by binding to specific 
peroxisome proliferator response elements (PPREs) in the promoters of 
target genes. There are three isoforms of PPARs; a, 6 and y which are 
encoded by separate genes. Alternate promoter usage and splicing
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generates three PPARy variants: 1, 2 and 3 (Elbrecht et a!., 1996). PPARy3 
is essentially expressed in the large intestine, PPARy2 is expressed primarily 
in adipose tissue (Fajas et al., 1997) and PPARyl is expressed in a wide 
range of tissues including vascular smooth muscle (Law et al., 2000), heart 
and colon. Interestingly some PGI2 analogues have been shown to be PPAR 
ligands; in fact iloprost and carbacyclin can bind to and activate PPARa and 
PPARS (Forman e ta /., 1997).
PPARs are increasingly thought of as being involved in the control of cell 
proliferation following evidence that PPARy ligands caused growing 
fibroblasts and transformed adipocytes to withdraw from the cell cycle 
(Altiok et al., 1997). PPARy has also been demonstrated to have anti-cancer 
properties as well as inhibiting human smooth muscle cell proliferation in 
vitro  (Zahradka et ai., 2003). All of this makes PPARy a possible target in 
downstream IP receptor signalling.
1.3.1 Mechanisms o f PPAR activation.
1.3.1.1 PPAR structure
PPARs, like other nuclear receptors, possess a modular structure composed 
of functional domains. There are four main domains named A/B, C, D, and 
E/F (Figure 1.6) (reviewed in Desvergne and Wahli, 1999). The C domain, 
also known as the DNA binding domain (DBD), and the E/F domain, known 
as the ligand binding domain (LBD), are the most highly conserved regions 
across the receptor isoforms. The DBD consists of two zinc fingers that 
specifically bind PPREs. The LBD, located in the C-terminal half of the
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receptor, has been shown to be composed of 13 a-helices and a small 4- 
stranded p-sheet.
The ligand-dependent activation domain, AF-2, is located in the C terminus 
of the LBD and is involved in the generation of the receptors' co-activator 
binding pocket (Nolte e ta /., 1998). A ligand-independent activation function, 
AF-1, is found in close proximity to the N terminus of the receptor in the A/B 
domain (Werman et al., 1997). The D domain is a hinge region that can 
modulate the DNA binding ability of the receptor and is involved in co­
activator interaction.
NH
AF1
A/B
DBD [~AF2/LBD~|
COOH
AGGTCA-X-AGGTCA
PPRE
Figure 1.6 PPAR structure. (AF1) activating function -1, (DBD) DNA binding domain, (AF - 
2) activating function -2, (LBD) ligand -binding domain, (PPRE) peroxis ome proliferator 
response element.
1 .3 .1 .2  Ligand binding
Classically PPARs are activated upon binding of a ligand to the LBD. 
Following this, PPARs heterodimerise with the retinoid X receptor (RXR). Like 
PPARs, RXR exists as three distinct isoforms: RXRa, p, and y, all of which are 
activated by the endogenous agonist 9-c/s retinoic acid (Mangelsdorf et a!.,
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1992), however the specific roles of these different isoforms of the 
PPAR: RXR complex have not yet been elucidated. The PPAR: RXR 
heterodimer binds to PPREs (Figure 1.7). PPREs are direct repeat elements 
consisting of two 6-base-pair consensus sequences (AGGTCA) separated by 
a single nucleotide spacer.
r
Figure 1.7 Mechanism of PPAR activation via ligand binding. Once activated the PPAR:RXR 
heterodimer translocates to the nucleus where it binds to the PPRE. Co-activators are also 
recruited leading to the regulation of gene transcription downstream. (RXR), retinoic acid 
receptor, (RA) retinoic acid, (PPRE) PPAR response element.
PPARs also recruit co-activators which are required for the successful 
increase in gene transcription; among these are also CBP/p300 and PGC-1. 
Co-activators such as CBP/p300 and steroid receptor co-activator (S R C )-l
PPAR RXR cytoplasm
co-activ
r->gene transcription
nucleus
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possess histone acetylase activity able to remodel chromatin structure. 
Another set of co-activators, including members of the DRIP/TRAP complex 
such as PPAR binding protein (PBP)/TRAP220), form a bridge between the 
nuclear receptor and the transcription initiation machinery (reviewed in 
Berger and Moller, 2002). The exact role of a third group of co-activators, 
which includes PGC-1, RIP140, and ARA70, is not well understood at the 
molecular level. A possibility is tha t co-activators with histone acetylase 
activity bind to PPAR/RXR receptors bound to the PPRE. These then disrupt 
nucleosomes, and "unfold" the chromatin structure proximal to the 
regulatory region of a gene. DRIP/TRAP complexes are then recruited and 
provide a link to the basal transcription machinery. This eventually results in 
the initiation of transcription (Berger and Moller, 2002).
PPARs can be activated by a variety of different natural and synthetic ligands 
(Desvergne and Wahli, 1999). Long-chain polyunsaturated fa tty  acids and 
the ir lipo-oxygenase derived metabolite, leukotriene B4, are the natural 
ligands for PPARa, whereas hypolipidemic drugs from the fibrate family are 
specific synthetic ligands. Long-chain fa tty acids are also the endogenous 
ligands for PPARS, and there is evidence that PGI2 is also a ligand for this 
PPAR isoform (Forman et a\.t 1997). PPARy is activated by the natural 
ligands 15-Deoxy-A12,14- prostaglandin J2 (Forman et al., 1995) and 9- and 
13-hydroxyoctadecadienoic acid (Hampel et al., 2006) as well as the insulin- 
sensitizing drugs from the thiazolidinedione (TZD) family, such as 
rosiglitazone and troglitazone, which are potent pharmacological ligands 
(Lehmann e ta /., 1995; Murphy and Holder, 2000).
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1.3 .1 .3  Phosphorylation
In addition to their direct ligand binding activation, PPARs are substrates for 
several kinases activated by a variety of endogenous or exogenous signals. 
PPAR phosphorylation regulates its trans-activating function, in a ligand- 
dependent or independent manner according to the isoform and/or cellular 
context (reviewed in Diradourian e ta /., 2005).
Much of the literature on PPAR phosphorylation concentrates on PPARa. 
Treatment of hepatocytes with insulin has been shown to increase 
phosphorylation of this PPAR isoform. The extracellular signal-related kinase 
ERK-MAPK appears to be responsible for this phosphorylation (Shalev e t a/., 
1996). In addition, in vitro kinase assays have demonstrated tha t p38 MAPK 
phosphorylates serine residues located within the A/B domain of PPARa 
(Barger et a/., 2001) and calcium-dependent protein kinase (PKC) a and (311 
can phosphorylate the serine residues 179 and 230 and increase PPARa 
transcriptional activity in human liver cells (Blanquart e ta /., 2004).
Of major interest to this project is the ability of PKA to phosphorylate PPARs. 
Lazennec and colleagues (Lazennec e t a/., 2000) have shown that activated 
PKA results in the phosphorylation of all PPARs including PPARy and this 
event was reversible using the PKA antagonist, H-89. Looking specifically at 
PPARa these investigators have shown that PKA-dependent phosphorylation 
enhances PPAR activity both in the absence and presence of exogenous 
ligands.
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1.3 .2 PPARy
PPARy plays a key role in the differentiation of adipocytes (Oberfield et at.,
1999). Interestingly there is evidence showing that carbacyclin too promotes 
term inal differentiation of preadipose cells from clonal lines and enhances 
differentiation of adipose precursor cells from murine or human adipose 
tissue (Negrel et al., 1989; Vassaux et at., 1992). The transcription factors 
C/EBPP and C/EBP5 are critical for the differentiation of adipocytes and it 
has been demonstrated that the increase in cAMP levels caused by IP 
receptor activation is necessary and sufficient to up-regulate the rapid 
expression of these factors (Aubert et al; 2000).
Thiazolidinediones such as pioglitazone, troglitazone and rosiglitazone are all 
potent PPARy ligands and are on the market as treatm ent for type I I  
diabetes (reviewed in Meriden, 2004). Troglitazone however, was withdrawn 
due to hepatotoxic effects. They have been shown to decrease blood 
pressure in hypertensive rat models (Dubey et al., 1993) as well as inhibit 
neointimal formation of balloon-injured vessels in rats (Law et at., 1996). 
The latter may be a result o f suppression of the mitogen activated protein 
kinase (MAPK) pathway (Goetze et at., 1999) and inhibition of proliferation 
and migration of vascular smooth muscle cells by these ligands (Law et al.,
1996).
Thiazolidinediones have been reported to have both PPARy dependent and 
independent effects. For example, troglitazone has been reported to 
decrease matrix metalloproteinase 9 (MMP9), the effect being mimicked by 
15d-PGJ2 suggesting involvement of PPARy (Marx et al., 1998). 
Interestingly, iloprost also has been shown to attenuate MMP-9 expression in
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PASMC (Growcott et al., 2006). However, iNOS mRNA expression can be 
induced by troglitazone and not 15d-PGJ2 (Hattori et al., 1999), highiighting 
potential PPARy independent effects of this drug. The different effects of 
these two drugs may be explained possibly by their ability to recruit different 
PPARy co-activators. The latter effects of troglitazone may be mediated in 
part through a-tocopherol (Law e t al., 2000). Because rosiglitazone lacks a- 
tocopherol, it is thought to be a more 'pure' ligand than the other 
thiazolidinediones and its vascular effects are likely to be mediated 
exclusively through PPARy.
1.3.2.1 PPARy and cell proliferation
There is a growing body of evidence for PPARy mediating inhibition of cell 
proliferation. The PGJ2 metabolite, 15-deoxy-A1214-PGJ2, a PPARy ligand 
(Forman et al., 1995; Kliewer e t al., 1995), as well as rosiglitazone, both 
strongly inhibit vascular smooth muscle cell proliferation (Sasaguri et al., 
1992; Ward e t al., 2004). Interestingly they induce Gi arrest like PGI2 and 
its stable analogues. This arrest is thought to be retinoblastoma (Rb)- 
dependent given that in the absence of Rb, activation of PPARy results in 
cells accumulating in the G^M phase of the cell cycle, endo-reduplicating 
and undergoing apoptosis (Fajas et al., 2003). 15d-PGJ2 has also been 
shown to inhibit cyclin D1 expression and stimulate expression of the CDKI 
p21Cipl (Miwa et al., 2000). p21c,pl is normally induced by several 
physiological stimuli that inhibit cell proliferation such as TGF(3 and NO 
(Ishida et al., 1997; Ishida e t al., 1999). In addition both troglitazone and 
rosiglitazone attenuated mitogen induced degradation of p27Kipl, a CDKI 
which negatively regulates growth in a variety of cell types including
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vascular smooth muscle cells, thus inhibiting cyclin-cdk activity and 
phosphorylation of Rb causing Gi arrest (Sherr and Roberts, 1999).
Activation of PPARy by both troglitazone and 15d-PGJ2 can suppress 
thromboxane synthase gene transcription in macrophages (Ikeda et al.,
2000) as well as inhibiting thromboxane synthase mRNA expression and 
thromboxane-mediated cell growth in vascular smooth muscle cells 
(Sugawara et al., 2002). I t  is thought that this effect of PPARy is not 
achieved through binding to PPRE, but rather via a protein-protein 
interaction with the transcription activator protein S p l (Sugawara et al.,
2002). Also of interest is rosiglitazone's ability to increase prostanoid (PGD2 
and PGE2) production in rat vascular smooth muscle cells at the level of 
both COX-2 expression and prostanoid formation (Bishop-Bailey and 
Warner, 2003). Moreover 15d-PGJ2 activation of PPARy induces endothelial 
cell apoptosis (Bishop-Bailey and Hla, 1999) and lack of PPARy expression, 
via stable transfection of a dominant-negative PPARy construct, inhibits 
apoptosis and facilitates cell growth and angiogenesis (Ameshima et al.,
2003).
Thiazolidinediones are also being tested as anticancer agents. There is 
however, controversy concerning the role of PPARy in cancer. The anticancer 
evidence includes in vitro and in vivo studies suggesting inhibition of 
proliferation and differentiation (Sarraf et al., 1998). In addition, enhanced 
PPARy signalling has also been shown to restrain breast cancer (Suh et al.,
1999) and naturally occurring somatic mutations in the PPARy gene have 
been reported in colorectal carcinomas (Sarraf et al., 1999). Against this, 
there is evidence showing tum or promoting activity of PPARy ligands in
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mouse models of cancer (Lefebvre et al.r 1998; Saez et al., 1998) as well as 
evidence suggesting that the anticancer effects of these agents are 
independent of PPARy (Palakurthi et a!., 2001). This may highlight the 
importance of cell or tissue type in determining the eventual cellular effects 
of PPARy activation.
Of major interest, is the apparent down-regulation of PPARy in patients with 
IPAH (Ameshima et al., 2003). Microarray gene expression screening has 
shown a decrease in PPARy transcripts in random lung tissue samples from 
IPAH patients (Geraci e ta /., 2001). PPARy is normally abundantly expressed 
in human lung tissue especially in the endothelial cells. This expression was 
reduced or lacking in all angiogenic plexiform lesions of the pulmonary 
hypertensive lung as well as in the vascular lesions of a severe pulmonary 
hypertension rat model (Taraseviciene-Stewart e ta /., 2001).
1.3 .3 PPAR5
Unlike PPARy, PPARS is generally considered a stimulator of proliferation in a 
variety of cell types. The PPARS agonist, GW501516 can stimulate 
proliferation of human breast and prostate cancer cell lines as well as 
increasing intestinal polyp growth (Stephen et al., 2004). Moreover, this 
increase in cell proliferation was mainly observed in the absence of serum. 
GW501516 also prevented apoptosis stimulated by complete growth factor 
removal in colorectal cancer cell lines and this response was absent in cells 
lacking PPARS (Stephen e t al., 2004). With regards to the vasculature, 
PPARS has been shown to be up-regulated in vascular lesion formation and 
over-expression of this PPAR isoform in VSMC causes post-confluent cell 
proliferation by increasing both cyclin A and CDK2 as well as decreasing p57
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(Zhang et al., 2002). PPARS activation appears to increase the expression of 
vascular endothelial growth factor (VEGF) in macrophages and VSMC 
(Bamba et al., 2000; Yamakawa et al., 2000) as well as enhancing COX-2 
gene expression and increasing the proliferation of human hepatocellular 
carcinoma cells (Glinghammar et al., 2003).
However there is also evidence supporting a pro-apoptotic role for PPARS. 
Hatae and colleagues (Hatae et al., 2001) even suggest that the apoptotic 
effects of prostacyclin are mediated by PPARS. They showed that they could 
increase apoptosis in HEK-293 cells by over-expressing PGIS and tha t this 
effect was a result of endogenous PPARS activation. In addition, Ali and 
colleagues (Ali et al., 2006) suggest a role for PPARS in mediating the 
antiproliferative effects of treprostinil in lung fibroblasts. However the 
authors of this study could only observe a small activation of PPARS (in HEK- 
293 cells overexpressing this PPAR isoform) and this only occurred with high 
concentrations of treprostinil (30 pM or more). In addition they did not have 
an internal control for their PPARS reporter gene assays. Furthermore, 
although treprostinil (100 pM) was marginally more potent in w ild-type mice 
it was still able to inhibit proliferation in PPARS knockout mice.
1.3.4 PPARa
PPARa is an important lipid sensor and regulator of the cellular energy- 
harvesting metabolism. I t  has been shown to play a key role in the 
regulation of cellular uptake, activation and (3-oxidation of fa tty  acids 
(reviewed in Berger and Moller, 2002). PPARa has been shown to up- 
regulate the expression of the fa tty acid transport protein (Martin et al.,
1997), a protein that transports fa tty acids across the cell membrane. PPARa
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is also thought to be involved in the transcription of long chain fa tty  acid 
acetyl-CoA synthase (Schoonjans et al., 1996), ACO (Dreyer et al., 1992), 
enoyl-CoA hydratase/dehydrogenase multifunctional enzyme (Marcus et at.,
1993) and keto-acyl-CoA thiolase (Zhang et al., 1993), enzymes in the 
peroxisomal (3-oxidation pathway.
PPARa has been a target for treatm ent of dyslipidemia and atherosclerosis. 
Fibrates, the main PPARa agonists, have substantial triglyceride lowering 
effects as well as modest HDL-raising efficacy (reviewed in Linton and Fazio,
2000). The mechanism by which PPARa lowers triglycerides is likely to 
include the suppression of hepatic apo-CIII gene expression while also 
stimulating LPL gene expression (Schoonjans et al., 1996; Blanquart et al.,
2004). In addition, PPARa agonists also appear to have anti-inflam m atory 
effects, particularly in VSMC (Devchand et al., 1996; Chinetti et al., 2001).
Novel data shows that PPARa may also have a role in controlling smooth 
muscle proliferation. Gizard and colleagues (Gizard et al., 2005) have shown 
tha t the PPARa agonist, GW7647, inhibits proliferation of VSMC by 
controlling cell cycle progression into the S phase, similar to what has been 
demonstrated with PPARy activation. PPARa appears to cause Gi phase 
arrest by inducing the cell-cycle regulator and tum or suppressor gene p l6 . 
Although there is emerging data on the anti-proliferative effects of PPARS 
(Ali et al., 2006) and PPARa (Gizard et al., 2005), the greatest body of 
evidence still concentrates PPARy as the main regulator of VSMC 
proliferation.
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1.4 Thesis aims
The main aim of the present study is to improve our understanding of the 
mechanism(s) by which PGI2 analogues inhibit cell proliferation and to 
address the role of the IP receptor in mediating these effects.
In order to elucidate the importance of the IP receptor, a stable HEK-293 cell 
line expressing this receptor was used to examine the effects of i) PGI2 
analogues and ii) the antagonists of various transduction components in the 
signalling pathway, on cell proliferation and cAMP production.
Because there is evidence in the literature that PKA can phosphorylate and 
activate PPARy (Lazennec et al., 2000) and that some PGI2 analogues can 
also directly bind to PPARa and PPARS (Forman et al., 1997), we 
hypothesised that PGI2 analogues would also activate PPARy and that this 
pathway would contribute to their anti-proliferative effects. Using a specific 
PPARy reporter gene assay, we sought to determine whether PPARy could be 
a downstream signalling component of the IP receptor pathway or act as an 
alternative intracellular target for PGI2 analogues (Figure 1.8).
Finally, we sought to establish the role of the IP receptor in native human 
PASMC and compared the signalling mechanism observed in cells from 
'control' patients to those derived from IPAH patients. Because of the faster 
rate of proliferation observed in IPAH versus control PASMC and in light of 
results obtained from the HEK-293-IP stable line we hypothesised that IPAH 
PASMC may lack or have down-regulated IP receptor expression. We sought 
to investigate whether this was true and whether PGI2 analogues could still 
inhibit their proliferation.
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Figure 1.8 Potential pathways mediating the anti-proliferative effects of PGI2 analogues. 
PPARKmay be activated directly by cell permeable analogues or be a downstream target 
for PKA. (PGI2) prostacyclin, (IP) prostacyclin receptor, (AC) adenylyl cyclase, (PKA) 
proein kinase A, (cdk) cyclin dependent kinase, (CREB) cAMP response element binding 
protein, (MAPK) mitogen activated protein kinase, (PI3K) phosphoinositide-3 kinase.
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2. Materials and experimental protocols
The main focus of the present study was to investigate the role of the IP 
receptor in the anti-proliferative properties of PGI2 analogues and to 
elucidate the signalling pathway downstream of receptor activation. This 
was assessed firstly in a newly established HEK-293 cell model stably 
expressing the IP receptor, or the control empty vector, as well as in native 
human pulmonary artery smooth muscle cells isolated from the lungs of 
IPAH or control patients.
Expression and localisation of the IP receptor in the various cell types was 
explored by RT-PCR, using especially designed primers, and 
immunofluorescent staining, using a novel IP-receptor specific antibody 
designed during this project. Functionality of the receptor was tested by 
measuring increases in intracellular cAMP upon stimulation with the PGI2 
analogue treprostinil with an ELISA-like assay.
To assess the proliferative response of cells to PGI2 analogues a simple yet 
strong and reproducible proliferation assay was optimised using an 
automated cell counter. Various antagonists and other pharmacological 
tools were used in this assay to dissect potential signalling pathways, 
including the novel IP receptor antagonist R01138452 developed by Roche 
(Palo Alto, California) (Bley et a l., 2006). To test the hypothesis of a 
potential role for PPARy in the PGI2 signalling pathway a dual reporter 
luciferase assay was optimised to measure PPARy activation and to take 
into account the non-specific effects of our drugs of interest on full length 
promoters present in many commercially available luciferase plasmid 
constructs. The protocol was used extensively to attempt to dissect the
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mechanism of activation of this nuclear receptor. The present chapter 
outlines more specifically all the assays, techniques and tools used in all the 
experiments contributing to this thesis as detailed above.
2 .2  Cell cu ltu re
2.2.1 General Features
The cells used in this project were principally HEK-293 cells, an 
immortalised cell line of human origin derived from primary embryonic 
kidney cells transformed by exposure to sheared adenovirus DNA 
(adenovirus type 5)(Graham et al., 1977). Their morphology is markedly 
epithelioid and they tend to continue dividing even after confluence is 
reached. A stable HEK-293 line expressing the IP receptor gene was 
established by Prof. Andrew Tinker at UCL and was used extensively in this 
project. These cells were generated by transfecting in a eukaryotic 
expression vector, pcDNA3.1/Zeo (Invitrogen, Paisley, UK), into which the 
human IP receptor gene was cloned. HEK-293 cells stably transfected with 
pcDNA3.1Zeo were generated as a control.
Human pulmonary artery smooth muscle (HPASM) cells were also used 
extensively in the project. Cells originated from the distal pulmonary 
arteries of the explanted lungs of 3 children suffering from IPAH who 
underwent lung or heart/lung transplantation and adult ('contror) samples 
were obtained at lobectomy for bronchial carcinoma and lung 
transplantation from 3 patients with normal pulmonary arteries (Female, 54 
years, lobectomy; Male, 51 years, lung transplant for emphysema; Male, 57 
years, lung transplant for emphysema; courtesy of Dr. John Wharton,
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Imperial College London; ethical approval, Brompton Harefield & NHLI REC 
01-210).
2 .2 .2  Stable transfection o f HEK 293 cells
A suspension of HEK-293 cells was transfected with pcDNA3.1/Zeo using 
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's 
instructions. Briefly, 2 pg of DNA was mixed with 250 pi of OptiMEM 
(Invitrogen) and 2.5 pi of Lipofectamine 2000 was mixed with another 
250pl of OptiMEM. Both were incubated for 5 mins at room temperature 
prior to mixing the two together and incubating for a further 20 mins at 
room temperature. 400 pi o f the DNA/Lipofectamine mixture was added to 
2 ml of cells at a concentration of 1.3 x 106 per ml and mixed gently by 
pipetting followed by gentle shaking for 10 minutes. Transfected cells were 
then plated onto 6 well plates containing MEM (Invitrogen) + 10% FBS and 
no antibiotics. One 6-well plate would contain untransfected cells as a 
control. 48 hours post transfection, the media was replaced with media 
containing 400 pg/ml of zeocin to select for transfected cells. Following 
approximately one week of culture in the selective medium, individual 
zeocin resistant colonies were isolated using a sterile thin tipped cotton bud 
and transferred to 96 well plates for eventual expansion to T-75 flasks.
2 .2 .3  Isolation and characterisation o f human peripheral pulmonary  
arteria l smooth muscle cells (PASMC)
Three children suffering from IPAH had a bilateral lung or heart/lung 
transplant and the explanted lungs were taken with parental consent and 
local ethical permission (REC# 05/Q0508/45) and used for isolation of
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pulmonary arterial smooth muscle cells. The children were 1) (IPAH 1; 
1664) male aged 7 years 2) (IPAH 2; 1666) female aged 5 years and 3) 
(IPAH 3; 1672) male aged 5 years. All three had been receiving a 
continuous intravenous infusion of epoprostenol for 2 years combined with 
bosentan for more than 1 year. Lungs were obtained immediately after 
transplantation and bathed in ice cold PBS during dissection. Several 
peripheral pulmonary arteries were dissected away from the peripheral 
airway tree in one lower lobe and the adherent lung parenchyma and the 
adventitial layers were removed. 8-10 terminal branches were taken, each 
having an external diameter of approximately 250 pm. These arteries were 
collected into phosphate buffered saline (PBS) (Sigma) containing penicillin 
(300 pg/m l), streptomycin (300pg/m l) and gentamycin (180 pg/m l) where 
they remained for 45 mins at 4°C. They were then dissociated by incubation 
in a protease cocktail, containing elastase (Lome Laboratories, Reading, UK) 
0.125 m g/m l, collagenase (Sigma) 0.25mg/m l, trypsin inhibitor (Sigma) 
0.06 m g/m l, bovine serum albumin 3.75 mg/ml and MEM vitamins 2.5pl/m l 
dissolved in DMEM/F12 buffered with HEPES and NaHC03 at 37°C, with 
continuous agitation for 30-45 mins. Dissociation was stopped by addition of 
growth medium (DMEM/F12 + 10% foetal bovine serum & penicillin and 
streptomycin) and cells were pelleted by centrifugation at 350g. They were 
re-suspended in growth medium and plated into uncoated 25 cm2 flasks. In 
all the primary cultures the majority of cells settling and growing were 
fusiform and poorly spread with lamellipodia at both leading and trailing 
edges. Colonies of epithelioid cells were only seen in primary cultures. Cells 
were maintained in growth medium. At passage 1 and all later passages the 
cells grew rapidly and formed dense multilayered sheets of weakly oriented
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fusiform cells that had a structure distinct from that of fibroblasts isolated 
from the adventitia of the proximal arteries of the same lung. Further 
characterisation of the PASM cells was carried out by immunohistochemical 
staining of confluent cell monolayers for smooth muscle-specific proteins, a- 
smooth muscle actin (clone 1A4, Sigma) and smooth muscle myosin heavy 
chain (MHC, clone SMemb, Yamasa Corp, Japan). In addition samples from 
each cell isolate were electrophoresed and blotted onto nitrocellulose then 
stained to show expression of a-smooth muscle actin, smooth muscle MHC 
(clone hSM-v, Sigma) and caldesmon (clone hHCD, Sigma). The isolation 
and characterisation of these PASM cells was carried out by Dr. Sue Hall, 
Institu te of Child Health, UCL.
2.2 .4  Cell maintenance and subculture
HEK-293 cells were grown in MEM containing Earle's salts and L-glutamine 
(Invitrogen, Paisley, UK) supplemented with 10% foetal bovine serum (FBS) 
(o f European origin; Invitrogen) and 1% Penicillin-Streptomycin (from a 
10,000 units/m l stock) (Invitrogen). IP receptor stable line cells were 
selected for by adding zeocin (400pg/m l) (Invitrogen) to the medium. 
DMEM/F12 1:1 with 10% FBS and penicillin/streptomycin media was used 
for smooth muscle cells. All cell types were kept at 37°C in a humidified 
incubator with 95% air and 5% C02. Cells grew as a monolayer on the 
surface of plastic tissue culture flasks (Sarstedt, Leicester, UK). All work 
with live cells was carried out under sterile conditions in a laminar flow 
tissue culture hood, using sterile and autoclaved equipment.
Cells were typically sub-cultured when they became 80-90% confluent. The 
medium was aspirated off, cells were washed with Ca2+ and Mg2+ free
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phosphate buffered saline (PBS) (Invitrogen) warmed at 37 °C removed and 
then treated with enough IX  trypsin/EDTA (0.05%  trypsin, 0.53 mM 
EDTA*4Na; Invitrogen) to cover the flask for 1-2 mins. When all cells were 
dislodged, an excess of media containing FBS was added to neutralize 
trypsin. Cells were pelleted by centrifugation at 300 g for 5 mins at 25 °C 
and re-suspended in fresh medium at an approximate density of 1-2 x 106 
cells/ml. Cells were then plated in new sterile culture flasks in a ratio 
ranging from 1:10-1:15 (or as required by protocol) by dilution in fresh 
medium.
HEK-293 cells were utilised for experimental procedures between passages 
4 and 12. HPASM cells were utilised between passages 6 and 10.
2 .2 .5  Freezing down and reviving cell lines
I f  cells needed to be stored over a long period of time they were frozen 
down and cryo-preserved in liquid nitrogen. This was done by dislodging the 
cells from the flask with trypsin and pelletting them. They were then re­
suspended in MEM containing 10% FBS, 1% Pen/Strep and 10% DMSO, 
aliquoted in 1 ml cryovials (5 aliquots were obtained from a confluent T-75 
flask) and quickly chilled on ice. Subsequently they were kept at 4 °C, -20 
°C and -80 °C for 20 mins at each temperature in order tha t the cells 
should freeze down gradually before being placed in a liquid nitrogen cell 
bank. To revive cells from their frozen state, they were de-frosted in a 37 
°C water bath and immediately re-suspended in 5 ml of fresh medium and 
plated in a T-25 flask. After 24 hr cells were washed with PBS to remove all 
traces of DMSO and the media replaced. Cells were then cultured as normal.
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2.3 Sem i-quantitative reverse transcriptase polymerase chain 
reaction (RT-PCR)
2.3.1 Total RNA isolation from mammalian cells
Total RNA isolation from cultured cells was achieved using an RNeasy Mini 
kit (Qiagen, Crawley, UK). Cells from a confluent T75 culture flask were 
washed with PBS then harvested by treatm ent with trypsin/EDTA for 2 
mins, pelleted by centrifugation at 300g for 5 mins and the supernatant 
removed. Cells were disrupted and re-suspended in 600 pi of lysis buffer 
RLT containing 6pl p-mercaptoethanol. The sample was then homogenised 
thoroughly before adding 600 pi of 70% ethanol. 600 pi of the sample was 
then applied to an RNeasy mini column, centrifuged for 30 seconds at 
16000 g and the flow-through discarded. This step was repeated with the 
remaining 600 pi of lysate. Following this, 700 pi of wash buffer RW1 was 
applied to the column, centrifuged for 30 s and again the flow-through was 
discarded. The column was washed twice with 500 pi of buffer RPE, once for 
15 s and then for 2 mins. The column was finally transferred to a sterile 
1.5ml Eppendorf and the RNA eluted with 25-50 pi of molecular biology 
grade water.
2.3 .2 Measurement o f DNA and RNA concentration
The concentration of purified DNA and RNA was measured by recording 
absorbance at 260 nm of a 1 ml solution of molecular biology grade water 
containing between 2 and 10 pi of RNA or DNA obtained from the final 25pl- 
50pl elution in the previous step (~0.05-0.2 pg) in a spectrophotometer 
(Cecil CE2041; Cecil Instruments, Cambridge, UK) using a quartz cuvette.
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Before measuring the samples the spectrophotometer was zeroed using 
water alone. Using the relationship of 1 absorbance unit = 50 pg/m l of 
double stranded DNA or 40 pg/ml of RNA, and taking into account the 
dilution factor, the amount of DNA or RNA could be calculated. All RNA and 
DNA preparations were re-dissolved in molecular biology grade water or 
endotoxin free buffer TE (Qiagen) and stored at -20  °C when not in use.
2 .3 .3  Forward strand cDNA synthesis using SuperScript™ II reverse 
transcriptase
DNA polymerase SuperScript™II reverse transcriptase (RT) (Invitrogen) 
was used to synthesise the complementary DNA strand from the total RNA 
isolated from cells. This is a point mutant of Moloney murine leukaemia 
virus RT which produces higher cDNA yields by eliminating RNase H activity. 
5 pg of total RNA was used as a template, 250 ng of random primers and 1 
pi of dNTP mix from a 10 mM stock were added and the volume was made 
up to 12 pi with molecular biology grade water. The mixture was heated to 
65 °C for 5 mins and then quickly chilled on ice. 4 pi of 5X first-strand 
buffer (250 mM Tris-HCI pH8.3, 375 mM KCI, 15 mM MgCI2) and 2 pi of 0.1 
mM dithiothreitol (DTT) were then added and incubated at 42 °C for 2 mins 
prior to addition of 1 pi of SuperScript™II RT. The reaction was then 
incubated at 25 °C for 10 mins followed by 50 mins at 42 °C which allows 
the RT to work optimally. Finally the reaction was inactivated by heating at 
70 °C for 15 mins.
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2.3 .4  Polymerase chain reaction
The polymerase chain reaction allows amplification of a target segment of 
DNA by up to a billion fold by design of apposite oligonucleotide primers 
complementary to the nucleotide sequence flanking both ends o f the DNA 
sequence. Suitable primers were designed using OLIGO™ software tha t will 
work out an oligunucleotide sequence of approximately the right length, 
with an appropriate GC content and will also suggest an optimal annealing 
temperature. PCR requires unique DNA polymerase enzymes that are stable 
at very high temperatures (e.g. Taq polymerase, isolated from thermophile 
bacteria).
PCR can be summarised into three steps: 1) denaturation; the double 
stranded DNA template is separated at a temperature of 95 °C 2) 
annealing; an optimal temperature around 55 °C allows hybridisation of 
primers to the DNA template and finally 3) DNA synthesis; the DNA 
polymerase 'elongates' the primer using the dNTPs provided in the reaction 
mixture to synthesise the complementary strand of the template 
downstream of the primers. This cycle is usually repeated between 25 and 
35 times resulting in exponential amplification of the required DNA 
sequence flanked by the oligonucleotide primers.
In this project Taq polymerase was used together with "Thermopol" buffer 
(20 mM Tris-HCI, 10 mM (NH4)2S04, 10 mM KCI, 2 mM MgS04, 0.1% 
Triton® X-100 pH 8.8) provided by the supplier or in some reactions the 
optimal concentration of Mg2+ was adjusted using a stock solution of MgCI2. 
dNTPs were supplied as 100 mM stock solutions and were mixed in a 
1:1 :1 :1  (dATP, dGTP, dCTP, dTTP) ratio to give a final concentration of 25
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mM for each dNTP. Primers were synthesised commercially by Sigma- 
Genosys (Pampisford, UK) and dispatched as desiccated stocks. These were 
dissolved in molecular biology grade water to obtain a final concentration of 
100 pmol/pl and the volume used was adjusted according to the 
concentration of oligonucleotide DNA used. Reactions were carried out in 
0.2 ml eppendorf tubes placed in a Peltier thermal cycler (DNA Engine 
Dyad®, MJ Research, Waltham, USA) and run following an appropriate 
cycling protocol.
2 .3 .5  RT-PCR o f human IP  receptor in cultured cells
To determine the presence or absence of RNA message for the human IP 
receptor in the various cell lines used in these studies, we performed PCR, 
using IP receptor specific primers, on cDNA synthesised from the total RNA 
isolated from these cells. Negative controls were carried out both by 
performing the RT step in the absence of superscript I I  RT as well as 
performing the PCR step in the absence of cDNA. Primers were designed to 
span across two exons (so as to be able to exclude the amplification of any 
genomic DNA which may be a contaminant in the cDNA preparation) and 
amplified a 204 bp fragment of the IP receptor. Primers were also designed 
to amplify a 363 bp sequence of the human Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene, a house keeping gene used as an internal 
control.
DNA sequences of primers:
Human IP receptor, accession id: NM_000960.3
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Forward 5' ATGTACCGCCAGCAGAAGCG 3'
Reverse 5' GAAGCGGAAGGCAAGGAGCTC 3'
Human GAPDH, accession id: NM_002046
Forward 5' AAGGTGAAGGTCGGAGTCAACG 3'
Reverse 5' GGCAG AG AT GAT G ACCCI I I IG 3'
PCR was carried out using the following cycling protocol with both sets of 
primers: 1.) 95 °C for 4 mins 2) 95°C for 30 s 3) 60 °C for 30 s 4) 72 °C for 
30 s 5) 72°C for 10 mins 6) 4 °C. Steps 2, 3 and 4 were repeated 30 times. 
Products of the PCR reaction were loaded onto a 1.5% agarose gel following 
addition of DNA loading buffer (5:1 ratio) to facilitate the loading of samples 
into the wells. A 100 base-pair (bp) DNA ladder was also loaded onto the 
gel in order to assess the size of the PCR products. Gels were prepared by 
dissolving 1.5 g of agarose (Sigma Aldrich, Poole, UK) in 100 ml of IX  Tris 
acetate EDTA (TAE). The solution was heated at full power in a microwave 
and allowed to cool slightly before the addition of 10 pi (100 pg) of the 
fluorescent intercalating dye ethidium bromide needed to visualise DNA 
bands. The gel was allowed to set in a slab configuration with the insertion 
of a plastic comb to generate wells for DNA loading. Prior to running, the gel 
was placed in an electrophoresis tank filled with fresh IX  TAE buffer and 
allowed to equilibrate. An electrophoresis voltage of 100 V was applied 
across the electrodes of the tank. The movement of the tracker dyes, 
bromophenol blue and xylene cyanol contained in the DNA loading buffer 
was used to judge sample migration distance. Once samples had migrated 
an appropriate distance, gels were viewed under ultra-violet (UV) light
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(312nm wavelength) using a dual intensity transillum inator (UVP Inc., 
Upland, California) equipped with a digital video camera set up to acquire, 
import and print photographs of the gel. The appropriate bands were 
excised from the gel and the DNA was extracted and purified using a Qiaex 
I I  gel extraction kit (Qiagen, Crawley, UK) before being sent to Cytomix 
(Cambridge, UK) for sequencing. Briefly gel sections were weighed and 
incubated for 10 mins with 3 volumes of QX1 buffer and 10 pi of QIAEX II  at 
50 °C. This allowed the agarose gel to dissolve while the nucleic acids were 
adsorbed onto the Qiaex I I  silica-gel particles. Samples were centrifuged for 
30 s and the supernatant removed. The pellet was washed in QX1 buffer 
once and PE buffer twice before being left to air-dry completely. The pellet 
was then resuspended in 20 pi molecular biology grade water, incubated at 
room temperature for 5 mins then centrifuged. The supernatant containing 
purified DNA was quantified and sent for sequencing.
2.4 Determ ination of IP  receptor protein expression and localization  
using antibodies.
2 .4 .1  Design o f novel IP  anti peptide antibody.
When the project was started there was no good commercially available 
specific IP receptor antibody. The Cayman antibody became available in the 
autumn of 2004. In 1998, Komhoff et al had used a polyclonal antibody 
generated against a synthetic peptide representing the N-terminal 
extracellular loop of the IP receptor to localize the receptor in the kidney 
(referred to from now on as the N1 antibody). In order to provide us with a 
tool for investigating IP receptor protein expression and localisation, we 
developed a novel polyclonal IP receptor anti-peptide antibody as well as
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generating a stock of antibody raised against peptide sequence used by 
Komhoff and colleagues. Both the Cayman and the N1 antibodies were 
designed to recognise a peptide sequence within the extracellular N terminal 
tail of the IP receptor. The peptide sequence of the N1 antibody is 
RNLTYVRGSVGPAT, whereas the Cayman antibody targeted an overlapping 
sequence shifted to the N terminus (MADSCRNLTYVRGSVG). Because these 
antibodies were directed to the N-terminal, a C-terminal peptide sequence 
was used to generate a novel antibody (RRDPRAPSAVGKE, amino acids 329- 
343). Peptides corresponding to the amino acid sequences for the C l and 
N1 antibodies were synthesized and conjugated to haemocyanin before 
injection into rabbits using standard protocols (Eurogentec Seraing, 
Belgium). To ensure that the antibodies were specifically reacting with the 
peptide antigen it was necessary to affinity purify the antibodies present in 
the terminal bleed. This was achieved by immunoaffinity purification against 
the peptide antigen coupled to a solid support. Imm unoaffinity purification 
was carried out using the affigel gel-10 (Biorad, Hemel Hempstead, UK) by 
Ms Nuria Battle, a technician in the laboratory.
2 .4 .2  Immunofluorescent staining
Cells were cultured on 8 well Falcon™ slides (BD Biosciences, Oxford, UK) 
coated with a 0.01% (w /v) solution of poly-L-lysine (Sigma), washed briefly 
with PBS and fixed with 4% paraformaldehyde (Sigma) for 10 mins at 4 °C. 
Cells were washed again with PBS twice for 10 minutes at 4 °C prior to 
permeabilisation with 0.4% Triton X-100 (Sigma) for 20 mins at 4 °C. Cells 
were washed as before and incubated for 4 hr with an excess volume of 
blocking solution (2% (w /v) fraction V bovine serum albumin (Sigma), 5%
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(v /v ) goat serum (Sigma), 0.2% Triton X-100 (Sigma). During the blocking 
step anti-hIP antibodies (Cayman or personally designed) were prepared in 
PBS and centrifuged at 10,000 g for 5 mins at 4 °C to remove any 
aggregated material. To check for non-specific binding of the primary 
antibody, antibodies would be pre-incubated with the control peptide (4 
pg/pl of antibody) for three hr to allow for the antibody to bind to the 
peptide. 100 pi of primary antibody (±  control peptide) (1:100 dilution) was 
layered onto each well and incubated overnight in a moist chamber at 4 °C. 
Cells were washed with PBS four times for 15 mins at 4 °C and 100 pi of 
goat 488-conjugated anti-rabbit IgG, Alexa Fluor 488 (Invitrogen), together 
with a nuclear stain, TO-PRO-3 (Invitrogen), were applied (1:300 dilution) 
and incubated for 1 hr in a moist darkened chamber at room temperature. 
Cells were again washed in the dark, three times with PBS and once with 
distilled water to remove any residual salts. Slides were allowed to air-dry 
completely following the removal of the multi-chamber unit. Vectashield 
(Vector Laboratories Inc, Burlingame, USA), a non fluorescent anti-fade 
specialised mounting medium, was layered onto the slides before fixing 
cover slips in position with commercially available clear nail varnish. Slides 
were stored at -20  °C.
2.4 .3  Visualisation of immunostained cells
Slides were viewed and analysed at X60 magnification (water immersion 
lens) using a Bio-Rad Radiance 2000 laser scanning confocal head mounted 
on a Nikon TE1000 (Hemel Hempstead, UK). Green fluorescence of 
FITC/Alexa 488 and far red fluorescence of TO-PRO-3 were measured at an 
excitation/emission wavelength of 492/520 nm or 644/657 nm,
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respectively. Images of cells were taken at a focal plane taken from the 
middle of the cell of 0.1pm thickness. Images were studied using Bio-Rad 
LaserPix 4.0 software.
2.5 M easurem ent of cAMP levels
Cyclic AMP is thought to be the main second messenger mediator in the IP 
receptor signalling pathway. I t  is synthesized from ATP by membrane- 
bound adenylyl cyclase and is neutralized by hydrolysis to AMP by 
phosphodiesterases; therefore the concentration of cAMP in a cell is a 
function of the ratio of the rate of synthesis from ATP by adenylyl cyclase 
and its rate of breakdown to AMP by specific phosphodiesterases. Measuring 
cAMP was important in the present study to investigate receptor function 
and signalling.
2.5 .2  cAMP sample preparation and purification
Cells were grown to 70-80% confluence in 6 well plates then starved in low 
serum (0.1% ) medium for 48 hr. Media was then changed to one containing 
10% FBS ± treatm ent and cells were incubated for 30 mins. In the case of 
treatm ent with antagonists, cells were pre-treated for 1 hr with the 
antagonists prior to addition of treprostinil for 30 mins.
Media was then aspirated from the plates and these were washed once with 
PBS. 250 pi of 0.1M HCI (VWR international, Lutterworth, UK) was then 
added to each well and incubated for 20 mins at room temperature. Cells 
were scraped with a rubber policeman and further dissociated by pipetting 
up and down until the suspension was homogenous and transferred to an
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Eppendorf tube, centrifuged at lOOOg for 10 mins and the supernatant then 
decanted into a clean test tube.
2 .5 .2  Protein assay
In order to correct for total protein concentration in experiments, a 
standard colorimetric assay based on the Bradford assay (Bradford, 1976) 
was used on the cell extracts. An eight point standard curve (0 to 2 m g/m l) 
of bovine serum albumin (BSA, Invitrogen) was loaded in triplicate on a 
clear 96 well plate. Cell extracts were diluted sufficiently to ensure tha t the 
protein concentration was in the range of the standard curve and loaded in 
triplicate into separate wells. 25 pi of reagent A (Biorad) followed by 200 pi 
of reagent B were then added to each well. The plate was gently shaken for 
15 mins and the absorbance read at 690 nm in a GENios absorbance plate 
reader (TECAN, Reading, UK). Protein concentration of samples was 
calculated from the standard curve, by first subtracting the background 
reading from the blank, and then finally multiplying by the dilution factor of 
the sample.
2 .5 .3  cAMP enzyme linked immunoassay
To measure the cAMP levels in cell samples a competitive enzyme 
immunoassay was used (Cyclic AMP ACE EIA kit, Cayman Chemical, Ann 
Arbor, MI). This assay is based on competition between free cAMP and a 
cAMP-acetyl cholinesterase (AChE) conjugate (cAMP tracer) for a limited 
number of cAMP-specific rabbit antibody binding sites. Because the 
concentration of cAMP tracer is kept constant whereas the concentration of 
cAMP in the samples varies, the amount of cAMP tracer which binds to the
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antibody is inversely proportional to the concentration of cAMP in the 
sample. This antibody-cAMP (either free or tracer) complex binds to the 
mouse monoclonal anti-rabbit IgG that has been previously attached to the 
well. Once the plate has been washed to remove any unbound reagents the 
amount of cAMP in a sample can be quantified by developing the plate using 
Ellman's reagent which contains the substrate to AChE. This enzymatic 
reaction emits a yellow colour that absorbs strongly at 412 nm and 
subsequently can be determined spectrophotometrically. A summary of the 
protocol is shown in Figure 2.1. AChE has several advantages over other 
enzymes commonly used for enzyme immunoassays: it does not self 
inactivate during turnover which allows multiple development of the assay if 
accidentally spilled. In addition, it is highly stable under assay conditions 
and it is not inhibited by common buffer salts and preservatives.
Y = mouse monoclonal antibody
= blocking proteins 
S = Acetylcholinesterase linked to cAMP (tracer
V  = specific antibody to cAMP 
°  = Free cAMP
Y Y Y Y
Y Y Y Y
1. Plates are pre-coated 
with mouse monoclonal 
antibody and blocked 
with a formulation of 
proteins
2. Wells incubated with 
tracer, antiserum and 
either standard or 
unknown sample
3. Wells washed to 
remove all unbound 
reagents
4 . Wells developed 
with Ellman's
reagent
Figure 2.1. Schematic representation of the cAMP enzyme immuno linked assay. Adapted 
from Cayman Chemicals instruction manual.
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The assay was performed following manufacturer's instructions. Briefly, 
plates were set up to contain two blank (Blk) wells, two non-specific binding 
(NSB) wells, two maximum binding (B0) wells and an eight point standard 
curve run in duplicate. Each sample was also assayed in duplicate. Samples 
for the standard curve were prepared by serially diluting a provided stock 
solution of 3000 pmol/ml cAMP, and adding these to the appropriate wells. 
Cell samples to be tested were diluted to a final protein concentration of 
0.5mg/m l and added to the appropriate wells. Blank wells were left empty, 
all other wells were treated with 100 pi of EIA buffer followed by 50 pi of 
cAMP AChE tracer and 50pl of cAMP antiserum (apart from NSB wells where 
the latter was not added). The plate was covered and incubated for 18 
hours at 4°C. The plate was then washed 5 times with the provided wash 
buffer and developed by adding 200pl of Ellman's reagent to each well and 
left in the dark on an orbital shaker for 90 mins. The plate was read at a 
wavelength of 420 nm in a spectrophotometer (GENios, TECAN, Reading, 
UK). The results are expressed as %B/B0 (%  sample or standard bound/ 
maximum bound). This was calculated by subtracting the average value of 
the NSB wells from the average values of the B0 wells to produce the 
corrected B0 or corrected maximum binding. The absorbance value for 
samples and standards were also corrected by subtracting the NSB average, 
dividing by the corrected B0 and multiplying by 100. The cAMP 
concentration of the samples was determined by extrapolating the values 
from the standard curve of %B/B0 plotted against the cAMP concentration.
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2.6 Cell proliferation assays
To assess proliferation, cells were plated in 6 well plates at a density of 1 or 
2 x 104/m l, in 2 ml of media containing 10% FBS. Cells were allowed to 
grow for 24 hr before starving them in a low serum medium (0.1% ) or, in 
the case of HEK-293 WT, in media without serum. Cells were then kept in 
'starving' conditions for 48 hr. Subsequently cells were incubated for 48 hr 
in media containing either 10% FBS (±  treatm ent or solvent control) or 0- 
0.1% serum (control). The same batch of FBS was used for the m ajority of 
the experiments presented in this thesis to lim it the variability in terms of 
growth factor composition and concentration. The same media and plating 
cell density were used for those studies in which proliferative characteristics 
of the cells were directly compared. For this purpose cells were incubated 
with media containing 10% FBS and were counted at 24 hr intervals (±  
treatm ent). Samples were prepared for counting by washing the cells with 
PBS, dislodging them with 500 pi of trypsin/EDTA and re-suspending 
thoroughly with MEM containing 10% FBS in a total volume of 2 ml. 500 pi 
of cell suspension was diluted at a ratio of 1:10 in cell-pack diluent (Malvern 
Instruments Ltd, Malvern, UK) to give a total volume of 5 ml in the sample 
beaker. Cells were counted using an automated cell counter, Sysmex F- 
520P (Malvern Instruments Ltd, Malvern, UK) which uses a direct current 
electronic resistance method of particle counting and sizing. The particle- 
counting detector block on the instrument has a transducer with an 
aperture of 100 pm and an internal and external electrode (Figure 2.2). The 
cell pack diluent is electrically conductive and when the transducer and 
electrodes are immersed in it allows a constant direct current to flow 
between the internal and external electrodes. When a cell passes through
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the aperture during the counting process it decreases the flow of current, 
increasing the resistance between the electrodes. This resistance causes a 
voltage change between the electrodes proportional to the volume of the 
cell. These small voltage changes are detected and amplified by the 
instrument and electrical interference or artificial signals are eliminated by 
an electronic filte r circuit.
The particle size distribution analyzer, PDA-500, processes particle detection 
signals from the F-520P and works out particle counts and information on 
particle volume. These data are transferred to a PC which analyses volume 
information for each particle and will calculate and display particle 
distribution in terms of volume or diameter equivalent to volume as well as 
total count per ml. Figure 2.3 shows an example particle distribution 
analysis and cell count using this set-up. Here, HEK cells expressing the IP 
receptor are counted with no FBS, with FBS, and with FBS + UT-15.
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voltage
source
small voltage 
'appears across 
the electrodes
resistor
H'lH1
aperture
sample beaker
internal_
electrode
external
electrode
particles
transducer particles
suspension
Figure 2.2. Sysmex F-520P particle-counting detector block. Adapted from the Sysmex F- 
520P Operator’s manual
Particle distribution analysis allows the determination of dead or lysed cells 
as they are represented as a smaller peak ahead of the main peak on the 
distribution curve. PDA-500 allows you to reanalyse the curve to exclude 
counts from such peak (Figure 2 .4). Checks were performed to ensure the 
accuracy of our cell counter by recounting samples using a haemocytometer 
and trypan blue (0.4 % ; Invitrogen) exclusion, table 2.1 shows the direct 
comparison data for figure 2.3 obtained using the latter method.
This protocol was preferred to other methods used to measure cell 
proliferation, such as the tritium-labelled ( [ 3H]) thymidine incorporation and 
MTT yellow tetrazolium salt (MTT) assays due to its low cost and high 
throughput capabilities. It  is simple, requires little cell manipulation and has
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few protocol steps reducing the chances of experimental errors and 
not involve the handling of radio-active substances as is the case with 
thymidine incorporation assays.
does
[3H]-
INUMBER BAS El
[NUMBER BAS El
[NUMBER BASE!
Figure 2.3 Figure showing the particle distribution analysis of three example cell counts as 
achieved with the Sysmex F-520P and PDA500 set-up. A. HEK-293-IP cells grown in MEM 
containing 0.1% FBS. B. HEK-293-IP cells grown in MEM containing 10% FBS and C. HEK-293 IPr 
cells grown in MEM containing 10% FBS + 100nM treprostinil (UT). The total cell count per ml is 
highlighted in yellow on the right.
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Figure 2.4 Figure showing the determination of dead cells by the Sysmex F-520P and PDA 
500 system in a sample of distal human pulmonary artery cells grown in DMEM-F12 + 0.1% 
FBS. A. Presence of a smaller peak indicates a number of lysed and dead cells. B. PDA 
500 allows the reanalysis of the data to exclude the smaller peak and adjusts total cell 
count per ml (highlighted in yellow).
Treatment Meas. 1 2 3 4 5 Mean Diln. Adjusted Final Concn
- FBS 45 56 42 42 39 44.8 9.0 9.0 x 10A4
+ FBS 101 123 98 104 89 103.0 20.6 2.1 x 10A5
+ FBS + Trep 65 66 52 70 44 59.4 11.9 1.2 x 10A5
Table 2.1 Table showing results from counting cells from the same set of samples analysed in 
figure 2.3 using a haemocytometer. Cells were pelleted and reconstituted in 400 pi of media (5X 
concentrated) and the solution added inbetween the haemocytometer slide and the cover slip. 
Cells were counted from 5 separate quadrants (for the same sample) and the average was then 
adjusted to account for the re-concentration.
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2.7 PPARy ac tiva tion  re po rte r assays
2.7.1 Dual Luciferase R eporte r assay
Reporter genes have been used extensively to study gene expression and 
regulation in eukaryotic cells and are used as indicators of transcriptional 
activity. The luciferase reporter gene is not expressed endogenously and its 
presence is sensitively assayed for. Luciferase reporter plasmid vectors 
contain a modified coding sequence of the luciferase gene cloned from the 
firefly (Photinus pyralis). Firefly luciferase functions as a genetic reporter 
immediately upon translation and catalyses a reaction that releases a 
photon, the total amount of light emitted during a given time interval being 
proportional to reporter activity.
A dual reporter system involving simultaneous expression of the 
'experimental' reporter and a 'control reporter' in a single system was used 
to provide an internal control that serves as the baseline response. 
Normalising experimental reporter activity to the control reporter activity 
minimises experimental variability caused by differences in cell viability and
Firefly luciferase
Luciferin + ATP + O2 -► Oxyiuciferin + AMP + PPi + CO2 + Light
Mg2+
Renilla luciferase
Coelenterazine + O2 -► Coelenteramide + C02 + Light
Figure 2.5 Bioluminescent reactions catalysed by firefly and Renilla luciferases.
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transfection efficiency, non-specific effects on the promoter as well as 
differences in pipetting volumes, cell lysis efficiency and assay efficiency. 
Renilla luciferase activity (from the sea pansy Renilla reniformis) was used 
as our control reporter. Firefly and Renilla luciferases, because of their 
distinct evolutionary origins, have dissimilar enzyme structures and 
substrate requirements thus allowing to selectively discriminate between 
their respective bioluminescent reactions (Figure 2.5).
We found that treprostinil had a striking non-specific effect on the full 
length thymidine kinase promoter present in many commercially available 
vectors including the pTK-RL vector (Promega) commonly used in this type 
of study (Figure 2.6 A-B). Surprisingly, this was also observed with
i .  ■  t k >
untreated TREP 0-1— ^ ^ -
untreated TREP
■  B  ! ' W i
untreated  ROSI ^ _ 'untreated
Figure 2.6 The effects of treprostinil (TREP) and rosiglitazone (ROSI) on the full length 
thymidine kinase (TK) promoter contained in the pRL-TK vector (TREP, A; ROSI, B) or the 
minimal TK (mTK) promoter contained in the pMLUC-2 vector (TREP, C; ROSI, D). HEK- 
293-IP cells were transiently transfected with LFABP(DR1)4-TK-GL3 and either pRL-TK or 
pMLUC-2. Cells were stimulated after 48 hours with 10% FBS in the absence (untreated) 
or presence of TREP or ROSI (both 1 pM). Renilla luciferase activity was determined after 
24 hr. Results are expressed as mean fold increase in Renilla luciferase light units relative 
to untreated ± s.e.m. (n=12, 3 separate transfections), n.s. = non-significant, ** = P<0.01. 
~* = F< 0.001
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of study (Figure 2.6 A-B). Surprisingly, this was also observed with 
rosiglitazone albeit to a lesser extent. As such a minimal thymidine kinase 
promoter, a shortened version (120-140 bp) of the full length (716 bp) TK 
promoter with retained functionality, proved to be essential in plasmids 
used in our luciferase based reporter gene assays in order to minimise noise 
levels. Figure 2.6 (C-D) illustrates how using this latter type of promoter 
significantly reduced the occurrence of these non-specific effects to much 
lower, albeit still significantly different, levels.
2.7.2 Plasmids
A chimeric receptor containing the yeast GAL4 DNA binding domain fused to 
human PPARy was created by insertion of a GAL4 DNA binding domain 
encoding fragment into the mammalian expression vector pcDNA3 
(Invitrogen) to generate the vector GAL4-pcDNA3. The PPARy LBD fragment 
was digested with BamHI and Notl and ligated into the vector GAL4- 
pcDNA3, which had been digested with the same enzymes to generate 
GAL4-hPPARy-pcDNA3. The reporter plasmid for these GAL4 chimeric 
receptors (pGAL5TKpGL3) contains five repeats of the GAL4 response 
element (UAS) upstream of a minimal thymidine kinase in the pGL3 
luciferase expression vector (Promega, Southampton, UK). GAL4-pcDNA3, 
GAL4-hPPARy-pcDNA3 and pGAL5TKpGL3 were kindly provided by Professor 
Bart Staels (Pasteur Institute, Lille, France). The control vector, pMLuc2 
(Merck Biosciences, Nottingham, UK), contains the minimal thymidine 
kinase promoter adjacent to the Renilla luciferase gene. Figure 2.7 
summarises the vectors and their activities in the luciferase reporter gene 
assay.
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2 .7 .3  Transient transfections o f HEK-293 cells
Cells were co-transfected with pGAL5TKpGL3, pMLuc-2 and either GAL4- 
hPPARY-pcDNA3 or GAL4-pcDNA3 using Lipofectamine 2000 (Invitrogen). 
Lipofectamine 2000 was chosen over other lipofectamines because of its 
high efficiency, its ability to transfect cells in suspension and its efficacy in 
the presence of serum. We found that transfection of cells in suspension 
was necessary in order to achieve homogenous transfection efficiency 
throughout the 96 well plates thus further minimising variability caused by 
transfection efficiency and pipetting.
GAL 4-hPPARK-pcDNA3 GAL 4-pcDNA3
(Expression vector) (Control vector)
PPARk activation
GAL 4-PPARk 
fusion protein
pGAL5TKpGL3
(Reporter vector)
pMLuc-2 
(Internal control vector)
Figure 2.7 Schematics of vectors used in the dual luciferase reporter gene assay and their 
function. Cells were transfected with the reporter vector, pGAL5TKpGL3, the internal, 
control vector, pMLuc-2 and either the expression vector, GAL-4-hPPARy-pcDNA3 or the 
control vector GAL-4-pcDNA3. The expression vector generates a GAL-4-PPARy fusion 
protein that upon activation with a PPARy ligand binds to one of the 5 copies of the GAL4 
element on the reporter vector. This results in the production of firefly luciferase which can 
be detected and quantified. The internal control vector generates Renilla luciferase light 
which can be distinguished from firefly luciferase and is used to normalise the luciferase 
readings to control for transfection efficiency
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Cells were kept in suspension at a density of 1.2-1.3 x 106 cells/ml. A total 
of 3.6 pg of plasmid DNA (3 pg pGAL5TKpGL3, 300 ng pMLuc-2 and 300 ng 
GAL4-hPPARy-pcDNA3 or GAL4-pcDNA3) was dissolved into 400 pi of 
OptiMEM and 4 pi of Lipofectamine 2000 was dissolved in another 400 pi 
OptiMEM. Both were incubated at room temperature for 5 mins before 
mixing them together and incubating for a further 20 mins. Following this 
incubation, the lipofectamine mixture was added to 4 ml of the cell 
suspension and cells swirled for approximately 15 mins before plating out 
into 96 well plates. HEK-293 WT and IP-r cells were plated in 100 pl/well at 
a 1:20 and 1:10 dilution respectively. One column of wells was kept for 
untransfected cells to control for background luminescence.
2 .7 .4  M easurem ent o f repo rter activ ity
Cells were allowed to recover for 48 hr before the media was changed to 
MEM containing 10% FBS (±  drug). The assay measures luciferase
2 50 5 10 1 5 20 3 0
Untreated
treprostinil
Time (hours)
Figure 2.8 Time course of luciferase transcription. Cells were transfected with GAL4- 
hPPARY-pcDNA3, pGAL5TKpGL3 and pMLuc-2 and allowed to settle for 48 hours. Cells 
were then either left untreated or treated with 1pM treprostinil. Luciferase measured at 
several time points. Results are expressed as mean luciferase light units normalised to 
Renilla luciferase ± s.e.m. (n=4).
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expression cumulatively. Luciferase is a relatively stable compound and will 
not degrade readily once produced. Using this protocol allows transcriptional 
activation to be detected as early as 4 hr, with the signal peaking after 
about 24 hr (Figure 2.8).
Luciferase activity was therefore assayed at this time point, using either a 
Single or Dual Luciferase Assay kit (Promega) according to the 
manufacturer's instructions. Briefly cells were washed with PBS prior to 20 
mins incubation with 20 pl/well of 1 x passive lysis buffer (100 mM 
potassium phosphate [pH 7.8], 0.2% Triton X-100, 0.5 mM DTT). The cells 
in lysis buffer were then frozen down and thawed out for maximal lysis 
before re-plating at lOpl/well into an opaque 96 well plate suitable for use 
in the Tropix TR717 microplate luminometer (Applied Biosystems, 
Warrington, UK). After a 2 s delay, the light signal produced by luciferase 
was read for 10 s following the injection of 100 pi luciferase reagent 
(Promega). The light signal from the Renilla luciferase was then initiated by 
the injection of 100 pi of Stop & Glo™ reagent (Promega) and the signal 
was again read for 10 s after a 2 s delay.
2.8 Pharmacological reagents
Drugs were usually prepared under sterile conditions as lOmM or lOOmM 
stock solutions in DMSO or other appropriate solvents. Treprostinil 
(treprostinil sodium, remodulin) was provided as an aqueous solution of 0.6 
mg/ml and obtained from United Therapeutics (Washington, MD) and 
cicaprost was provided in a buffer (9.9 mM Tris, 152 mM NaCI and 176 mM 
ethanol) at a concentration of 0.5 mg/ml and obtained from Schering AG 
(Berlin, Germany). The IP receptor antagonist ROl 138452 was donated by
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Roche (Palo Alto, CA) and GW7647 by GlaxoSmithKline (Research Triangle 
Park, NC). Carbacyclin (carbaprostacyclin) and H-89 were purchased from 
Biomol (Exeter, UK), Rp-cAMPS from Biolog Life Science Institute (Bremen, 
Germany), rosiglitazone from Alexis Corporation (Lausanne, Switzerland), 
2'5'-dideoxyadenosine (DDA), pertussis toxin (PTx) and L165,041 from 
Merck Biosciences (Nottingham, UK), forskolin, 3-Isobutyl-l-m ethylxanth ine 
(IBMX), quercetin, wortmannin, adenine 9-p-D-arabinofuranoside (Ara-A) 
and 5-Aminoimidazole-4-carbaxamide 1-p-D-ribofuranoside (AICAR) from 
Sigma-Aldrich (Poole, UK).
2.9 Statistical analysis
All data are presented as mean ± s.e.m. of n observations. IC50 values were 
determined using the sigmoidal dose-response curve fitting routine in 
GraphPad Prism 4 (Graphpad Software Inc. w ww. graph pad. corrU using 
equation 2.1. For cell growth curves a variation of the sigmoidal dose 
response curve, the Boltzmann or Hill function was used to fit data. I t  allows 
for a bottom and top plateu and allows for a variable slope to better 
represent the lag phase of cell growth. For a single intervention between 
two groups an unpaired Student's t-test was performed. A t-tes t with 
Welch's correction was used if variances were significantly different between 
the two groups. For comparisons between 3 or more groups a one-way or 
two-way ANOVA test was used. Where appropriate a Bonferroni post-test 
correction for multiple comparisons was made. P values < 0.05 were 
considered to be statistically significant.
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Y =  -----------------------------
1 + io(L09lcso-x)
Equation 2.1 Equation used to fit a sigmoidal dose response curve. Ai= initial Y value, A2 
= final Y value, IC50, the concentration of an inhibitor that is required for 50% of the 
maximal inhibitory response.
A i  +  ( A 2 - A i )
Y —
i
1  +  1 0  Lo9EC50-X> 
V slope >
Equation 2.2 Boltzmann sigmoid equation used to fit proliferation curves. A: = initial Y 
value, A2 = final Y value, EC^ = response halfway between A1 and A2. ‘Slope’ describes the 
steepness of the curve.
2.10 Further s ta tis tica l considera tions
In the proliferation studies presented in this thesis data was normalised and 
expressed as percentage growth relative to the untreated control, i.e. the 
difference in the growth response between cells starved in 0 .1%  FBS and 
growing in 10% FBS. This was necessary in order to minimise the noise of 
intra-experimental growth variability. The untreated control was given the 
arbitrary value of 100%. It  was felt however that by attributing the value of 
100% with no standard error would have been misleading as we would not 
be accounting for the variation in control cell growth as well as errors 
resulting from cell counting measurements. By not possessing error bars
95
2. Materials and experimental protocols
the threshold for a treatm ent to be statistically significant would have been 
considerably lower. A solution was to extrapolate error bars for the control 
by dividing individual control values by the average for the control group. 
By doing this the average will always be 1 (or 100%) and all the individual 
normalised values could be used to determine the standard error of the 
mean. As shown in figure 2.9, analysing results with or w ithout S.E.M error 
bars for the control made a difference to the resulting P values. This type of 
analysis was carried forward for all proliferation studies where the control 
treatm ent was normalised to 100% as well as luciferase assay experiments 
in chapter 4 where control bars were attributed a value of 1.
I f  data was pooled from more than one cell isolate for each cell type, for 
example when pooling two different HEK-293-Zeo or HEK-293-IP clones, or 
when pooling HPASM cells from 2 or 3 different IPAH or normal patients, a 
Student's t-tes t (2 different isolates) or ANOVA (3 different isolates) was 
performed to check that the distribution between the isolates was not 
significantly different. Data was thus only pooled if it followed that the 
distribution between isolates was not significantly different. In chapter 3 
and 4, 2 isolates were always pooled to represent HEK-293-Zeo or HEK- 
293-IP cells. Figure legends in chapter 5 will state how many isolates were 
pooled for each experiment involving HPASM from normal or IPAH patients.
96
2. Materials and experimental protocols
co
?
03l_
G)
o
k _Q.
* ; P = 0.046
I----------------------------- 1
untreated GW9662
B
co
'•M
03
0)
ok_Q.
n.s.;P = 0.282
I----------------------------- 1
untreated GW9662
Figure 2.9 Figure demonstrating the difference in P values when analysing data with or without 
S.E.M error bars for the untreated control. In this example, growth arrested HEK-293-IP cells were 
stimulated with MEM + 10% FBS and either left untreated or treated with 1 /xM GW9662. Cells 
were counted 48 hours following treatment. Data is expressed as % proliferation relative to the 
proliferative response mediated by 10% FBS alone and expressed as mean ± S.E.M. (n=9). A. 
Control expressed as 100% with no S.E.M bars. B. Individual untreated control values were divided 
by the average for the control group and the resulting normalised data was used to calculate S.E.M 
for the control. P values derived using student’s t-test.
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Chapter 3
Relationship between cAMP 
generation and cell proliferation in a 
HEK-293 cell line stably expressing
the IP receptor
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3.1 Introduction
The IP receptor is a cell surface G-protein coupled receptor consisting of 
seven transmembrane domains (Coleman et al., 1994; Narumiya et at., 
1999). The human IP receptor gene (PTGIR) spans approximately 7.0 kb 
and is composed of three exons separated by two introns and has been 
assigned to human chromosome 19 (Ogawa et al., 1995). I t  encodes a 
protein with a predicted molecular weight of 41 kDa, though the protein can 
be post-translationally modified, which can give rise to a protein of ~50-60 
kDa. Modification can take the form of glycosylation, isoprenylation or 
palmitoylation and this can affect surface expression, G protein coupling 
and effector signalling (Smyth et al., 1998; Miggin et al., 2002; Miggin et 
al., 2003; Hata and Breyer, 2004).
The IP receptor is the main target for PGI2 and its stable analogues, 
although these agents can also bind with significant affin ity to other 
prostanoid receptors including EPX, EP2, EP3 and EP4 (Kiriyama et al., 1997; 
Hata and Breyer, 2004). In addition some analogues are known to be 
ligands for the nuclear receptors PPARa and PPAR5 (Hertz et al., 1996; 
Forman et al., 1997) thus PGI2 analogues have multiple targets which may 
mediate their effects. Upon activation, the IP receptor causes an elevation 
of intracellular cAMP via direct coupling to Gs and stimulation of adenylyl 
cyclase (Nakagawa et al., 1994; Boie et al., 1994) and subsequent 
activation of PKA. This mechanism is thought to account for the anti­
proliferative effects of PGI2 and its analogues in smooth muscle cells 
(Wharton et a!., 2000; Clapp et al., 2002; Phillips et al., 2005).
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I t  has been established that increasing intracellular cAMP levels directly 
inhibits smooth muscle cell proliferation both in vivo and in vitro and that 
these growth inhibitory effects can be completely reversed by the inhibition 
of PKA (Indolfi et al., 1997). In addition there is evidence showing that 
over-expression of AKAP75, a prototypic A-kinase anchor protein which 
anchors PKA to the membrane, inhibits proliferation of smooth muscle cells 
(Indolfi et al., 2001). The authors of the study suggest that membrane 
targeting of PKA leads to suppression of SMC growth by amplifying and 
stimulating cAMP-PKA signalling, resulting in increased activation of cAMP- 
induced transcription and increased levels of the CDKI p27kipl. Moreover, a 
very recent study has linked PKA to the differentiation effects of iloprost in 
VSMC (Fetalvero et al., 2006). Both the PKA antagonist, myrPKI, and the 
ablation of the catalytic subunits of PKA via small interfering RNA (siRNA) 
inhibited the iloprost induced up-regulation of smooth muscle differentiation 
markers such as calponin, h-caldesmon and SM-a-actin (Fetalvero et al., 
2006). In addition it has recently been shown that a PKA antagonist can 
reverse the inhibitory effects of cicaprost on PDGF-induced mitogenesis in 
rat VSMC (Phillips et al., 2005), the only study to date to have provided 
evidence for the much hypothesised role of PKA in PGI2 analogue-mediated 
effects on cell growth.
In the present study, to better delineate the role of the IP receptor in 
modulating cell growth, a HEK-293 cell model was established in which the 
IP receptor was stably expressed (HEK-293-IP) and experimental data on 
these cells was compared to cells lacking the receptor (HEK-293-WT and 
HEK-293-Zeo). To validate this system and confirm that the HEK-293-IP 
cells did indeed express the IP receptor we performed RT-PCR to assess
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mRNA levels and immunohistochemistry to assess protein expression in the 
three different HEK-293 cell lines.
Antibodies make invaluable tools when assessing the expression and 
localisation of a protein. No antibody against the IP receptor was 
commercially available until the autumn of 2004, when an antibody was 
marketed from Cayman Chemical (Ann Arbor, Michigan). In 1998 Komhoff 
and colleagues (Komhoff et al., 1998) had developed an antibody targeting 
the N-terminal of the IP receptor and used it to describe the localisation of 
this receptor in the kidney. To my knowledge these were the only antibodies 
available during the course of my investigation although very recently a 
study exploring the localisation of the human IP receptor in the 
endometrium utilised a Santa Cruz (Santa Cruz, California) antibody 
targeted to the C-terminal of the IP receptor (Smith e ta /., 2006).
In the present study we developed a novel anti-peptide antibody directed to 
the C-terminal of the IP receptor. This antibody was compared with the 
Cayman and the Komhoff antibodies and used to investigate receptor 
expression and localisation in cells used in our investigations. Generating a 
specific antibody or identifying the most reliable and specific antibody to the 
IP receptor will clearly be an extremely valuable tool for future studies.
The newly established HEK-293 cell line was used to characterise the IP 
receptor in isolation, in particular to establish the significance of this 
receptor in mediating the effects of PGI2 analogues and the extent to which 
these effects can be attributed to the classical cAMP pathway. Using various 
pharmacological tools, experiments were designed to dissect the molecular
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mechanisms involved in PGI2 signalling, including the role of PKA, especially 
as they relate to the inhibition of cell proliferation.
RESULTS
3.2 RT-PCR confirms presence of mRNA in H EK -293-IP  cells
Two clonal isolates of the IP receptor (HEK-293-IP) and control (HEK-293- 
Zeo) HEK-293 stable cell lines were generated using a standard transfection 
protocol (see chapter 2). Using specific primers to amplify a 204 bp 
sequence of the IP receptor, RT-PCR was performed on cDNA produced by 
5pg of total RNA to confirm presence or absence of mRNA message in each 
cell type. A band of the appropriate size can be seen in lanes for both clonal 
isolates of HEK-293-IP cells (Figure 3.1 A) confirming presence of the IP 
receptor. To verify that the band visualised corresponded to the 204bp 
sequence of the IP receptor, the band was excised from the gel, the DNA 
purified and sent for sequencing (Cytomyx, Cambridge, UK). A sequence 
alignment of 162 base pairs of the product was performed using 
MegaBLAST rwww.ncbi.com) which detected a 92.6% sequence identity to 
the human IP receptor (accession id: gi/39995095/ref/NM_000960.3). The 
expectation value (E-value) was 5e'26 ruling out the possibility that the 
sequence match was by chance related to another gene. No other 
sequences from any species showed any significant homology.
Very faint bands are present in both clonal isolates of HEK-293-Zeo cells 
(Figure 3.1 A) and HEK-293-WT (Figure 3.1 B) potentially suggesting weak 
expression of the IP receptor in these cells. The latter observation was
102
3. cAMP generation and cell proliferation in HEK-293-IP cells
500bp■
1OObp■ 
500bp-
200bp■
MW IP1 IP2 Zeo1 Zeo2 |P1 |P2 Zeo1 Zeo2
GAPDH
-RT
B MW WT
500bp —
100bp—
Figure 3.1 PCR was performed on reverse transcriptase cDNA products of 5/xg of total RNA from 
two isolates of HEK-293-IP (A), HEK-293-Zeo (A) and HEK-293-WT (B) using IP receptor specific 
primers to amplify a 204 bp region of the receptor sequence and GAPDH primers to amplify a 363 bp 
band of this house-keeping gene as control. Reverse transcriptase controls (-RT) were negative in all 
cases. Identity of the IP receptor product was confirmed by DNA sequencing. This is a representative 
result which has been reproduced at least three times using different RNA preparations.
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somewhat surprising given the described lack of prostanoid receptors in 
HEK-293 cells (Abramovitz et al., 2000), however this low level of mRNA 
expression does not indicate presence of mature functional receptor protein 
as we show further on. Absence or, in the case of HEK-293-WT, near 
absence of bands in the negative control lanes (lack of RT) confirms the 
absence of genomic DNA contamination in the RNA samples (Figure 3.1 A & 
B). To ensure that similar amounts of cDNA were used for PCR, the samples 
were assessed for the expression of GAPDH as a housekeeping gene. 
Specific human GAPDH primers amplified a band of the correct size (363 
bp) in all HEK-293-IP and HEK-293-Zeo cDNA samples. Presence of a band 
of the right magnitude and of a similar intensity was observed in all lanes 
(Figure 3.1 A) except, of course, in the absence of RT.
3.3  The C l antibody appears specific for the IP  receptor
To test whether the newly designed C l antibody was specific for the IP 
receptor, both western blotting and fluorescence immunohistochemistry 
were performed on cells stably transfected with the IP receptor (HEK-293- 
IP) and cells lacking the receptor, namely HEK-293-Zeo.
Western immunoblotting with the C l antibody developed here is currently 
being optimised by Dr. Sue Hall (Institute of Child Health, UCL) and 
encouragingly a band of ~60 kDa could be observed in HEK-293-IP protein 
samples which was near-absent in HEK-293-Zeo (Figure 3.2; figure 
provided by Dr. Hall). Dr. Hall also looked at the expression o f the IP 
receptor in smooth muscle cells from "norm al" (Normal 1 = 00/05 and 
Normal 3 = 99/09 in figure 3.2) and IPAH patients (IPAH1 = 1664, IPAH 2
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= 1666 and IPAH 3 = 1672 in figure 3.2), these results are described in 
more detail later in the thesis (chapter 5).
C l antibody staining can be visualised in HEK-293-IP (Figure 3.3 A) but not 
in HEK-293-Zeo (Figure 3.3 B) cells suggesting that this antibody is indeed 
specific for this receptor. Cells were fixed and permeabilised as previously 
described in the methods (see section 2.4.2) and then stained with the C l 
antibody (1:100 dilution), by incubating cells overnight. Visualisation was 
carried out using a goat anti-rabbit FITC conjugated Alexa-Fluor 488 
(green) secondary antibody (1:300). TO-PRO-3 (red) was used to visualise 
the nuclei. The staining is abundant in HEK-293-IP cells and appears to be 
localised at the cell membrane although it is also strongly expressed in the 
cytoplasm. To test whether the latter may have been due to increased 
receptor internalisation during cell growth, we investigated the effect of 
starving cells prior to incubation with the antibody. Staining cells tha t had 
been previously growth arrested for 48 hrs in MEM containing 0.1% FBS 
showed a similar pattern of cytoplasmic staining, although the concentration 
of staining at the cell margins appeared more intense, possibly indicating 
more receptor at or close to the membrane (Figure 3.3 C & D).
To control for possible non-specific staining by the fluorescent secondary 
antibody, cells were incubated in the absence of the primary antibody, C l. 
Under these conditions, no staining was observed in either HEK-293-IP or 
HEK-293-Zeo cells (Figure 3.4 A & B) confirming the specificity of the 
primary antibody. A further control was performed with the antigenic 
peptide, which should compete with the primary antibody, and thus prevent 
the signal from the secondary from being visualised. To perform this, cells
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were pre-incubated for 3 hrs with the antigenic peptide prior to exposure 
with the primary antibody. Again no fluorescent signal was apparent (Figure
3.4 C), strengthening the validity of this antibody as specifically binding to 
the IP receptor.
3.3.1 Immuno-staining with the N1 and the Cayman antibodies
In order to compare the novel C l antibody to the commercially available 
Cayman antibody and the N1 antibody previously utilised by Komhoff e t al, 
(1998) we performed the same experiments as above using these two 
antibodies. Signal could be detected with both antibodies in the HEK-293 IP 
cells (Figure 3.5 A & C), though the pattern of staining differed from our 
antibody in that it was largely associated around or in the nucleus. 
Moreover, staining, albeit less, could be visualised in HEK-293-Zeo cells 
(Figure 3.5 B & D). Taken together, this suggests that these two antibodies 
probably lack specificity for the IP receptor.
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Figure 3.2 Lab work carried out by Dr. Sue Hall who also provided this figure. The C1 antibody was 
used to study expression of the IP receptor in HEK-293-Zeo, HEK-293-IP as well as normal (99/09, 
00/05) and IPAH (1664,1666 and 1672) vascular smooth muscle cells. The C1 antibody picks up a 
band at 60 kDa. Beta-actin was used as a positive control and all samples show the same 
expression of this protein.
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Figure 3.3 HEK-293 IP (A, C) and HEK-293 Zeo (B, D) cells stained with the C1 antibody. 
Growing (MEM + 10% FBS) (A,B) or starved (MEM + 0.1% FBS) (C,D) cells were fixed in 4% 
paraformaldehyde prior to staining with the C1 primary antibody (1:100 dilution). FITC conjugated 
Alexa fluor 488 (green) was used as a secondary antibody and TO-PRO-3 (red) was used to stain 
nuclei (both at 1:300 dilution). Cells were visualised using a confocal microscope with a X60 
magnification water immersion lens. Images of 0.1 jjm  thickness were taken from the middle of the 
cells. Images are not derived from a Z-series but were taken as a single image at a level were 
nuclear staining was intense.
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Figure 3.4 Immunohistochemistry controls. A & B Growing HEK-293-IP and HEK-293-Zeo cells 
were fixed in 4% para-formaldehyde and immuno-stained with FITC conjugated Alexa fluor 488 
(green) and TO-PRO-3 (Red) in the absence of primary antibody (both 1:300 dilution) C. Growing 
HEK-293-IP pre-incubated with C1 blocking peptide (4 /yg//yl) prior to staining with primary antibody 
(1:100 dilution). Images are not derived from a Z-series but were taken as a single image at a level 
were nuclear staining was intense.
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Figure 3.5 Growing HEK-293-IP and HEK-293-Zeo cells were fixed in 4% para-formaldehyde and 
immuno-stained with the Cayman IP receptor antibody (1:100) (A,B) or the N1 antibody (1:100) 
(C,D). FITC conjugated Alexa fluor 488 (green) was used as a secondary antibody and TO-PRO-3 
(red) was used to stain nuclei (both at 1:300 dilution). Images are not derived from a Z-series but 
were taken as a single image at a level were nuclear staining was intense.
110
3. cAMP generation and cell proliferation in HEK-293-IP cells
3.4  The IP  receptor in H EK -293-IP  cells is functional
After confirming the presence of RNA message and protein expression of 
the IP receptor in HEK-293-IP cells, a cAMP assay was performed to 
establish the functionality of the receptor in these cells. As expected, when 
HEK-293-IP cells were treated with the PGI2 analogue treprostinil (1 pM) for 
30 mins, the intracellular levels of cAMP greatly increased by ~40 fold (n=4, 
P=0.0013; Figure 3.6 A), confirming that the IP receptor is indeed 
functional. In contrast, the HEK-293-Zeo cells displayed no significant 
increase in the intracellular cAMP levels upon treatment with treprostinil at 
the same concentration and for the same time (Figure 3.6 B). This would 
suggest the absence of a functional receptor in these cells. Basal, untreated 
levels of cAMP were significantly higher in HEK-293-Zeo than in HEK-293-IP 
cells (39.5 vs 9.3 pmol/mg, n = 3-6, P<0.05)
3.5 Presence of the IP  receptor alters the proliferative rate of HEK- 
293 cells
One of the main phenotypic differences initially noted between cells with 
and without the IP receptor was a discrepancy in their proliferation rate. 
HEK-293-IP cells had a much reduced growth rate compared to either HEK- 
293-Zeo or HEK-293-WT cells (Figure 3.7). After 4 days of growth in media 
containing 10% FBS, cells expressing the IP receptor had grown 
approximately 50% less (HEK-293-WT, n=9 and HEK-293-Zeo and HEK- 
293-IP, n=18, P<0.001) than cells not expressing the receptor. Similar 
growth characteristics were observed for all clonal isolates of HEK-293-IP 
and HEK-293-Zeo tested (Figure 3.8).
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Figure 3.6 Cyclic AMP measurements in HEK-293-IP (A) or HEK-293-Zeo (B) cells. In both cases, 
cells were stimulated with 10%FBS ± either treprostinil (TREP; 100 nM). Cyclic AMP was extracted 
30 mins after TREP stimulation and measured using an enzyme immunolinked assay. Results 
expressed as mean pmol of cyclic AMP per mg of total protein ±  s.e.m (measurements in duplicate 
of 3-4 experiments). **=p< 0.01.
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Figure 3.7 Proliferation curves of HEK-293-Zeo (■), HEK-293-IP (•) and HEK-293-WT (▲) cells. 
Growth arrested cells were stimulated with 10% FBS and counted at different time points as shown. 
Data shown as mean ± S.E.M. (n=9-18). *** = P<0.001.
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Figure 3.8 Proliferation curves of two clonal isolates of HEK-293-Zeo, 1 (■ ) and 2 (A) and two 
clonal isolates of HEK-293-IP, 1 (•) and 2 (♦). Growth arrested cells were stimulated with 10% FBS 
and counted at different time points as shown. Data shown as mean ± S.E.M. (measurements in 
triplicate of 3 experiments).
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One possible explanation for the lower proliferation rate found in the cells 
expressing the IP receptor was thought to be basal activation of the 
receptor by endogenously produced PGI2. This theory was tested in two 
ways. Firstly, the novel IP receptor antagonist ROl 138452 (subsequently 
referred to as IPRA from here onwards) was used to block any basal 
activation of the receptor. Secondly, indomethacin, a non-selective COX 
inhibitor, was used to block the endogenous production of PGI2 
(summarised in Figure 3.9 A). However, treatm ent with either of these two 
agents failed to restore the proliferation rate of HEK-293-IP cells to that of 
HEK-293-Zeo or HEK-293-WT cells (Figure 3.9 B), suggesting that basal 
activation of the receptor is not the reason for their slower proliferation 
rate. This conclusion is further supported by the observation that the basal 
level of cAMP measured in HEK-293-IP cells (9.31 ± 3.14 pmol/mg) was 
actually lower when compared to HEK-293-Zeo (39.50 ± 7.43 pmol/mg 
protein, n=3-6, P<0.005; Figure 3.6 A & B). On the contrary, one would 
have expected cAMP levels to be higher in the IP receptor expressing cells if 
indeed there was increased basal activation of the receptor due to 
endogenously produced PGI2 production or enhanced receptor coupling to 
Gs.
3 .6  Effect o f G i/G 0 inhibition.
The unexpected lower basal level of intracellular cAMP in HEK-293-IP cells 
raised interesting questions. One hypothesis based on this result was that 
the IP receptor is indeed basally activated but is additionally coupled to the 
inhibitory G protein, Gi. The G( protein inhibits adenylyl cyclase activity thus 
keeping intracellular levels of cAMP suppressed.
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Figure 3.9 A. Schematics of the possible effect of the COX-2 antagonist indomethacin (INDO) and 
the IP receptor antagonist R01138452 (IPRA) on the hypothesised basal activation of the IP 
receptor by endogenously produced PGI2. (AC), adenylyl cyclase. B. Growth arrested HEK-293-IP 
cells were stimulated with 10% FBS and either left untreated (•) or were treated with INDO (■, 10 
/xM) or IPRA (A,  1 /xM). Cells were counted at different time points as shown. Data shown as mean 
± S.E.M. (measurements in triplicate of 3-6 experiments), (n.s. = non significant)
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In order to determine whether the IP receptor was indeed coupled to the Gj 
protein, intracellular cAMP was measured in both HEK-293-Zeo and HEK- 
293-IP cells incubated with the G j / G 0 inhibitor, pertussis toxin (PTx, 100 
ng/ml) for 16 hr. PTx catalyses the ADP-ribosylation of the a subunit of the 
Gj and G 0 proteins, uncoupling them from their membrane bound receptor 
and thus preventing its activation (Watts and Neve, 2005). By inhibiting Gj, 
PTx abolishes the suppression on adenylyl cyclase resulting in higher cAMP 
levels. Thus in HEK-293-IP cells, PTx significantly increased the levels of 
cAMP from 9.31 ±  3.14 pmol/mg in untreated cells to 34.07 ± 7.43 
pmol/mg in treated cells (n=6, P<0.05; Figure 3.10). In contrast, PTx had 
no effect on the basal level of cAMP in HEK-293-Zeo cells suggesting 
minimal Gi coupling to adenylyl cyclase under basal conditions in a cell line 
not expressing the IP receptor.
The effect of inhibiting GJG0 on cell proliferation was also investigated using 
PTx. As one would predict, the PGI2 analogue treprostinil (100 nM, 48 hrs) 
inhibited proliferation in HEK-293-IP cells by 46.6 ± 5.5% (n=8, P<0.005) 
compared to 10% FBS alone (Figure 3.11 B) but not in cells lacking the IP 
receptor (Figure 3.11 A). Furthermore, incubation with PTx in the absence 
of treprostinil also significantly inhibited the proliferation of HEK-293-Zeo 
cells by 24.8 ± 6.7% (n = 12, P<0.01) and HEK-293-IP cells by 42.5 ± 9.7% 
(n=8, P<0.01). PTx further potentiated the inhibitory effect of treprostinil, 
though this was only significant in HEK-293-IP cells (74.8 ± 6.8%, n=8, 
P<0.05). The observation that PTx inhibits proliferation in HEK-293 cells 
both in the presence and absence of the IP receptor suggests that the 
effects of suppressing G j / G 0 coupling may not be wholly related to the IP 
receptor. However because significant potentiation to treprostinil does occur
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Figure 3.10 Effect of inhibiting G, with pertussis toxin (PTx) on basal cAMP levels. HEK-293-Zeo 
(black bars) and HEK-293-IP (red bars) cells were grown in MEM + 10% FBS and either left 
untreated or stimulated with PTx (100 ng/ml) for 16 hrs. Cyclic AMP was extracted and measured 
using an enzyme immunolinked assay. Results expressed as mean pmol of cyclic AMP per mg of 
total protein ± S.E.M. (measurements in duplicate of 3 (HEK-293-Zeo) or 6 (HEK-293-IP) 
experiments. *=p<0.05.
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Figure 3.11 Comparison of the effects of treprostinil (TREP) and Pertussis Toxin (PTx) on HEK-293- 
Zeo (A) and HEK-293-IP (B) cells. Growth arrested cells were were stimulated with 10% FBS and 
either left untreated or were treated with TREP (100 nM), PTx (100 ng/ml), or a combination of both. 
Cells were pretreated with PTx for 16 hrs prior to stimulation with TREP. Cells were counted 48 hrs 
following treatment. Data expressed as mean % proliferative response relative to proliferation 
mediated by 10% FBS alone ± S.E.M. (n=8-12). * = P<0.05, ** = P<0.01, n.s.= not statistically 
significant.
119
3. cAMP generation and cell proliferation in HEK-293-IP cells
in HEK-293-IP cells it suggests that Gj and/or G0 have some specific 
inhibitory effect on the anti-proliferative response of this PGI2 analogue.
3.7 The IP  receptor m ediates the effects of PGI2 analogues.
A principle concern of this thesis was to find out whether the IP receptor is 
solely responsible for mediating the cAMP-elevating and growth-inhibitory 
effects of certain PGI2 analogues. The novel IP receptor antagonist, IPRA 
would be expected to block any rise in cAMP generated by treprostinil if the 
IP receptor were indeed exclusively mediating the effects of this analogue. 
As shown previously, 100 nM treprostinil (30 mins) raised the intracellular 
cAMP levels only in HEK-293-IP cells (Figure 3.12). Inhibiting the receptor 
by pre-treating cells with 1 pM IPRA for 1 hr, significantly reduced the rise 
in cAMP induced by treprostinil from 459.5 ± 79.4 pmol/mg (n=4) to 30.1 ±
4.5 pmol/mg (n=3, P<0.001) (Figure 3.12).
In proliferation assays, treatment with neither treprostinil nor carbacyclin 
(both at 1 pM for 48 hrs) inhibited proliferation of HEK-293-Zeo cells (Figure 
3.13 A). The fact that the cell permeable analogue carbacyclin did not 
inhibit the proliferation of cells lacking the receptor suggests that there are 
no alternative intracellular targets (for example PPARs) present in HEK-293 
cells that could mediate the anti-proliferative effects of this agent. 
Moreover, treprostinil completely blocked the proliferation of HEK-293-IP 
cells, whereas carbacyclin was significantly less effective (P<0.05), at the 
same concentration, inhibiting proliferation by only 69.3 ± 11.1% (n=12) 
relative to untreated control cells (Figure 3.13 B). Proliferation assay results 
are expressed as the mean % proliferation rate at 48 hrs in cells incubated 
in 10% FBS relative to the proliferation rate of cells kept in 0-0.1%  FBS for
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the same length of time. Normalisation was necessary because the growth 
response to FBS was variable. Figure 3.14 displays a representative assay 
where results are expressed in total cell number. Experiments were only 
included in our data analysis if there was between a two and a three fold 
increase in the proliferation rate between cells stimulated with 10% FBS 
and those cultured in 0-0.1%  FBS.
In studying the cell proliferation responses of HEK-293-IP cells, the dose- 
response curves to treprostinil and carbacyclin (48 hr treatm ent) further 
indicate the difference in potency of these two PGI2 analogues (Figure 
3.15). Treprostinil inhibited FBS stimulated growth with an IC50 of 16 nM 
compared to carbacyclin, which has an IC50 of 116 nM. The effects of 
treprostinil on cell growth were long lasting as shown in Figure 3.16. HEK- 
293-IP cells were left to replicate with or without treatment of 1 pM 
treprostinil and counted every 24 hrs for 5 days. Under these conditions, 
proliferation was almost completely inhibited for the duration of the 
experiment, indicating that treprostinil remained effective for up to 5 days.
To further confirm the role of the IP receptor in PGI2-regulated growth 
control, IPRA was used in proliferation assays. Treatment of HEK-293-IP 
cells with 100 nM IPRA for 48 hrs showed a small but non significant 
inhibition of proliferation (17.8 ± 8.3%, n = l l ,  P=0.23). As expected, 
treatment with 100 nM treprostinil for 48 hrs greatly inhibited proliferation 
relative to untreated control by 77.9 ± 3.3% ( n = l l ,  P<0.001), an effect 
which was almost completely reversed in the presence of IPRA ( n = l l ,  
PcO.001; Figure 3.17).
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Figure 3.12 Cyclic AMP was measured in HEK-293-IP (black bars) or HEK-293-Zeo (red bars). In 
both cases, cells were stimulated with 10%FBS ± either TREP (100 nM) or IPRA (1 pM) or a 
combination. Cells were pretreated with IPRA for 1 hr prior to stimulation with TREP. Cyclic AMP 
was extracted 30 mins after TREP stimulation and measured using an enzyme immunolinked assay. 
Results expressed as mean pmol of cyclic AMP per mg of total protein ± S.E.M. (measurements in 
duplicate of 3-4 experiments). ***=p<0.001.
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Figure 3.13 Comparison of the effects of treprostinil (TREP) and carbacyclin (CARBA) on HEK-293- 
WT (A) and HEK-293-IP (B) cells. Growth arrested cells were stimulated with 10% FBS and either 
left untreated (solvent control) or were treated with TREP (1 /xM) or CARBA (1 /xM). Cells were 
counted 48 hrs following treatment. Data expressed as mean % proliferative response relative to 
proliferation mediated by 10% FBS alone ± S.E.M. (n=12). * = P<0.05, *** = P<0.001
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Figure 3.14 Representative proliferation assay comparing the effects of treprostinil (TREP) on HEK- 
293-WT (A) and HEK-293-IP (B) cells. Growth arrested cells were either stimulated with 0.-0.1% 
FBS or stimulated with 10% FBS in the absence or presence of DMSO (1:10000) or TREP (1 /*M). 
Cells were counted 48 hrs following treatment. Data expressed as mean cell number (xIOVml) ± 
S.E.M. of one experiment performed in triplicate (n=3).
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Figure 3.15 Dose response curves for treprostinil (TREP) and carbacyclin (CARBA). Growth 
arrested HEK-293-IP cells were stimulated with 10% FBS ± TREP (•) or CARBA (■) at different 
concentrations and counted after 48 hrs. IC^for TREP = 16 nM, IC^for CARBA = 116 nM Data 
expressed as mean % proliferative response relative to proliferation mediated by 10% FBS alone ± 
S.E.M. (measurements in triplicate of 3 separate experiments). ** = P<0.005.
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Figure 3.16. Proliferation curves of HEK-293-IP cells either left untreated (■) or treated with 
treprostinil (TREP, •, 1 /*M). Growth arrested cells were stimulated with 10% FBS ± TREP and 
counted at different time points as shown. Data shown as mean ± S.E.M. (measurements in triplicate 
of 4 experiments). *** = P<0.001
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Figure 3.17 Growth arrested HEK-293-IP (red bars) cells were stimulated with MEM + 10% FBS 
and either left untreated or treated with TREP (100 nM), IPRA or a combination. Cells were 
pretreated with IPRA for 1 hr prior to stimulation with TREP. Cells were counted 48 hours following 
treatment. Data expressed as mean % proliferative response relative to proliferation mediated by 
10% FBS alone ± S.E.M. (n=11). = P<0.001
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3.8 Role of cAMP in regulating treprostinil effects on cell 
proliferation
To find out whether the effects of treprostinil on both cAMP levels and 
proliferation could be mimicked by activating adenylyl cyclase to increase 
cAMP levels directly, HEK-293-IP and HEK-293-Zeo cells were exposed to 
forskolin in both cAMP and proliferation assays. Forskolin, a plant diterpene, 
is a well known direct activator of adenylyl cyclase. So far nine isoforms of 
adenylyl cyclase have been identified (AC1-AC9) and forskolin can strongly 
activate all bar one, AC9 (Watts and Neve, 2005) thus making it one of the 
most widely used tools with which to study the cAMP pathway. Treatment 
with 10 pM forskolin for 30 mins significantly increased the intracellular 
levels of cAMP in HEK-293-Zeo cells from 39.5 ± 7.4 pmol/mg in untreated 
cells to 994.7 ± 83.2 pmol/mg (n=3, P<0.001). The same occurred in HEK- 
293-IP cells, although slightly more potently, (13.0 ± 5.7 pmol/mg in 
untreated cells vs 1353 ± 22.7 pmol/mg in forskolin-treated cells, n = 3, 
P<0.001; Figure 3.18). When cells were co-treated for 30 mins with both 
treprostinil (100 nM) and forskolin (10 pM), the effects of these agents were 
not potentiated (Figure 3.18) seemingly as if the cAMP-elevating response 
to either agent is saturated in HEK-293-IP cells and maybe the two agents 
are activating the same pool of adenylyl cyclase.
Surprisingly, in HEK-293-Zeo cells forskolin, like treprostinil, did not have 
any significant effect on cell proliferation (Figure 3.19 A). Furthermore 
although forskolin stimulated a considerable increase in cAMP in both cell 
types, it only inhibited proliferation in cells expressing the IP receptor. As 
shown in Figure 3.19 B, treatment with 10 pM forskolin for 48 hrs
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Figure 3.18 HEK-293-Zeo (black bars) and HEK-293-IP (red bars) cells were stimulated with MEM + 
10% ± FORSK (10 \lM) or TREP (100 nM) or a combination as shown. Cyclic AMP was extracted 
after 30 mins and measured using an enzyme immunolinked assay. Results expressed as mean 
pmol of cyclic AMP per mg of total protein ± S.E.M. (measurements in duplicate of 3 (HEK-293-Zeo) 
or 6 (HEK-293-IP) experiments. = P<0.001.
129
3. cAMP generation and cell proliferation in HEK-293-IP cells
Figure 3.19 HEK-293-Zeo (A) and HEK-293-IP (B) cells were grown in MEM + 10% FBS and either 
left untreated or stimulated with FORSK (10 /xM), IBMX (10 /xM), TREP (100 nM) or a combination 
as shown. Cells were counted 48 hours following treatment. Data expressed as mean % proliferative 
response relative to proliferation mediated by 10% FBS alone ± S.E.M. (n=6). * = P<0.05, ** = 
Fc0.01,~* = P<0.001.
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completely inhibited the proliferation of HEK-293-IP cells to about the same 
level as 100 nM treprostinil (84.5 ± 6.6% inhibition in forskolin treated cells 
compared with 93.4 ± 16.1% inhibition in treprostinil treated cells, n=6). 
Contrary to what was observed in cAMP assays, combined treatm ent with 
forskolin and treprostinil did potentiate the anti-proliferative effect of either 
drug alone. Why this was observed remains unclear but could potentially 
involve differential compartmentalisation of cAMP as explained in more 
detail in the discussion.
3-isobutyl-methylxanthine (IBMX) is a widely used non-selective 
phosphodiesterase (PDE) inhibitor that decreases the activity of both cAMP 
and cGMP-dependent PDEs and thus can be used to increase levels of 
intracellular cAMP. Like forskolin and treprostinil, treatment with 100 pM 
IBMX for 48 hrs only inhibited the proliferation of HEK-293-IP cells (n=6, 
P<0.001; Figure 3.19). Thus cAMP and proliferation are only linked if there 
is an IP receptor present in the cell.
To test whether anti-proliferative and cAMP elevating effects of treprostinil 
were mediated by adenylyl cyclase, HEK-293-IP cells were pre-treated with 
the adenylyl cyclase antagonist, 2'5'- dideoxyadenosine (DDA) prior to 
stimulation with treprostinil. DDA inhibits adenylyl cyclase by binding to the 
inhibitory binding domain (P site). Treatment with 100 pM DDA alone for
1.5 hrs unexpectedly significantly increased the levels of cAMP from 13.4 ± 
5.4 pmol/mg to 45.0 ± 7.2 pmol/mg, (n = 3, P<0.05; Figure 3.20). Pre­
treatment with DDA for 1 hr prior to stimulation significantly inhibited the 
treprostinil-induced rise in cAMP, reversing it from 528.6 ± 55.3 pmol/mg to
193.9 ± 50.3 pmol/mg (n = 3, P<0.01). However, DDA did not appear to
131
3. cAMP generation and cell proliferation in HEK-293-IP cells
suppress the response to treprostinil completely although this was not 
statistically significantly different from treatment with DDA alone (P=0.099; 
Figure 3.20).
In proliferation assays, DDA alone had a small inhibitory effect on HEK-293- 
IP cells (33.4 ± 3.2% inhibition compared to untreated controls, n=8, 
PcO.OOl; Figure 3.21). When cells were pre-treated with DDA prior to 
stimulation with treprostinil, DDA significantly inhibited the anti-proliferative 
effect of treprostinil, proliferation being similar to that found with DDA alone 
(n=8, P<0.001). From our data it appears that adenylyl cyclase mediates 
about 75% of the anti-growth response, although incomplete inhibition may 
reflect the small rise in cAMP observed in the presence of DDA.
3.9 Role of PKA in regulating treprostinil effects on cell proliferation
I t  is generally assumed that the high levels of cAMP generated by PGI2 
analogue induced activation of adenylyl cyclase will activate PKA and inhibit 
cell proliferation. Therefore the role of PKA in the anti-proliferative effects of 
IP receptor activation in HEK-293 cells was assessed by blocking the 
activation of PKA and seeing what effect this had on treprostinil-induced 
inhibition of proliferation in HEK-293-IP cells. Two PKA inhibitors were used; 
H-89 and the more PKA specific agent, Rp-MB-cAMPS. Treatment for 48 hrs 
with either 10 pM H-89 or 100 pM Rp-MB-cAMPS alone resulted in a small 
but non-significant increase in proliferation of HEK-293-IP cells compared to 
the same cells grown in 10% FBS containing mono-butyryl (a control for 
Rp-MB-cAMPS treatment). The marked inhibitory effect of 100 nM 
treprostinil on cell proliferation was significantly reduced by pre-treating 
cells for 30 mins with H-89 (n = 12, PcO.001) or with Rp-MB-cAMPS (n = 18,
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P<0.01; Figure 3.22) suggesting that PKA is indeed involved in mediating 
the effects of treprostinil. Both antagonists, however, failed to restore 
proliferation of HEK-293-IP cells to the level observed in cells treated with 
the antagonists alone (P<0.05). This suggests that there may be an 
additional PKA-independent component to the antiproliferative effects of 
treprostinil. Similarly to DDA, PKA antagonists appeared to reverse the anti­
proliferative effects by approximately 75%, suggesting that a further 25% 
of the response must be mediated by a cAMP-PKA independent mechanism.
3 .1 0  Sum m ary
• A HEK-293 stably transfected cell line expressing the IP receptor was 
generated and characterised and used to study IP receptor signalling 
pathways.
• A novel specific antibody for the IP receptor was developed and 
characterised and used to investigate the localisation of this receptor in 
HEK-293 cells
• The novel antibody was shown to be more specific than other antibodies 
used in the literature.
• Physical presence of the IP receptor slows the proliferation rate of HEK- 
293 cells and is crucial in mediating the anti-proliferative effects of PGI2 
analogues.
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Figure 3.20 HEK-293-IP cells were stimulated with MEM + 10% FBS ± 2’5'-DDA (100 /xM) or TREP 
(100 nM) or a combination as shown. Cells were pretreated with 2’5’-DDA for 1 hr prior to stimulation 
with TREP. Cyclic AMP was extracted 30 mins after treatment with TREP and measured using an 
enzyme immunolinked assay. Results expressed as mean pmol of cyclic AMP per mg of total protein 
± S.E.M. (measurements in duplicate of 3 experiments). *=p<0.05, ** = P<0.01, *** = P<0.001
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Figure 3.21 Growth arrested HEK-293-IP (red bars) cells were stimulated with MEM +10% FBS and 
either left untreated or treated with TREP (100 nM) or 2’5’-DDA (100 /*M) or a combination as 
shown. Cells were pretreated with 2’5’-DDA for 1 hr prior to stimulation with TREP. Cells were 
counted 48 hours following treatment. Data expressed as mean % proliferative response relative to 
proliferation mediated by 10% FBS alone ± S.E.M. (n=8). *** = P<0.001
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Figure 3.22 Growth arrested HEK-293-IP cells were stimulated with MEM + 10% FBS and either left 
untreated or treated with H-89 (10 /xM), Rp-MB-cAMPS (100 /xM), TREP (100 nM) or a combination 
as shown. Cells were pretreated with H-89 nor Rp-MB-cAMPS for 30 mins prior to stimulation with 
TREP. Cells were counted 48 hours following treatment. Data expressed as mean % proliferative 
response relative to proliferation mediated by 10% FBS + mono butyryl (MB) alone ± S.E.M. (n=12- 
18). * = P<0.05, ** = FcO.01, = P<0.001
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• Presence of the IP receptor alters the proliferative response of HEK-293 
cells to cAMP-elevating agents.
• Pre-coupling of the IP receptor to the Gj protein may account for the 
lower basal cAMP levels in HEK-293-IP cells compared to control cells.
• The anti-proliferative and cAMP-elevating effects of treprostinil in HEK- 
293-IP cells were almost completely reversed using a novel IP receptor 
antagonist.
• The main signalling pathway involved in the anti-proliferative effects of 
treprostinil appears to be mediated by Gs dependent activation of 
adenylyl cyclase, cAMP and PKA.
• The latter pathway appears to account for ~75% of the anti-proliferative 
response to treprostinil, possibly suggesting the presence of additional 
cAMP-PKA independent mechanism/s.
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3.11 Discussion
3.11.1 Establishment and characterisation o f the HEK-293-IP cell 
line
In native smooth muscle cells it is likely to be harder to dissect the 
signalling pathway of the IP receptor because PGI2 analogues have affinity 
for other prostanoid receptors, which are present in these cells, and until 
very recently there was no IP receptor antagonist to analyse the role of 
these different pathways. A HEK-293 cell line stably expressing the IP 
receptor (HEK-293-IP) was generated in this project to better understand 
the role of the IP receptor in isolation. RT-PCR and immunohistochemistry 
confirmed the presence of the receptor in these cells. In parallel, a HEK- 
293-Zeo cell line was generated to control for any non-specific effects of 
stable transfection. This was done by stably transfecting cells with a plasmid 
encoding resistance to the antibiotic zeocin. RT-PCR in these cells as well as 
in wild type cells (HEK-293-WT) showed virtual absence of the receptor. The 
functionality of the receptor was shown by using a cAMP assay and 
assessing whether stimulation of cells increased intracellular cAMP levels in 
an IP receptor antagonist reversible manner. As predicted this occurred in 
the HEK-293-IP cells and not in the HEK-293-Zeo cells, again validating the 
model used in these studies.
Although the HEK-293 cell line does not possess the same sophisticated 
level of biochemical processes and interactions as native pulmonary artery 
smooth muscle cells do (of particular interest to this project), they retain 
many advantages that make them ideally suited to this study. This cell line 
has been used extensively as an expression tool since it was generated over
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25 years ago (Graham et al., 1977). The principal reason for using a HEK- 
293 cell line in this project was the ability to study the properties of our 
protein of interest, the IP receptor, in isolation from other receptors of the 
same, or different families which may be activated by PGI2. Other 
characteristics which make it such a popular tool are its fast and easy 
reproduction and maintenance; the relative ease and high efficiency of 
transfection that can be achieved using a wide range of methods and the 
faithful translation and processing of proteins (Thomas and Smart, 2005).
The HEK-293-IP cell line is also a valuable tool which helped us characterise 
novel antibodies. Immunohistochemistry was performed using an anti-IP 
receptor antibody developed and generated during this project. This 
antibody (C l)  was raised against a peptide at the C-terminal of the protein 
providing a different target to the Komhoff et al (N l)  and the Cayman 
antibodies. The antibody staining was abundantly visualised at the 
membrane as well as in the cytoplasm of stably transfected HEK-293 cells. 
The pattern of expression was in fact analogous to that shown by Smyth et 
al (1998) in HEK-293 cells transfected with a hemagglutinin (HA)-tagged 
human IP receptor construct (HA-hIP) and stained with an anti-HA antibody. 
The similarity between the IP receptor localisation described in HEK-293- 
HA-hlP (Smyth et a!., 1998) and in HEK-293-IP cells in the present study 
further strengthens the validity of our newly developed C l antibody. The 
abundant presence of staining in the cytoplasm may be attributed to the 
nature of over-expressing the IP receptor in these cells. Because of the 
large quantity of receptor produced in these cells, receptor density at the 
plasma membrane may be saturated hence many receptors may be 
excessively internalised.
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Based on using our HEK-293-IP cell line, the C l antibody appeared to be 
selective for the IP receptor, whereas this did not appear to be the case for 
either the N1 or the Cayman antibody. In the study by Komhoff et al (1998) 
they assessed the specificity of the N1 antibody by performing Western 
immunoblotting on membrane fractions from human platelets. Platelets are 
a good positive control as they are known to abundantly express IP receptor 
which functions as a counteracting pathway for the pro-aggregatory actions 
of thromboxane (Oliva and Nicosia, 1987). The study detected a diffuse 
band with an apparent molecular mass of about 52 kDa (Komhoff et al., 
1998) although as mentioned before the predicted molecular weight of the 
IP receptor from the open reading frame of its cDNA is 41 kDa (Nakagawa 
et at., 1994). The study attributed the discrepancy between the apparent 
and the predicted molecular weight to glycosylation of the IP receptor. 
However no negative control showing lack of a band in a cell extract known 
to lack the IP receptor was shown. In terms of immunohistochemistry the 
study did confirm specificity by pre-absorbing the purified N1 antibody with 
an excess of the peptide to which it was raised against, and showed 
labelling could be blocked by pre-incubation. This does not entirely exclude 
non-specific binding of the antibody to other proteins exhibiting a similar 
epitope. Moreover, instead of the predicted membrane localisation, 
expression was predominately observed around the nuclear region, which 
could potentially point to lack of specificity.
The Cayman antibody has also not been studied extensively and no 
immunohistochemistry appears to have been previously performed using 
this antibody. The company claims that the antibody detects a band at 67 
kDa on a Western immunoblot and again attributes the higher molecular
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weight than predicted by the gene product to post-translational 
modifications.
I t  appears that the short immunohistochemical study provided in this thesis 
is to date the most controlled comparison of these three antibodies. The 
HEK-293-Zeo cell line serves as a good negative control to run alongside 
our HEK-293-IP cells. By targeting the internal terminus of the IP receptor 
protein, this antibody may also be more useful in the event of the 
extracellular portion of the receptor being more susceptible to degradation 
by proteases and general cell culture maintenance. A further commercially 
available antibody available from Santa Cruz (Santa Cruz, California) was 
used in a very recently published study on the role of the IP receptor in 
angiogenesis in the endometrium (Smith et al., 2006). Like C l the Santa 
Cruz antibody also targets the C-terminal of the receptor although the 
company does not provide the amino acid sequence of the peptide to which 
the antibody was raised against. Staining of endometrial sections with this 
antibody shows plasma membrane localization of the IP receptor with some 
cytoplasmic immunoreactivity also present (Smith et al., 2006). This is 
again very similar to the expression picked up with C l possibly indicating 
that the two are designed to recognise very similar receptor regions. 
However, even with the late advent of a similar antibody, the new tool 
developed in this study will prove extremely useful in future studies to 
better understand the expression and localisation of the IP receptor.
Having established the stable HEK-293 cell lines, the first phenotypical 
difference noted between the two cell types was that HEK-293-IP cells had a 
lower rate of proliferation than cells lacking the receptor. I t  was
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hypothesised that this lower rate may be caused by basal constitutive 
activation of the IP receptor, leading to the classical anti-mitogenic effects 
of cAMP known to occur in many cell types including vascular smooth 
muscle cells (Indolfi et al., 1997; Fukumoto et al., 1999; Wharton et al., 
2000; Clapp et al., 2002). We presumed that this constitutive activation 
may be brought about by endogenously produced PGI2. This appeared not 
to be the case, as was shown by the lack of effect of the IP receptor 
antagonist (IPRA) on the basal rate of proliferation. In addition, blocking the 
putative endogenous production of PGI2 with the non-selective COX 
antagonist indomethacin had no effect on HEK-293-IP growth. By blocking 
COX, indomethacin inhibits the production of all prostanoids including those 
which have opposing effects to PGI2 such as the mitogenic prostanoid TXA2. 
However, this should have no effect in a HEK-293 cell line system due to 
the absence of the required prostanoid receptors in these cells. A study by 
Abramovitz et al (2000) found no significant specific binding of a variety of 
prostanoid receptor ligands (e.g. PGE2, PGD2, PGF2, iloprost, and the 
thromboxane receptor agonist, U46619) to membranes prepared from 
mock-transfected HEK-293 cells.
3.11.2 Multiple G Protein coupling to the IP  receptor
Basal intracellular cAMP levels were lower in HEK-293-IP cells than in HEK- 
293-Zeo, again suggesting the absence of tonic Gs activity. However, upon 
treatment with PTx, which irreversibly inhibits G( and G0 activity, cAMP 
levels in HEK-293-IP cells approached levels close to those measured in 
HEK-293-Zeo. This strongly suggests that the IP receptor can also couple to 
G|. Although PTx is able to act on both Gi or G0, the former is a more likely
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candidate in light of a study in HEK-293 cells transiently transfected with a 
CFP-IP receptor construct and a YFP-tagged G 0 protein. The study 
demonstrated that in the absence of agonists, the IP receptor coupled to G s 
but found no evidence that this occurred with G 0 (Nobles et al., 2005). 
Although the study showed that the IP receptor is indeed coupled to G S/ it 
must not be assumed that this association renders the G s protein active. In 
contrast there may be constitutive activation of Gi pre-coupled to the IP 
receptor in the HEK-293-IP cells which represses adenylyl cyclase activity, 
thus maintaining low levels of cAMP as we found in this project.
Constitutive activation of Gi by the IP receptor has never been described; 
however there is ample experimental evidence in the literature supporting 
the existence of receptors tightly associated to their respective G protein 
and ensuing constitutive activation in the absence of ligand. This is the case 
for the CBi-canabbinoid receptor (Vasquez and Lewis, 1999), the melatonin 
(Melia) receptor (Roka et al., 1999) and the vasoactive intestinal peptide 
(VCAP1) receptor (Martin, 2002). Vasquez and Lewis suggested that the 
CB-1 receptor, because of its tight pre-association with G i/G 0 in the absence 
of ligand, sequesters a proportion of the available Gj/G0 protein pool. This 
leads to a reduction of available GJG0 protein, restricting activation by other 
Gj/Go coupled receptors. The study demonstrated that expression of the 
Gj/Go-coupled CB1 receptor attenuated the ability of a2-adrenergic 
receptors (a2AR) and somatostatin receptors to activate Gj/G0 in superior 
cervical ganglion neurons (Vasquez and Lewis, 1999). Similarly, expression 
of the Gs-coupled serotonin receptor, 5-HT7 (5-hydroxytryptam ine-7), 
attenuated adenylyl cyclase activation by other Gs coupled receptors 
expressed endogenously in HEK-293 cells, an effect shown to be
143
3. cAMP generation and cell proliferation in HEK-293-IP cells
independent of agonist binding (Andressen et a l 2006). I t  is possible 
therefore that a similar mechanism may underlie the observation that HEK- 
293-IP cells have a slower proliferative rate than wild type cells. Although in 
need of extensive further investigation, it is plausible to think that because 
of its high affinity and potential pre-coupling to Gi, the over-expressed IP 
receptor may be sequestering the pool of Gi necessary for the activation of 
ERKs by growth factors and other proliferative pathways.
G protein coupling of the IP receptor has been the subject of intensive 
debate. Namba and colleagues (Namba et a l 1994) showed that the 
murine IP receptor (mIP), when stably expressed in Chinese hamster ovary 
(CHO) cells, coupled independently to Gs and Gq. Iloprost increased cAMP 
and IP3 levels; the latter was insensitive to pertussis toxin as well as to a 24 
hr pre-treatment with cholera toxin, which degrades Gs (Namba et al., 
1994). Degrading Gs, nevertheless did result in a loss of the iloprost- 
induced rise in cAMP. In other studies, where the human IP receptor has 
been expressed in HEK-293 cells, independent coupling to Gs and Gq was 
demonstrated but no coupling to Gj was observed (Miggin and Kinsella, 
2002). Previously, Lawler and colleagues (Lawler et al., 2001) 
demonstrated that the mIP receptor, when expressed in HEK-293 cells, 
could only couple to Gq or Gj after coupling to Gs had first occurred and that 
such a process required PKA-mediated phosphorylation of the receptor. This 
is in contrast to studies in CHO cells where Gq coupling was not dependent 
on Gs and PKA (Chow et al., 2003). Some of the conflicting data may be 
explained by the fact that IP receptor coupling to different G proteins may 
be a cell-type dependent phenomenon.
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In native cells, there does appear to be a clear role for Gj/G0 involvement in 
mediating or modulating responses to PGI2 analogues. A PTx-sensitive G 
protein appears to mediate the vasodilatory effects of iloprost in the porcine 
cerebral circulation (Zucker and Leffler, 1998) and be required for the 
antiproliferative effects of cicaprost in mouse aorta (Kothapalli e ta /., 2003). 
The former study concluded that the IP receptor is linked to PLC, activating 
a component of adenylyl cyclase through a PKC-dependent phosphorylation. 
In rat tail artery the relaxant responses to cicaprost were substantially 
potentiated after pre-treatment with PTx (Orie et al., 2006), an effect 
similar to what was observed in HEK-293-IP cells, suggesting that Gi/Go 
coupling is not necessary for treprostinil-mediated inhibition of proliferation 
but rather is exacting some inhibitory influence on the responses to this 
agent.
3.11.3 Role o f the IP  receptor in mediating the anti-proliferative  
effects o f treprostinil
The present study demonstrates that the IP receptor alone can mediate the 
anti-proliferative effects of PGI2 analogues. The effects of treprostinil could 
be significantly reversed by the novel specific IP receptor antagonist, 
R01138452. In addition, both treprostinil and carbacyclin could only inhibit 
proliferation of HEK-293 cells transfected with the IP receptor. The IC50 for 
the anti-proliferative effects of treprostinil was found to be approximately 
16 nM. This value is similar to that observed previously in native human 
pulmonary artery smooth muscle cells where treprostinil inhibited serum- 
induced proliferation with an IC50 of 4.2 nM (Clapp et al., 2002) supporting 
a common mechanism likely to be through the IP receptor. These results
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are in agreement with data from IP receptor knockout mice whereby 
cicaprost was not able to inhibit the proliferation of cultured aortic smooth 
muscle cells from these mice even though it retained a strong anti- 
mitogenic effect in cells from wild type mice (Kothapalli et al., 2003). It 
would appear that the IP receptor is essential to mediate other PGI2- 
dependent cellular functions too since cicaprost could no longer produce 
hypotension or inhibit platelet aggregation in IP receptor knockout mice 
(Murata et al., 1997).
I t  has been suggested that the PGI2 analogues may have anti-proliferative 
effects independent of the IP receptor. Both carbacyclin and iloprost have 
been shown to bind and activate the PPARa and PPAR5 nuclear receptors 
(Hertz et al., 1996; Forman et al., 1997). Carbacyclin, however did not 
inhibit proliferation in HEK-293-WT cells thus excluding an IP-receptor 
independent mechanism. In addition, treprostinil was actually more potent 
than carbacyclin in HEK-293-IP cells, and it is generally thought that the 
former is much less cell-permeable. These observations suggest that drug 
cell-permeability does not confer an anti-proliferative advantage and 
strengthens the fact that these agents function primarily by activating the 
cell surface IP receptor.
Proliferation assays were performed in the presence of foetal bovine serum 
as we felt that serum, compared to treatment with just one growth factor, 
triggers proliferative pathways more akin to what would be observed in 
vivo. Serum in fact contains a plethora of hormone factors to stimulate cell 
growth and proliferation including platelet derived growth factor (PDGF) and 
insulin-like growth factor (IGF-1). There are therefore a number of different
146
3. cAMP generation and cell proliferation in HEK-293-IP cells
pro-proliferative pathways which are activated by serum, mainly the PI3 
kinase, the STAT and the MAPK-ERK pathways. In addition to growth 
factors, serum contains transport and binding proteins which take care 
among other things of the supply of hormones, minerals and lipids. A 
frequent critique of utilising serum is that batches can vary greatly in the 
amount and composition of growth factors and that there may be non­
specific effects due to the presence of other serum proteins. To control this 
as much as possible, the same batch of FBS was used for the majority of 
the experiments in this thesis.
3.11.4 Role o f cAMP in cell proliferation
In the present study we have confirmed that the anti-proliferative effects of 
treprostinil are primarily mediated by adenylyl cyclase as demonstrated by 
the reversal of the anti-mitogenic effects of the former with the antagonist, 
2'5'-dideoxyadenosine (DDA). Treprostinil-induced cAMP-elevation could 
also be significantly reversed with both IPRA and DDA; in both cases this 
correlated with a reversal of its growth effects in HEK-293-IP cells. These 
observations are in accordance with previous studies in the literature which 
demonstrated the reversal of PGI2 analogue-induced inhibition of 
proliferation with DDA in human PASMC (Wharton e ta /., 2000; Clapp e ta /., 
2002) and rat VSMC (Phillips et a/., 2005). In addition activating adenylyl 
cyclase directly with forskolin also inhibited proliferation in these cells as did 
inhibiting phosphodiesterases with IBMX. These results support a classical 
Gs pathway for treprostinil and an anti-proliferative role for cAMP.
Forskolin activated adenylyl cyclase and increased cAMP in both HEK-293-IP 
and control cells although in the former cell type forskolin-induced cAMP-
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elevation was significantly higher than in HEK-293-Zeo cells. This may be 
attributed to a process termed heterologous sensitisation. Acute activation 
of Grcoupled receptors inhibits adenylyl cyclase and attenuates cAMP 
accumulation; in contrast prolonged activation of Gi, as may occur in HEK- 
293-IP cells in the absence of ligand, typically sensitises adenylyl cyclase to 
subsequent activation by forskolin or Gs-coupled receptors (Watts and Neve, 
2005). This was first demonstrated by Sharma and colleagues for the Gi/0 
coupled morphine-activated 5 opioid receptors (Sharma e ta /., 1975). Later 
Thomas and Hoffman (Thomas and Hoffman, 1987) proposed a model in 
which the persistent activation of Gj-coupled receptors induces heterologous 
sensitisation in a PTX-sensitive, G protein-dependent fashion, resulting in 
enhanced cAMP responsiveness. The mechanism remains unknown but 
possibly involves alterations in Gs, Gj or adenylyl cyclase.
Although treprostinil appears to inhibit proliferation via a classical cAMP 
dependent mechanism, cAMP levels do not exclusively correlate with growth 
in all cases observed in this project. This is demonstrated by the following 
observations: 1) HEK-293-Zeo cells have a higher basal level of cAMP which 
is actually associated with a higher rate of proliferation. 2) Forskolin 
increases cAMP in HEK-293-Zeo cells but does not inhibit their proliferation. 
3) The higher level of cAMP induced by forskolin compared to treprostinil 
does not correlate with a more pronounced inhibition of proliferation in HEK- 
293-IP cells; the two agents in fact display roughly the same level of 
inhibition. The same was observed in human pulmonary artery smooth 
muscle (HPASM) cells where the cAMP-elevating properties of PGI2 
analogues did not correlate with their anti-proliferative effects (Clapp et al., 
2002). The explanations for these observations are not clear but suggest
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that the mere presence of the IP receptor modulates the response to cAMP 
elevating agents.
Cyclic AMP is one of the most studied second messenger signalling 
molecules. In many cases it is thought to be anti-proliferative and this 
effect has been attributed mainly to the ability of cAMP to inhibit the 
extracellular signal-related kinase (ERK) signalling pathway, the activity of 
which appears essential for the proliferation of many cell types, although 
other targets may also mediate these effects (reviewed in Dumaz and 
Marais, 2005). Cyclic AMP, via the activation of PKA, suppresses ERK 
signalling through its ability to target the serine/threonine-specific kinase C- 
RAF, a mechanism involving the uncoupling of RAS signalling to C-RAF 
(Figure 3.23)(Dumaz and Marais, 2005). In addition cAMP has also been 
shown to inhibit vascular smooth muscle cells by up-regulating p21, an 
inhibitor of G I cyclin-dependent kinases, and the tumour suppressor gene 
p53, which has been shown to induce cell cycle arrest at the G l/S  border 
(Hayashi e ta l., 2000).
However cAMP can also be pro-proliferative as has been shown in different 
cell types, including rat pheochrymocytoma PC12 cells, melanocytes and 
thyroid cells (Dumaz and Marais 2005) as well as in polycystic kidney 
epithelial cells (Belibi et al., 2004). The mechanism here is again thought to 
involve the ERK signalling pathway but in contrast to targeting C-RAF, cAMP 
is thought to act via B-RAF and this is linked to stimulation of proliferation. 
However, models to explain ERK activation are incomplete and may involve 
RAS, Rapl, Src , PKA and 14-3-3 as well as B-RAF (Figure 3.23) (Dumaz 
and Marais, 2005).
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Cyclic AMP signalling however is not as simple as the set of linear cascades 
described above might suggest. There are nine isoforms of adenylyl 
cyclases, eight phosphodiesterase families that hydrolyse cAMP, three PKA 
catalytic and four regulatory subunits and over thirty different AKAPs. Other 
than PKA, there are a number of other cAMP effectors, among these there 
are two Epacs (exchange proteins directly activated by cAMP), up to six 
cAMP-gated channels and cAMP-response-element-binding-protein (CREB) 
(Dumaz and Marais, 2005). Furthermore, the consequences of biological 
signalling have been shown to depend on cell type and specific cellular 
contexts. Suffice it to say, that the cAMP signalling pathway is exceptionally 
intricate and complex, and our understanding of its regulation
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Figure 3.23 The diverse effects of cAMP on cell proliferation can depend on the 
responses of C-RAF and B-RAF. The inhibition of the ERK mitogenic pathway by cAMP 
is linked to C-RAF inhibition. In contrast ERK activation by cAMP is attributed to B-RAF. 
The latter mechanism is still poorly understood but may involve Ras, Rap1, Src, PKA
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is far from complete. The global measurement of intracellular cAMP, 
therefore, probably trivialises the complexity of the cAMP signalling 
pathway.
Evidence is accumulating about the compartmentalisation of adenylyl 
cyclase and cAMP signalling into micro-domains within the cell and such a 
possibility would help explain some of the apparent inconsistencies in the 
cAMP responses observed in this project. I t  has been shown that cAMP 
kinetics are quite transient at the membrane compared with a gradual 
accumulation of cAMP in the cytoplasm and that these different cAMP 
localisations may have distinct signalling consequences (Cooper, 2005). This 
theory was first proposed in 1983 by Buxton and Brunton when they made 
a series of observations in cardiomyocytes that could only be explained by 
separate pools of cAMP in the same cell (Buxton and Brunton, 1983). A 
recent study has demonstrated that cicaprost and cilostamide, a PDE 
inhibitor, could both attenuate rat distal PASMC proliferation to a similar 
degree, however their cAMP elevating effects were markedly different, the 
former agent generating a far greater cAMP increase than the latter (Phillips 
et at., 2005). The authors of this study also suggest that this observation 
may be attributable to cAMP 'compartmentalisation' allowing small changes 
in cAMP levels within different subcellular environs to cause significant 
change in cellular functions. Although it is tempting to attribute this concept 
of'compartmentalisation' to the diverse effects of cAMP on growth observed 
in this project further investigations will be required.
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3.11.5 Role o f PKA in cell proliferation
We addressed the question of whether PKA was involved in mediating the 
anti-proliferative effects of IP receptor activation by treprostinil. As the main 
effector of cAMP it is generally thought that PKA mediates its anti­
proliferative effects. Research by Indolfi and colleagues (1997) 
demonstrated that inhibition of PKA reversed the neointimal formation 
induced by aminophylline, a phosphodiesterase inhibitor drug (Indolfi et al., 
1997) and a more recent study has shown it is crucial in mediating PGI2 
analogue induced differentiation of smooth muscle cells (Fetalvero et al., 
2006). Although Phillips and colleagues have recently elucidated PKA's 
involvement in inhibiting the anti-proliferative effects of cicaprost on PDGF- 
induced growth (Phillips et al., 2005) ours is the first study to investigate 
the role of PKA in treprostinil-driven inhibition of serum-induced 
proliferation. Both PKA antagonists H-89 and Rp-MB-cAMPS reversed the 
anti-proliferative effects of treprostinil in HEK-293-IP cells. Again this 
strongly supports a role for cAMP and ensuing PKA activity in producing 
these effects.
Both PKA antagonists however did not appear to fully reverse the growth 
inhibition of treprostinil. Cells pre-treated with PKA antagonists prior to 
stimulation with treprostinil failed to proliferate as much as cells treated 
with PKA antagonist alone. There are several possible explanations. Firstly, 
the concentration of antagonists used may not have been fully blocking PKA 
activity. The doses used however, were the maximal doses used in 
experiments reported in the literature. Secondly the antagonists may have 
some non-specific effects on other kinases. H-89 is often quoted as being a
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relatively specific blocker of PKA because of its lack of interaction with 
adenylyl cyclase or any phosphodiesterases (Hidaka and Kobayashi, 1992). 
However, a study by Davies and colleagues (Davies e ta /., 2000), found that 
H-89 affected several other types of protein kinases when they investigated 
the supposed specificity of a wide range of protein kinase inhibitors. H-89 in 
fact was found to inhibit 8 protein kinases out of the 24 that were tested by 
more than 80%. In addition there were three kinases (MSKI, S6K1 and rho- 
kinase II (ROCKII)) that were inhibited with a similar or greater potency 
than for PKA. This highlights the fact that care must be taken when 
interpreting results using this agent. Rp-MB-cAMPS is however, a more 
specific PKA antagonist being the Rp isomer of a cAMP analogue. This 
antagonist displayed the same effects as H-89, strengthening the validity of 
the results.
The most likely hypothesis is that additional PKA-independent pathways 
may be operating including signalling pathways activated by the IP receptor 
coupling to other G proteins. Indeed, some studies question the role of the 
cAMP/PKA pathway in mediating PGI2 effects altogether. According to a 
study by Kothapalli and colleagues (2003), cicaprost inhibits proliferation by 
inhibiting cyclin A expression. This occurs as a result of cicaprost inhibiting 
CRE occupancy by CREB as well as inhibiting the expression of the cell cycle 
regulator, cyclinE-cdk2. Furthermore the study shows that the actions of 
cicaprost are completely reversed in cells treated with PTX suggesting that 
in this context the IP receptor is mainly signalling through Gj to inhibit 
proliferation. This however does not concur with the observations of the 
present study where PTX in fact potentiated the effects of treprostinil on cell 
growth suggesting that Gs and the ensuing activation of adenylyl cyclase
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and not Gj is responsible for the anti-proliferative effects of treprostinil in 
our system.
Epacs are a family of cAMP-regulated guanine nucleotide exchange factors 
(cAMPGEFs) that mediate diverse cAMP-dependent cellular processes, 
including integrin-mediated cell adhesion, vascular endothelial cell barrier 
formation and cardiac myocyte gap junction formation but is independent of 
PKA signalling (reviewed in Holz et al., 2006). The latter property of Epacs 
suggests they could have a potential role in mediating some of the PKA- 
independent effects of PGI2 analogues we have observed in HEK-293-IP 
cells. In future studies their role could be tested with novel Epac-selective 
cAMP analogues (ESCAs) which fail to mimic cAMP at low concentrations.
In conclusion, we have shown that the IP receptor is crucial in mediating 
the anti-proliferative effects of treprostinil and that the majority of these 
effects appear to work via the classical Gs-adenylyl cyclase-PKA pathway. 
Further study is necessary to elucidate the signalling pathways downstream 
from PKA and the significance of potential PKA independent pathways. The 
possibility of a role for the nuclear receptor PPARy in the cAMP-PKA 
dependent mechanism or even as a mediator of a cAMP-PKA independent 
pathway was the subject of further investigation.
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Chapter 4
Can PGI2 analogues activate PPARy? 
Consequence for cell proliferation
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4.1 Introduction
PGI2 and its stable analogues classically mediate their biological effects by 
binding to the IP receptor activating adenylyl cyclase and triggering 
signalling through the cAMP/PKA cascade. This study so far has shown that 
IP receptor-mediated anti-proliferative effects largely involve cAMP but may 
also be regulated by pathways independent of cAMP and PKA.
In addition to activating cell surface receptors PGI2 is also a ligand for 
PPARs, a family of nuclear transcription factors that bind to specific PPREs 
in the promoter region of target genes to regulate their expression (Lim 
and Dey, 2002; Wise, 2003). The PPAR family comprises of three isoforms, 
a, 5 (p) and y, which are activated by a broad spectrum of ligands, 
including hypolipidemic agents and derivatives produced by the cyclo- 
oxygenase and lipoxygenase pathway to regulate biological processes such 
as lipid metabolism and insulin sensitivity (Willson and Wahli, 1997; 
Desvergne and Wahli, 1999; Lehrke and Lazar, 2005). Because of the 
complex interaction of prostaglandins with PPARs, the function of 
endogenous regulation by PGI2 has been hard to tease out. Nonetheless, 
PGI2 signalling through PPARS is thought to have important roles in embryo 
implantation (Lim et al., 1999), tumourgenesis (Gupta et al., 2000, 
Fukumoto et al., 2005) and apoptosis (Hatae et al., 2001). I t  is less clear if 
PGI2 is a major endogenous ligand for PPARa and PPARy.
Stable PGI2 analogues like iloprost and carbacyclin (cPGI2), also act as PPAR 
ligands, directly binding to and causing transcriptional activation of PPARa 
and PPARS in vitro (Forman et al., 1997). The latter may in part mediate 
the anti-proliferative effects of treprostinil in lung fibroblasts (Ali et al.,
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2006). Surprisingly no information exists about whether these analogues 
can regulate PPARy. Interestingly, the relatively selective IP receptor 
agonist, cicaprost does not bind or promote activation of either PPARa or 
PPARS (Forman et al., 1997). Thus, cicaprost has often been used 
experimentally to distinguish between mechanisms involving cell surface IP 
receptors and PPARs (Wise, 2003; Lim and Dey, 2002). Moreover, PPAR 
activation is readily observed in cells not expressing the IP receptor (Hatae 
et al., 2001; Hertz et al., 1996; Forman et al., 1997), and this has led to 
the assumption that this receptor plays little role in directly regulating PPAR 
function. However, PPARs are substrates for several kinases, including PKA, 
which can phosphorylate all isoforms and enhance PPAR activity both in the 
absence and presence of ligands (Lazennec et al., 2000). This raises the 
intriguing possibility that the IP receptor may contribute to the regulation of 
PPARs.
The aim of this study was therefore to investigate whether PGI2 analogues 
could regulate PPARy activity. Given its wide expression in vascular tissue 
and the immune system, and its broad role as a suppressor of 
inflammation, tissue injury and cell proliferation, particularly in the lung 
(Standiford et al., 2005), PPARy could represent an important therapeutic 
target for PGI2 analogues. Using a cell-based reporter gene assay, the 
effects of PGI2 analogues on PPARy activity were examined, and the role of 
the IP receptor was assessed using the IP receptor antagonist (ROl 138452; 
IPRA) in HEK-293 cell lines stably expressing either the IP receptor or the 
empty plasmid. The protocol was optimised to take into account non­
specific effects of pharmacological agents on plasmid vectors as well as to 
better control for transfection efficiency and experimental error (see section
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2.7.1). Pharmacological tools were used to further dissect the mechanism 
of PPARy activation and proliferation was assessed using the same protocol 
used extensively in chapter 3.
RESULTS
4 .2  Effect of rosiglitazone on PPARy activation
A reporter gene expressing the ligand-binding domain (LBD) of PPARy 
(Gelman et a l., 1999) was transiently transfected into HEK-293-IP cells and 
activity measured using a luciferase-based assay. To test the functionality 
of the PPARy construct in our system, we investigated the effect of the 
specific PPARy agonist, rosiglitazone. At 1 pM this agent significantly 
increased luciferase levels by 4.86 ± 0.58 fold compared to untreated 
control (n=12, P<0.001), an effect essentially abolished by pre-treatm ent 
with the selective PPARy antagonist, GW9662 (1 pM; n=12, PcO.OOl; 
Figure 4.1). The antagonist alone had no effect on luciferase levels (Figure
4.1).
4.3  Effect of PGI2 analogues on PPARy activation
I t  has previously been reported that both PPARa and PPARS can be 
activated by PGI2 analogues (Forman et al., 1997), though it is not known 
whether such agents can activate PPARy. We therefore investigated the 
effects of PGI2 analogues on the PPARy reporter gene assay. Both 
treprostinil and carbacyclin significantly increased PPARy activity by 1.97 ± 
0.14 fold and 2.52 ± 0.13 fold respectively (n=12, PcO.OOl) at a 
concentration of 1 pM (Figure 4.2). Furthermore activation by both 
analogues was significantly reversed using 1 pM GW9662 (treprostinil,
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Figure 4.1 HEK-293-IP cells were transiently transfected with pGAL5TKpGL3, pMLUC-2 and either 
GAL4-pcDNA3 (control -  white bars) or GAL4-hPPAR^pcDNA3 (reporter -  black bars). After 48 hr, 
cells were stimulated with 10% FBS in the absence of drugs (untreated) or presence of rosiglitazone 
(ROSI, 1 /xM), GW-9662 or a combination as shown. Cells were pre-treated with GW9662 (PPAR7  
antagonist) for 1 hr prior to stimulation with ROSI. Luciferase activity was determined after 24 hr and 
normalised to Renilla activity. Results are expressed as mean fold increase in luciferase activity 
relative to untreated control ± s.e.m. (n=12,3 separate transfections). *** = P<0.001.
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Figure 4.2 Transiently transefected (as in Figure 4.1) HEK-293-IP cells were stimulated with 10% 
FBS (untreated) ± either treprostinil (TREP), carbacyclin (CARBA), GW9662 (all at 1 /xM) or a 
combination. Cells were pre-treated with GW9662 for 1 hr prior to the addition of agonists. Luciferase 
activity was determined 24 hr after FBS stimulation and normalised to Renilla activity. Results are 
expressed as mean fold increase in luciferase activity relative to untreated control ± s.e.m. (n=12, 3 
separate transfections). *=P<0.05, *** = P<0.001.
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n=12, P<0.05 and carbacyclin, n=12, P<0.001; Figure 4.2) supporting the 
notion that PGI2-mediated increase in luciferase activity is PPARy specific. 
Treprostinil induced-PPARy activation was also dose-dependent, with 
concentrations as low as 100 nM causing activation, an effect which peaked 
at around 10 pM (Figure 4.3). In addition, the relatively selective IP 
receptor agonist, cicaprost (1 pM) significantly increased luciferase 
activation by 2.2 ± 0.46 fold compared to untreated (n=16, P<0.05; Figure
4.4 C).
4 .4  Role of the IP  receptor in PG I2 mediated PPARy activation
Activation of PPARs via the conventional route occurs through binding of an 
agonist to the LBD and this mechanism appears to account for the effects 
of carbacyclin and iloprost on PPARa and PPARS (Forman et at., 1997). To 
test whether PPARy activation by treprostinil, carbacyclin and cicaprost 
occurs via either direct ligand binding or is mediated through activation of 
the IP receptor, we examined the effect of the IP receptor antagonist, 
R01183452 (IPRA), in cells containing or lacking the IP receptor. 
Treprostinil, carbacyclin and cicaprost all failed to significantly activate 
PPARy at 1 pM in HEK-293-IP cells pre-treated with 1 pM IPRA for 1 hr 
(Figure 4.4 A, B & C). This antagonist was not an inhibitor of PPARy 
activity, since it did not inhibit rosiglitazone activation; on the contrary 
there was a significant increase in luciferase activity from 8.05 ± 0.83 fold 
to 13.17 ± 2.84 fold in cells treated with IPRA (n=12, P=0.023; Figure 
4.5). Furthermore, in cells lacking the IP receptor, neither carbacyclin nor 
treprostinil activated PPARy even at the higher dose of 10 pM. This
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Figure 4.3 Transiently transefected (as Figure 4.1) HEK-293-IP cells were stimulated with 10% FBS 
(untreated) ± treprostinil (TREP) at varying concentrations as shown. Activation of PPARy 
transcription was assessed by measuring relative light units after 24hr of stimulation using a dual 
luciferase assay system. Luciferase activity was determined 24 hr after FBS stimulation and 
normalised to Renilla activity. Results are expressed as mean fold increase in relative luciferase 
activity above untreated control as ± s.e.m. (n=12,3 separate transfections). *** = P<0.001,
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Figure 4.4 Transfected HEK-293-IP cells were stimulated with 10%FBS (untreated) ± either 
treprostinil (TREP, A), carbacyclin (CARBA, B), cicaprost (CICA, C), IPRA (all at 1 /*M) or a 
combination where cells were pre-treated with antagonist for 1 hr. Luciferase activity was determined 
24 hr after stimulation and normalised to Renilla activity. Results are expressed as mean fold 
increase in luciferase activity relative to untreated control ± s.e.m. (n=12-16, 3-4 separate 
transfections). *=p< 0.05, ***=p< 0.001.
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Figure 4.5 Transfected HEK-293-IP cells were stimulated with 10%FBS (untreated) ± either 
rosiglitazone (ROSI), IPRA (all at 1 /M ) or a combination as shown (cells pre-treated with antagonist 
for 1 hr). Luciferase activity was determined 24 hr after stimulation and normalised to Renilla activity. 
Results are expressed as mean fold increase in luciferase activity relative to untreated control ± 
s.e.m. (n=12,3 separate transfections). * = P<0.05.
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Figure 4.6 Transfected HEK-293-Zeo cells were stimulated with 10%FBS alone (untreated) ± 
rosiglitazone (ROSI, 1 /xM), treprostinil (TREP) or (CARBA). Luciferase activity was determined 24 hr 
after stimulation and normalised to Renilla activity. Results are expressed as mean fold increase in 
relative luciferase activity from untreated control ± s.e.m. (n=12, 3 separate transfections).
*~=p<0 .0 0 1 .
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occurred despite the effectiveness of rosiglitazone at activating PPARy 
(Figure 4.6).
4 .5  Role of cAMP and PKA in PG I2 mediated PPARy activation
Having established that PGI2 analogues can activate PPARy through the IP 
receptor, we assessed whether activation involved the cyclic AMP pathway, 
possibly via a PKA-dependent phosphorylation of PPARy. Forskolin, a direct 
adenylyl cyclase activator failed to have any significant effect on luciferase 
activity in either HEK-293-Zeo or HEK-293 IP cells (Figure 4.7 A & B), even 
though it dramatically increased the levels of intracellular cAMP in both cell 
types (see Figure 3.21 B, chapter 3). This suggests that cAMP alone cannot 
directly activate PPARy. In addition, neither the adenylyl cyclase inhibitor, 
2'5'-dideoxyadenosine (DDA) nor the selective PKA antagonist Rp-cAMPS 
(both at 100 pM) significantly reduced activation of PPARy by treprostinil in 
HEK-293 IP cells (Figure 4.8).
The alternative, less specific PKA antagonist H-89 had a different effect to 
Rp-cAMPS. When HEK-293-IP cells were treated with 10 pM H-89 alone for 
24 hrs, the basal luciferase activity was lower relative to untreated control 
(0.47 ± 0.07 fold, n = 12, P<0.01; Figure 4.9) indicating that H-89 is having 
an effect on its own, maybe even blocking a kinase needed to drive optimal 
mTK promoter activity. When cells were pre-treated for 1 hr with H-89 prior 
to the addition of 1 pM treprostinil, the activating effect of this agent (2.04 
± 0.12 fold increase) was abolished (n=12, P<0.001) with luciferase levels 
dropping slightly below control levels to 0.73 ± 0.09 fold (Figure 4.9). As 
discussed in chapter 3, H-89, although marketed as a specific and potent 
PKA antagonist, can also inhibit a number of other kinases with the same
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Figure 4.7 Transfected HEK-293-Zeo cells (A) or HEK-293-IP cells (B) were stimulated with 10% 
FBS alone (untreated) or in the presence of forskolin (FORSK, 10 /xM). Luciferase activity was 
determined 24 hr after stimulation and normalised to Renilla activity. Results are expressed as mean 
fold increase in relative luciferase activity from untreated control ± s.e.m. (n=12, 3 separate 
transfections).
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Figure 4.8 Transfected HEK-293-IP cells were stimulated with 10%FBS alone (untreated) or in the 
presence of treprostinil (TREP; 1 /xM), 2’5’-DDA (DDA; 100 /xM), the PKA antagonist, Rp-cAMPS 
(100 /xM) or in combination as shown (cells pre-treated with antagonist for 1 hr). Luciferase activity 
was determined 24 hr after stimulation and normalised to Renilla activity. Results are expressed as 
mean fold increase relative to luciferase activity from untreated control ± s.e.m. (n=12, 3 separate 
transfections). *** = P<0.001.
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Figure 4.9 Transfected HEK-293-IP cells were stimulated with 10% FBS alone (untreated) ± H-89 
(10 /xM), treprostinil (TREP, 1 /xM), or a combination as shown. Cells were pre-treated with H-89 for 
45 mins prior to stimulation with TREP. Luciferase activity was determined 24 hr after stimulation and 
normalised to Renilla activity. Results are expressed as mean fold increase in luciferase activity 
relative to untreated control ± s.e.m. (n=12,3 separate transfections). ** = P<0.01, *** = P<0.001.
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potency as for PKA (Davies et a l,  2000). Taken together, these data 
suggest that the cAMP/PKA pathway is not a major mediator of PPARy 
activation by PGI2 analogues.
4 .6  An investigation into other putative mediators of PGI2-m ediated  
PPARy activation
4.6.1 Staurosporine-sensitive signalling
Although for the reasons shown above, it is unlikely that PKA is responsible 
for PPARy activation by PGI2 analogues, the fact that H-89 did have such a 
strong inhibitory effect on treprostinil-induced luciferase activity, leads us 
to assume that activation of PPARy is mediated via a kinase-dependent 
phosphorylation mechanism. PKCa and PKCpiI have been shown to 
phosphorylate PPARa in human liver cells at serines 179 and 230 which 
increases ligand-induced PPARa transcriptional activity (Blanquart et al., 
2004). Both serine sites are present in the D-E-F region, the same as 
present in our GAL4 construct. In addition it is an attractive hypothesis to 
think that a similar mechanism to that described with PKC and PPARa may 
occur in our system.
Staurosporine is a widely used cell permeable, potent (IC50 = 5 nM) but 
non-selective inhibitor of PKC (Tamaoki et al., 1986). To test the role of this 
kinase, HEK-293-IP cells were treated with 1 pM staurosporine, a 
concentration that should be sufficient to fully inhibit PKC. Treatment of 
HEK-293-IP cells with 1 pM staurosporine alone for 24 hrs had no effect on 
luciferase activity (n = 16, R=0.81; Figure 4.10). Pre-treatment with 1 pM 
staurosporine for 1 hr prior to stimulation with 1 pM treprostinil had no
170
4. PGh analogues, PPARy and cell proliferation
effect on treprostinil-mediated luciferase increase (n=16, P<0.73; Figure 
4.10). Conversely, when the dose of staurosporine was increased to 10 pM, 
the treprostinil-induced luciferase increase (2.19 ± 0.31 fold) was 
completely inhibited, with the levels falling below those of the untreated 
control (0.47 ± 0.15 fold, n = 16, RcO.001; Figure 4.10). Thus, the effects 
observed with 10 pM are not likely to be PKC dependent but rather one of 
many kinases that staurosporine can inhibit. Similar to the conclusions one 
draws from the results obtained with H-89, we still hypothesise tha t the 
mechanism involves a kinase, though it is unlikely to involve PKC, PKA, 
CaMKII, or myosin light chain kinase (MLCK), all of which should effectively 
be inhibited at 1 pM.
4 .6 .2  AMP-activated kinase
As is the case with IP receptor and PPARy activation, AMP-activated kinase 
(AMPK), a metabolite-sensing protein serine/threonine kinase, is known to 
inhibit proliferation at the G1 stage of the cell cycle (Igata et al., 2005) and 
more recently has been shown to be activated by thiazolidinediones (Han 
and Roman, 2006; LeBrasseur et a/., 2006).
To test whether AMPK could underlie PPARy activation, HEK-293-IP cells 
were first treated with the AMPK agonist, AICAR (100 pM). This agent failed 
to significantly activate PPARy (n = 12, P= 0.24; Figure 4.11), suggesting 
that AMPK alone cannot increase PPARy activity. To test whether AMPK was 
responsible for treprostinil-mediated PPARy activation, cells were pre­
treated for 1 hr with two inhibitors, quercetin (20 pM) and Ara-A (100 pM). 
Interestingly, AMPK is also potently inhibited by H-89 (Davies et al., 2000). 
Pre-treatment with these two antagonists produced two very different
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results. Quercetin had no significant effect on treprostinil induced PPARy 
activation (n=12, P=0.87). In contrast, Ara-A significantly inhibited PPARy 
activation by treprostinil, reversing luciferase levels from 2.03 ± 0.13 fold 
to 1.24 ± 0.19 (n=12, P<0.005; Figure 4.11). In light of these results the 
role of AMPK in this mechanism has not been proven.
4 .6 .3  G,/G0
As discussed in chapter 3, it is possible that the IP receptor may be pre­
coupled to Gj protein mediating some of the effects of receptor activation. 
To test whether Gi specifically had a role in mediating treprostinil-induced 
activation of PPARy, luciferase activity was measured in HEK-293-IP cells 
with or w ithout pre-treatment with PTx, an agent which prevents 
downstream signalling of G j/G 0. Treatment of HEK-293-IP cells with 100 
ng/ml of PTx for 40 hr alone had no effect on luciferase activity (n=16, 
P=0.61; Figure 4.12). When cells were pre-treated for 16 hrs with PTx 
before the addition of 1 pM treprostinil, there was a small but non 
significant increase in luciferase activity from 2.19 ± 0.31 fold in the 
absence to 3.15 ± 0.56 fold (n=16, P=0.1263) in the presence of PTx. 
These results suggest that activation of GJG0 is not a pre-requisite for 
PPARy activation by treprostinil (Figure 4.12).
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Figure 4.10 Transiently transfected (as before) HEK-293-IP cells were stimulated with 10% FBS 
alone (untreated) ± treprostinil (TREP, 1 jiM), staurosporine (STAURO, 1 or 10 nM) or a 
combination as shown. Cells were pre-treated with STAURO for 1 hr prior to stimulation with TREP. 
Luciferase activity was determined 24 hr after stimulation and normalised to Renilla activity. Results 
are expressed as mean fold increase in luciferase activity relative to untreated control ± s.e.m. 
(n=12,3 separate transfections). ** = P<0.01, *** = P<0.001.
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Figure 4.11 Transfected HEK-293-IP cells were stimulated with 10% FBS alone (untreated) ± 
AICAR (100 pM), Ara A (100 /*M) quercetin (QUERC, 20 /*M), treprostinil (TREP, 1 /xM) or a 
combination as shown. Cells were pre-treated with antagonists for 1 hr prior to stimulation with 
TREP. Luciferase activity was determined 24 hr after stimulation and normalised to Renilla activity. 
Results are expressed as mean fold increase in luciferase activity relative to untreated control ± 
s.e.m. (n=12,3 separate transfections). ** = P<0.01, ***=p<0.001.
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Figure 4.12 Transfected HEK-293-IP cells were stimulated with 10% FBS alone (untreated) ± 
treprostinil (TREP, 1 /xM), pertussis toxin (PTx, 100 ng/ml) or a combination as shown. Cells were 
pretreated with PTx for 16 hr prior to stimulation with TREP. Luciferase activity was determined 24 hr 
after stimulation and normalised to Renilla activity. Results are expressed as mean fold increase in 
luciferase activity relative to untreated control ± s.e.m. (n=16,4 separate transfections). ** = P<0 .0 1 .
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4.7 Role of PPARy in cell proliferation
To test whether PPARy underlies any of the anti-proliferative effects of 
treprostinil, HEK-293-IP cells were pre-treated with the relatively specific 
PPARy antagonist GW9662 prior to treatment with the PGI2 analogue. We 
wished to determine whether PPARy could account for the remainder of the 
PKA-independent effects of treprostinil on cell growth (Figure 4.13 A). Pre­
treatment of HEK-293-IP cells with 1 pM GW9662 for 1 hr significantly 
(P<0.05) reversed the anti proliferative effect of 100 nM treprostinil by 
about 23%. As shown in Figure 4.13 B, growth was 29.6 ± 3.6% (n=9) of 
the normal response to 10 % FBS in the absence of GW9662, rising to 44.4 
± 4.3% (n=9) in the presence of GW9662. These results suggest that 
PPARy may indeed have a role in mediating, at least in part, the anti­
proliferative effects of treprostinil.
To test the effect of direct activation of PPARy on cell proliferation, both 
HEK-293-IP and HEK-293-WT were treated with varying doses of 
rosiglitazone and counted after 48 hr. Surprisingly the presence of the IP 
receptor markedly altered the response to rosiglitazone in the two cell 
types. In HEK-293-IP cells, this agent inhibited proliferation in a dose- 
dependent (0.1-100 pM) manner (n=24, P<0.001; Figure 4.14). At high 
doses of above 10 pM we cannot exclude that the pronounced anti­
proliferative effects of rosiglitazone may be due to toxic effects of the drug, 
a severe limitation of the study is in fact the absence of data analysing cell 
death following treatment with these agents. In HEK-293-WT cells, 
rosiglitazone markedly increased proliferation over and above that observed
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in the presence of 10% FBS at doses below 30 pM and only inhibited 
proliferation at the highest dose (100 pM) (Figure 4.14). For example, at 10 
pM, rosiglitazone increased proliferation by 84.5 ± 19.5% over untreated 
control cells (n=18, P<0.001).
To determine the potential role of PPARa and PPAR6 on cell growth, the 
effect of agonists of these PPARs were also assessed. Somewhat similar to 
rosiglitazone, the PPAR5 agonist L165,041 had differential effects in the two 
cell types. In HEK-293-IP cells, this agent had no significant effect on 
growth over a wide concentration range (l-1000nM ). In contrast, in HEK- 
293-WT, the PPARS agonist increased cell proliferation, although the 
relationship was bell shaped (Figure 4.15). On the other hand, the PPARa 
agonist GW7647 appeared to have no consistent effect on growth in either 
cell type (Figure 4.16). Thus it would appear that the only PPAR able to 
inhibit the growth of HEK-293-IP cells, was the y isoform.
4 .8  Summary
• The PGI2 analogues treprostinil, carbacyclin and cicaprost activate 
PPARy in a luciferase based reporter gene assay.
• PPARy activation by PGI2 analogues was IP receptor dependent and 
likely to involve a phosphorylation mechanism.
• The mechanism of PPARy activation does not appear to involve the 
cAMP/PKA or PKC pathway.
• It  is yet unclear if AMPK has a role in mediating treprostinil induced 
PPARy activation.
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• Gj/Go activation is not a pre-requisite for PPARy activation by 
treprostinil.
• PPARy activation may account for the PKA independent anti-proliferative 
effects of treprostinil
• The IP receptor modulates the growth responses of PPARy and PPARS 
agonists.
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Figure 4.13 A. Schematics illustrating the inhibition of PPARy with GW9662 and the possible effect 
on TREP induced inhibition of proliferation. It also illustrates the hypothesis that PPARy may account 
for the remaining anti-proliferative effects which do not appear to be mediated by the PKA pathway. 
B. Growth arrested HEK-293-IP cells were stimulated with MEM + 10% FBS and either left untreated 
or treated with GW9662 (1 /xM), TREP (100 nM) or a combination as shown. Cells were pretreated 
with GW9662 for 1 hr prior to stimulation with TREP. Cells were counted 48 hours following 
treatment. Data expressed as % proliferation relative to proliferative response mediated by 10% FBS 
alone and expressed as mean ± S.E.M. (n=9). * = P<0.05.
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Figure 4.14 Effect of Rosiglitazone (ROSI) on cell proliferation. Growth arrested HEK-293-Zeo (■) 
and HEK-293-IP (•) cells were stimulated with 10% FBS ± the PPAR7  agonist, ROSI at the 
concentrations shown. Cells were counted after 48 hr and data shown as % cell proliferation relative 
to the proliferative response mediated by 10% FBS alone and expressed as mean ± S.E.M. (n=18). 
*•* = P<0.001
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Figure 4.15 Effect of L165,041 on cell proliferation. Growth arrested HEK-293-Zeo (■) and HEK- 
293-IP (•) cells were stimulated with 10% FBS ± the PPAR6  agonist, L165,041, at different 
concentrations and counted after 48 hrs. Data expressed as mean % proliferative response relative 
to proliferation mediated by 10% FBS alone ± S.E.M. (n=18).
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Figure 4.16 Effect of GW7647 on cell proliferation. Growth arrested HEK-293-Zeo (■) and HEK-293- 
IP (•) cells were stimulated with 10% FBS ± the PPARa agonist, GW7647, at different 
concentrations and counted after 48 hrs. Data expressed as mean % proliferative response relative 
to proliferation mediated by 10% FBS alone ± S.E.M. (n=18).
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4.9 Discussion
The present study makes the novel observation that activation of PPARy by 
PGI2 analogues is dependent on the presence of the IP receptor and 
appears to be distinct from the classical pathway of activation through 
direct ligand binding. This contrasts with earlier studies where PGI2 
analogues induced activation of PPARa and 5 in cells not expressing the IP 
receptor (Hertz et at., 1996; Forman et a/., 1997) but is consistent with a 
recent study reporting the absence of treprostinil effects on PPARy activity 
in wild type HEK-293 cells (Ali e ta /., 2006). The mechanism of activation is 
still unclear but is likely to involve phosphorylation, but not through cyclic 
AMP-dependent PKA. I t  is possible that such regulation may previously 
have been missed largely due to examination of PPAR function in cells 
lacking the IP receptor.
4.9.1 Potential mechanisms o f PPARy activation by PGI2 analogues.
The construct used in the luciferase assays contained the Gal4 DNA binding 
domain (DBD) fused to the C terminal part of the PPARy containing the D 
(hinge region), E (the ligand binding domain; LBD) and F domains (Gelman 
et a/., 1999). Thus, for treatm ent with a cell permeable analogue like 
carbacyclin, one might predict PPARy activation to occur in control HEK-293 
cells if the primary mechanism was indeed direct binding. Clearly this was 
not the case, with concentrations as high as 10 pM failing to significantly 
activate PPARy, despite previous data showing near maximal binding and 
activation of PPARa and PPARS with respect to their selective ligand
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activators (Forman et al., 1997). Interestingly, cicaprost, which does not 
bind to or activate either a or 6 isoforms (Forman et al., 1997) was also an 
effective activator of our PPARy construct, supporting the notion that 
receptor expression is crucial. However, it is still not possible to exclude the 
possibility that the IP receptor is required to promote ligand binding by 
these agents, at least for this PPAR isoform.
There is a growing body of evidence indicating that PPARs can be activated 
via phosphorylation (Diradourian et al., 2005; Gelman et al., 2005) and 
involve cell surface receptor activation. In rat adipocytes, both PPARa and 
PPARy are phosphorylated following treatment with insulin, an effect 
associated with enhanced transcriptional activity (Shalev et at., 1996; 
Zhang et at., 1996). This insulin-dependent phosphorylation has been 
attributed to activation of the mitogen activated protein kinase (MAPK) 
pathway, involving serine residues contained within the N-terminal ligand- 
independent activation domain (AF-1) of PPARa (Juge-Aubry et al., 1999) 
and PPARy (Zhang et al., 1996). Likewise, the eicosanoid, prostaglandin F2a 
(PGF2a), phosphorylates PPARy through a mechanism dependent on the FP 
receptor and the MAPK pathway (Reginato et al., 1998). Such 
phosphorylation by the FP receptor leads to an inhibition of adipogenesis in 
3T3-L1 cells through suppression of PPARy activity (Reginato et al., 1998).
Most of the PPAR phosphorylation sites described are located in the N- 
terminal (A/B domain; LBD). Since the construct used in this project lacks 
this domain, the data gathered here suggests there could be a 
phosphorylation site or a ligand independent activation site located in the 
C-terminal (D, E or F domain; DBD) to promote ligand-independent
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transcriptional activity. Alternatively, IP receptor activation could simply 
enhance endogenous ligand binding to the LBD, as is the case with 
phosphorylation of the A/B domain in PPARy (Shao et al., 1998) or 
phosphorylation of PPARa serine residues 179 and 230 by PKC (Blanquart 
et al., 2004). Another possibility is the promotion of recruitment or 
dissociation of co-factors. This may occur either via phosphorylation of 
PPARy or the co-activators themselves (Diradourian et al., 2005).
Given the ability of PKA to activate PPARy, both in the presence and 
absence of exogenous ligands (Lazennec et al., 2000) and the established 
coupling of the IP receptor to Gs (Namba et al., 1994), it was considered 
that IP receptor-dependent activation of PPARy would be reliant on cAMP 
and PKA activity. Cyclic AMP is known to regulate PPARS-mediated pre­
adipocyte proliferation and plays an important role in PPARS mediated gene 
transactivation (Hansen et al., 2001); however the exact mechanism 
remains unclear but may involve PKA. The authors of the latter study 
suggest that PKA's ability to influence heterodimerisation (Bhat et at., 
1994; Rochette-Egly et a!., 1995; Chen et al., 1999), DNA binding 
(Sugawara et al., 1994) and transactivation (Taneja et al., 1997; Sadar, 
1999) of other nuclear receptors may also mediate cAMP-dependent effects 
on PPARS. In addition it has been shown that increased cAMP levels 
diminish or abolish interaction between nuclear hormones and co­
repressors (Wagner et al., 1998; Lavinsky et al., 1998), another way in 
which the cAMP-PKA signalling mechanism may affect PPAR activation.
Surprisingly cAMP did not appear to play a major role in the IP receptor- 
dependent activation of PPARy. In this study forskolin failed to activate
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PPARy and both the adenylyl cyclase antagonist, DDA, and the specific PKA 
antagonist, Rp-cAMPS failed to significantly reverse the PPARy-activating 
effect of treprostinil.
By using truncated PPARa constructs, Lazennec and colleagues (2000) 
demonstrated that the AF-2 domain containing the LBD (as is present in 
our GAL4-PPARy construct) was the most important domain for 
transactivation by PKA activators. However, there are PKA phosphorylation 
sites mapped across the whole of the PPARy structure, the main site being 
located in the DBD. One can therefore not entirely exclude PKA-dependent 
effects if other truncated PPARy forms of the GAL4 construct were to be 
used. Moreover, it is possible that several domains of PPAR need to be 
phosphorylated in order for PKA to activate PPARy. In addition, the small 
(though not significant) reversal in activation caused by DDA and Rp-cAMPS 
suggests that there may be a small fraction of the effect dependent on a 
cAMP/PKA-dependent pathway.
I t  is not altogether surprising that cAMP does not appear to mediate the 
effects of PGI2 analogues on PPARy activity, since previous data from this 
and other laboratories also describe a distinctly cAMP-independent pathway 
that mediates the vascular relaxant responses to PGI2 analogues in blood 
vessels (Turcato and Clapp, 1999; Tanaka et al., 2004, Orie et al., 2006). 
Furthermore, the IP receptor is known to couple to multiple G-proteins 
including G i/G 0 and Gq (Wise and Jones, 2000), which may contribute in 
some way to PPARy activation. However, we can rule out an involvement of 
Gi/Go as pertussis toxin, rather than inhibiting the effects of treprostinil, 
actually potentiated PPARy activation somewhat. Likewise, the relaxant
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responses to cicaprost were significantly enhanced following PTx treatm ent 
(Orie et al., 2006), possibly suggesting that the IP receptor couples to 
G/'/Go to counterbalance the effects of Gs stimulation.
The PKA antagonist, H-89, not only significantly reduced basal PPARy 
activity in HEK-293-IP cells but also prevented treprostinil activation of 
PPARy. However, in light of data obtained with forskolin, DDA and 
RpCAMPS, and the fact that this agent has effects on a broad spectrum of 
kinases, we conclude that the effects observed with H-89 are probably not 
via PKA. Similarly 1 pM staurosporine, which should adequately block PKA 
(IC50 15 nM) (Meyer et al., 1989), also failed to inhibit the effects of 
treprostinil. Only the high, non-specific dose of 10 pM, had a dampening 
effect on treprostinil induced PPARy activation. Like H-89, staurosporine 
can inhibit a broad spectrum of kinases including PKC (5 nM), PKG (18 nM), 
CaMKII (20 nM), MLCK (21 nM) and ERK1 (1.5 pM) (Gschwendt et al., 
1994; Meggio et al., 1995). I t  is logical to suggest that treprostinil-induced 
PPARy activation is regulated by a phosphorylation mechanism and the 
latter may also be responsible for a basal level of activation. Whether 
phosphorylation occurs directly on the nuclear receptor or whether it works 
by regulating co-repressors or co-activators remains to be established.
AMP-activated kinase (AMPK) is a metabolite-sensing protein 
serine/threonine kinase (Hardie and Carling, 1997) which acts as a cellular 
fuel sensor and is an important mediator of exercise-induced glucose 
uptake in skeletal muscle (Hardie e ta /., 2003). I t  is mainly activated under 
stress conditions that are associated with an increased AMP/ATP ratio such 
as heat shock and hypoxia (Kemp et al., 2003). A number of signalling
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pathways have been reported to be regulated by AMPK through direct 
phosphorylation (Motoshima et al., 2006). There has been a growing body 
of evidence showing that activation of AMPK by the widely used AMP 
mimetic aminoimidazole-4-carboxamide ribonucleoside (AICAR) causes cell 
cycle arrest in a number of cell lines such as hepatoma HepG2 cells 
(Imamura et al., 2001), mouse embryonic fibroblasts (Jones et al., 2005) 
and human aortic smooth muscle cells (Igata et al., 2005).
The mechanism by which AMPK inhibits cell proliferation is still not entirely 
understood but it is thought to involve the accumulation of the p53 tum our 
suppressor via a phosphorylation of its Ser-15 residue and subsequent 
upregulation of the CDKI p21CIP (Motoshima et al., 2006) as well as 
upregulation of p27KIP (Rattan et al., 2005). Interestingly as with 
prostacyclin treatm ent and PPARy activation, AMPK activation, in serum or 
PDGF-BB stimulated smooth muscle cells, inhibits proliferation by causing 
cell cycle arrest at the G1 phase (Igata et al., 2005). In addition 
thiazolidinediones have been shown to activate AMPK although it is unclear 
whether this is through a PPARy-dependent or independent mechanism 
(Han and Roman, 2006; LeBrasseur et al., 2006).
AMPK was tested as a potential mediator of the pathway studied in this 
investigation. The reversal of treprostinil-mediated effects with the 
antagonists Ara-A and H-89 (also able to inhibit this kinase) made it an 
eligible candidate for PPARy activation. Against this, was the observation, 
that a third antagonist, quercetin, did not follow suit nor did the AMPK 
agonist, AICAR increase PPARy activity. Together these data provide mixed 
evidence both for and against a possible role for this kinase. Again, there
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are problems with agent specificity. H-89, quercetin, and Ara-A all have a 
number of other targets. The latter is in fact marketed by Sigma-Aldrich as 
an adenylyl cyclase antagonist. We cannot yet exclude AMPK as a mediator 
and testing with a further antagonist, iodotubercidine could shed more light 
on the involvement of this kinase.
Thus the nature of the signalling pathway involved in PPARy activation, 
remains to be fully elucidated. Currently we can exclude the direct role of 
both PKA and PKC whereas the role of AMPK warrants further investigation 
to resolve conflicting results. A mediator we are interested in looking at in 
future studies is the extracellular regulated kinase (ERK). ERK is able to 
phosphorylate PPARy and although direct phosphorylation sites have been 
located in the DBD (absent in our expression construct), one could 
hypothesise that other residues which can be activated by the ERK pathway 
might be present in the LBD of this nuclear receptor (Diradourian et al., 
2005). There is evidence in the literature for dose-dependent cicaprost 
phosphorylation of ERK (Chu et al., 2004). The authors of this study 
attribute ERK phosphorylation to PKC via IP receptor coupling to Gq as 
demonstrated by the reversal of cicaprost effects with 1 pM staurosporine, 
a concentration that has no effect in our investigation. They exclude the 
involvement of PKA by demonstrating lack of reversal with Rp-cAMPS. It  is 
however interesting that they do see a significant reversal with H-89, 
highlighting again the lack of specificity of this antagonist. What is of 
interest, however, is that they cannot fully exclude mediation by Gs. In fact 
forskolin could not upregulate ERK phosphorylation, akin to our not seeing 
any effect on PPARy activation with this cAMP-elevating agent, whereas, 
surprisingly, the specific Epac agonist CPTM-cAMP could cause ERK
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phosphorylation. Epacs can stimulate ERK via activation of Rap-GTPase 
(Wang et aI., 2006). As we can see in Figure 3.20 (chapter 3) we were able 
to inhibit most but not all treprostinil-dependent cAMP elevation with DDA. 
Therefore it could be possible that some cAMP may still be elevated in the 
presence of DDA and this could be free to activate Epacs rather than PKA. 
This may lead to ERK phosphorylation and subsequently PPARy 
phosphorylation and activation. This hypothesis could be tested 
pharmacologically by treating cells with cholera toxin (commercially 
available), the novel antagonist YM-254890 (Takasaki et al., 2004) and 
PD98059 (commercially available) to block GS/ Gq and ERK respectively. In 
addition a molecular approach could be taken and the three mediators 
could be inhibited using siRNA, or in the case of Gq/ by overexpressing a 
carboxyl-terminal peptide of Gaq (GqI).
Figure 4.17 summarises our current understanding of the signalling 
pathway responsible for IP receptor dependent PPARy activation.
4.9.4 Effect o f PPARy on cell proliferation
The effect of PPAR ligands on HEK-293 cell proliferation produced some 
unexpected findings. What was evident was that the presence of the IP 
receptor altered the proliferative response to rosiglitazone and 1165,041. 
PPARy ligands are generally known to inhibit proliferation of a number of 
different cell types including vascular smooth muscle cells (Law et al., 1996; 
Sarafidis and Lasaridis, 2006) but have also been shown to be pro- 
mitogenic by being able to increase mitogenic factors such as vascular 
endothelial growth factor (VEGF) (Yamakawa et al., 2000) or inducing 
formation of colon polyps (Saez et al., 1998). In this project, rosiglitazone
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appeared to enhance serum-induced proliferation of HEK-293-WT cells but 
at the highest dose used it actually inhibited proliferation. Whether or not at 
this dose it was causing cell death or apoptosis was not established in this 
study and is a significant lim itation of the work presented here. However 
there was no visible cell death observed when manually counting cells 
stained with trypan blue (Invitrogen) or in the shape of the distribution 
curves obtained from the PDA500 cell counting analysis system (data not 
shown).
In contrast, in HEK-293-IP cells, the PPARy ligand had a more distinct 
inhibitory effect across a wide concentration range. This response is similar 
to what is found in smooth muscle cells (Law et al., 1996; Ward et al., 
2004). Inhibition of proliferation was only significant at concentrations of 10 
pM or above raising the question of whether these are non-PPARy specific 
effects of the drug. However Ward et al (2004) have shown that the effect 
of 10 pM rosiglitazone could be totally reversed using 1 pM GW9662. 
Furthermore evidence shows that proliferation inhibition by 
thiazolidinediones can be replicated using the unrelated PPARy ligand, 15d- 
PGJ2 (Sasaguri et al., 1992; Ward e t al., 2004), supporting the notion that 
the effect is most probably PPARy dependent. In future studies we would 
like to use GW9662 or RNAi to block this PPAR isoform to establish the 
extent of PPARy involvement in our system. How PPARy is regulating cell 
proliferation is still unclear. Both troglitazone and rosiglitazone can 
attenuate the mitogen-induced degradation of the cdk inhibitor p27Kipl in 
smooth muscle cells causing Gi arrest (Sherr and Roberts, 1999). An 
alternative hypothesis is that activation of PPARy may be having an effect 
on the synthesis of PGI2. In support of this, a study has shown that PPARy
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activation can mediate the induction of COX-2 expression and synthesis, the 
precursor of PGI2 (Kalajdzic et al., 2002). This hypothesis could be tested in 
our cell model by measuring prostacyclin levels in treated versus untreated 
cells.
Figure 4.17 Potential signalling mechanisms regulating IP receptor-dependent PPARy activation. 
Solid blue lines indicate known direct association. Dotted blue lines indicate a potential 
phosphorylation of PPARy. Red dotted lines indicate an indirect association. Red solid cross 
indicates strong evidence against mediation; Red dotted cross indicates some negative data but 
necessitates further investigation.
In contrast to the findings that PPARy activation inhibits smooth muscle cell
proliferation, a study by Takeda et al (2001) observed that
thiazolidinediones as well as 15d-PGJ2 have a pro-proliferative effect on
vascular smooth muscle cells in the absence of growth stimuli. They
suggest that this was caused by a rapid induction of ERK phosphorylation 
leading to upregulation of cyclin D1 levels; such a mechanism is known to
7?cAMP
TPfcAMP
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underlie the effect of various growth factors including PDGF and bFGF. 
These observations are in direct contrast with studies by Ward et al (2004) 
and Ghosh et al (2003) who found no significant effect on ERK activity with 
thiazolidinediones. In fact the latter study suggested that ciglitazone 
reduces mesangial cell proliferation by inhibiting pathways downstream of 
ERK activation and that this inhibitory effect is exerted through a PPARy- 
dependent pathway (Ghosh et a l., 2003). One possibility to explain this 
discrepancy is that the vascular smooth muscle cells used in the study by 
Takeda et al (2001) could have lost their IP receptors and thus PPARy 
agonists are converted to preferentially activating the ERK pathway and 
stimulating cell growth.
The PPARy antagonist, GW9662, was able to produce a small but significant 
reversal of treprostinil mediated inhibition of proliferation in HEK-293-IP 
cells. This suggests that PPARy does indeed have some role, downstream 
from the IP receptor, in regulating PGI2 effects on cell growth. The extent to 
which GW9662 reversed the inhibition mirrored the magnitude of the 
effects that could not be blocked by the PKA antagonists, H-89 and Rp- 
cAMPS (see section 3.9). I t  is tempting to speculate that PPARy could 
indeed account for the PKA independent effects of treprostinil. In light of 
these results and those showing that activation of PPARy by treprostinil is 
IP receptor-dependent but PKA-independent, the PPARy pathway may be a 
separate mechanism which works in parallel to the classical cAMP/PKA 
pathway to mediate the anti-proliferative effects of PGI2.
HEK-293-WT cells also had a pro-proliferative response to the PPARS ligand 
L165,041 an effect which was absent in HEK-293-IP cells. PPARS ligands
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have been shown to promote proliferation of breast, prostate and 
hepatocellular cancer cell lines (Glinghammar et al., 2003; Stephen et al.,
2004) and enhance proliferation of vascular smooth muscle cells (Zhang et 
al., 2002). Since PPARS is associated with proliferation and tumour 
progression it might follow that HEK-293 cells, which are derived from an 
immortalised cell line, should respond this way. Absence of the response in 
HEK-293-IP cells may be taken as an indication that the IP receptor 
dampens down PPARS activity or that the cellular consequence of PPARS 
activation is altered by the presence of the IP receptor. Further work is 
required to distinguish between these possibilities.
These findings are important in furthering our understanding of how 
prostacyclin and PPARs interact to regulate cellular function. The idea that 
the IP receptor is crucial for PPARy activation by PGI2 may have 
physiological and therapeutic implications. PPARy is known to be important 
for cell differentiation and the regulation of cell growth, so that in diseases 
where there is loss of the IP receptor this could alter the control of these 
processes. I t  remains to be established whether the novel IP receptor- 
dependent PPARy signalling mechanism described in the present study is 
functionally relevant in native cells. Activation of PPARy could contribute to 
the beneficial effects of PGI2 analogues in the treatment of diseases such as 
pulmonary arterial hypertension and peripheral vascular disease.
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Chapter 5
An investigation into the mechanisms 
underlying the anti-proliferative 
effects of PGI2 analogues in PASMC 
derived from control and I PAH
patients.
195
5. PGh mechanisms in control and IPAH smooth muscle cells
5.1 Introduction
Idiopathic Pulmonary Arterial Hypertension (IPAH) is a progressive and 
incurable disease leading to right heart failure and death. Untreated, the 
median survival from the time of diagnosis is 2.6 years in adults (D'Alonzo 
e ta /., 1991) and only 10 months in children (Sandoval e ta /., 1995; Barst et 
a/., 1999). To date, the most efficacious treatment is a continuous 
intravenous infusion of epoprostenol, the sodium salt of prostacyclin, which 
improves pulmonary vascular resistance, haemodynamics, exercise 
tolerance and survival in patients who do not respond to vasodilatory 
therapy (Higenbottam et a/., 1993; Barst e t a/., 1994; Barst e t a/., 1996; 
McLaughlin e ta /., 1998).
The disadvantage of using epoprostenol is its short half life in vivo (2-3 
mins) meaning that continuous epoprostenol infusion is required in the 
clinical setting. After long-term use, complications arise from the indwelling 
central venous catheter, often giving rise to infection. This has led to the 
development of more stable PGI2 analogues, such as iloprost and treprostinil 
both of which show clinical benefit in the treatm ent of PAH. Iloprost has a 
half-life of 20-25 mins and can be delivered by inhalation. Using an 
ultrasonic nebuliser, minute particles (3-5 pm) of iloprost can reach the 
smallest airways and alveoli which are close to the intra-acinar arteries, a 
site of pulmonary vascular resistance in PAH (reviewed in Howard and 
Morrell, 2005). Iloprost may offer some advantages in that the drug will 
produce fewer systemic side affects, though several dosings are required 
per day, raising the issue of peak and trough effects of the drug. Treprostinil 
can be delivered subcutaneously, has a relatively long biological half-life of
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~2  hrs and is stable at room temperature. The major problem with its use 
subcutaneously is site pain so that an i.v. preparation has been developed 
and recently approved for clinical use (reviewed in Howard and Morrell,
2005).
Prostacyclin and its stable analogues are thought to slow the progression of 
pulmonary vascular disease and possibly even reverse the abnormal 
remodelling process, although there is no in vivo proof that this happens in 
humans. Inhaled iloprost has however, recently been shown to cause 
regression of PAH structural changes in a rat model of monocrotaline- 
induced PAH (Schermuly et al. b, 2005). Since this is a model presenting 
with medial thickening in the absence of significant lesion formation, it is 
difficult to assess what effect if any, these agents might have in advanced 
disease. In the clinical setting, both epoprostenol and the stable analogues 
lose their effectiveness in PAH patients suggesting that these agents alone 
cannot halt the disease progression in humans. In such patients, lung or 
heart-lung transplantation becomes the only option left (Haworth, 2002; 
Radley-Smith and Aurora, 2006). In these circumstances, the clinician 
cannot be certain that the patient continues to derive any benefit from PGI2 
when they are clearly deteriorating and, in any event, benefit might be 
attributable to the inotropic effect on the heart rather than directly affecting 
the pulmonary vasculature (personal communication, Professor S.G. 
Haworth).
I t  has been shown that in vitro replication of normal pulmonary artery 
smooth muscle cells (PASMCs) is reduced by PGI2 analogues (Clapp et al., 
2002). In the same study it was observed that treprostinil had a greater and
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more potent inhibitory effect on cell proliferation when compared to either 
iloprost, beraprost or cicaprost. There is, however, no certainty that PASMCs 
from patients with IPAH respond in the same manner, as no studies have 
been done using these cells, particularly in children in whom disease 
progression is faster than in adults. The antiproliferative effects of PGI2 
analogues in PASM cells are generally thought to be mediated through the 
IP receptor (Coleman et a!., 1994), though lack of a specific IP receptor 
antagonist until fairly recently (Clark et al., 2004) has hampered such 
confirmation. Supporting data does however come from studies showing 
lack of anti-proliferative effects of cicaprost on smooth muscle cells from 
IP'7" KO mice (Kothapalli et al., 2003). The equivalent data in human cells 
has yet to be reported.
In terms of mechanism, PGI2 analogues inhibit pulmonary arterial smooth 
muscle proliferation by a largely cAMP-dependent mechanism (Wharton et 
al., 2000; Clapp et al., 2002), though the pathway beyond this is much less 
clear and has not benefited from much investigation. A very recent study, 
has confirmed the importance of PKA in mediating iloprost-induced 
differentiation of vascular smooth muscle cells from a synthetic, proliferative 
phenotype to a quiescent, contractile phenotype (Fetalvero et al., 2006). 
Similarly, I found PKA antagonists inhibited analogue anti-growth responses 
in HEK-293 cells expressing the IP receptor (chapter 3). Furthermore, as 
shown in chapter 4, PGI2 analogues can also activate PPARy via the IP 
receptor, a mechanism largely independent of PKA. Whether this mechanism 
is relevant in VSMC has yet to be determined.
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In the present study we hypothesised that PASM cells in children with IPAH 
might not respond normally to prostacyclin analogues because either the IP 
receptor density had decreased and/or the receptor had become 
dysfunctional. Therefore, the expression and function of the IP receptor 
were examined by RT-PCR, immunohistochemistry and cAMP immuno-linked 
assays in PASMC grown from the explanted lungs of children with IPAH, all 
of whom had been on long term treatm ent with intravenous epoprostenol.
The role of the prostacyclin receptor in the regulation of cell proliferation in 
both control and IPAH PASMC was also studied and the downstream 
signalling pathways investigated using a range of pharmacological tools. 
Interestingly, distal PASM cells isolated from arteries of less than 1 mm in 
external diameter appear to be more susceptible to the anti-proliferative 
effects of PGI2 analogues than cells from proximal arteries with an external 
diameter greater than 8 mm (Wharton et al., 2000). Hence PASM cells from 
both control and IPAH patients were obtained from small peripheral vessels 
in the present study (see section 2.2.3).
In the present study I was able to confirm the presence of the IP receptor in 
treated end-stage pulmonary vascular disease, albeit at a lower expression 
level to normal cells. To my surprise I found that the signal transduction 
pathways regulating the effects of the PGI2 analogue switched from a 
mechanism involving cAMP in normal PASMC to one largely bypassing the IP 
receptor or cAMP in IPAH cells.
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RESULTS
5.2 Control and IPAH human PASM cells have different proliferative  
rates.
The first phenotypical difference noted between control and IPAH distal 
PASM cells was their markedly distinct proliferative rates. All three control 
cell isolates grew at a slower rate than IPAH cells (Figure 5.1). When the 
data are combined it is easy to see a significant difference in the 
proliferative rate (Figure 5.2). After 5 days of culture in DMEM:F-12 media 
containing 10% FBS, IPAH cells had grown 22.1 ± 1 . 1  fold (n=9) compared 
to a 10.5 ± 1.2 fold increase in control cells (n=13, P<0.001). This equates 
to IPAH cells having a proliferative rate double that of control cells.
This striking difference in proliferation rates between the two cell types is 
akin to tha t observed between HEK-293-IP and HEK-293-Zeo cells as 
described in chapter 3. This result led to the hypothesis that IPAH cells may 
lack or have a significantly decreased expression of the IP receptor causing, 
as in HEK-293-Zeo, an increase in cell proliferation in response to serum.
5.3 IP  receptor expression in control and IPAH cells
Using specific primers to amplify a 204bp sequence of the IP receptor as 
previously described, RT-PCR was performed on cDNA produced by 5pg of 
total RNA to confirm presence of IP receptor mRNA in the three control and 
IPAH cell isolates. A band of the appropriate size can be seen in the lanes 
for all control and IPAH cells (Figure 5.3 A & B) confirming the presence of 
the IP receptor in both cell types. Primers for the human GAPDH were used 
to amplify a 363 bp of this house-keeping gene in all cDNA samples.
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Figure 5.1 Distal HPASM cell isolates from three control (A) and three IPAH (B) patients were 
growth-arrested and subsequently stimulated with 10% FBS for varying times as indicated. Cells 
were counted at time 0 and then at 24 h intervals. Results are expressed as mean fold increase in 
proliferation from time 0 ± s.e.m. of at least 3 separate experiments performed in triplicate.
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Figure 5.2 Comparison of the proliferative rates of control (■) and IPAH (•) cells growing in 
DMEM:F12 containing 10% FBS. Cells were counted at time 0 and then at 24 h intervals. Results 
are expressed as mean fold increase in proliferation from time 0  ± s.e.m. of the combined 
proliferative rates of three isolates per cell type (see figure 5.1), n=9-13, *"=P<0.001.
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Figure 5.3. PCR was performed on reverse transcriptase cDNA products of 5/xg of total RNA from 
control (A) and IPAH (B) PASM cells using IP receptor specific primers to amplify a 204 bp region of 
the receptor sequence and GAPDH primers to amplify a 363 bp band of this house-keeping gene as 
control. Reverse transcriptase controls (-RT) were negative in all cases. The gel is a representative 
result which has been reproduced at least three times using different RNA preparations.
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The presence of a correct sized band of approximately the same intensity 
was observed in all lanes (Figure 5.3). Lack of bands in the negative control 
lanes (lack of RT) confirms the absence of genomic DNA contamination in 
the RNA samples (Figure 5.3).
The expression and localisation of the IP receptor protein was assessed 
using the C l antibody targeted to the C-terminal of the IP receptor which 
has been developed in this project and described in chapter 3 (see section 
3.3). In support of the RT-PCR data, staining was observed in normal 
HPASM cells (Figure 5.4 A-C). Noticeably weaker staining was observed in 
all three IPAH cell isolates (Figure 5.4 D-F). Together with Dr. Sue Hall's 
western blot (Figure 3.2), where weaker bands were seen in lanes loaded 
with IPAH cell protein compared with normal cell protein, these results 
suggest that while both types express IP receptor, expression is lower in 
pulmonary cells derived from IPAH patients. To control for possible non­
specific staining by the labelled secondary antibody, cells were incubated in 
the absence of the C l primary antibody, but in the presence of the FITC 
labelled secondary. Under these conditions, no staining was seen in either 
control or IPAH cells (Figure 5.5) confirming the absence of non specific 
secondary binding.
5.4  Effects of treprostinil on cAMP elevation in control and IPAH  
cells
After confirming that both control and IPAH cells express the IP receptor, 
the functionality of this receptor was tested by measuring cAMP levels in 
both cell types stimulated with treprostinil with or without pre-treatm ent 
with the IP receptor antagonist (IPRA). We chose a 30 mins stimulation
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period since we had previously observed this to be the peak cAMP elevation 
with treprostinil in HPASM cells (Clapp e ta /., 2002).
In control cells, cAMP was significantly elevated following treatm ent with 
100 nM treprostinil in isolate 1 (204.8 ± 37.0 pmol/mg vs 511.1 ± 20.8 
pmol/mg with treprostinil n=3 PcO.001) and isolate 3 (130.0 ± 23.4 
pmol/mg vs 465.1 ± 37.5 pmol/mg with treprostinil, n=3, P<0.001) (Figure 
5.6). No cAMP elevation was observed upon treatment with treprostinil in 
isolate 2 (310.3 ± 29.7 pmol/mg vs 347.3 ± 37.2 with treprostinil, n = 3, 
P=0.58) (Figure 5.6). In the two responsive cell types, pre-treatment with 1 
pM IPRA for 1 hr fully reversed the cAMP elevating effects of treprostinil 
restoring them back to levels found in untreated cells (n=3, P<0.001) 
(Figure 5.6).
As with the normal HPASM cells, only two out o f the three cell isolates of 
IPAH cells responded to treprostinil treatm ent with a significant increase in 
intracellular cAMP. In IPAH-1, cAMP rose from 157.9 ± 57.0 pmol/mg to 
653.6 ± 160.0 pmol/mg (n=3, P<0.05) and in IPAH-2 from 196.1 ± 44.0 
pmol/mg to 794.0 ± 27.3 pmol/mg upon treatm ent with 100 nM treprostinil 
(n=3, P<0.001) (Figure 5.7). Pre-treatment of the responsive cells with 
IPRA prevented the cAMP rise produced by treprostinil, with levels returning 
back to near-basal levels (Figure 5.7). Thus in both control and IPAH cell 
types only two out of the three isolates appear to have a functional IP 
receptor. However, we cannot rule out the possibility tha t higher 
concentrations or longer treatments with treprostinil may have given rise to 
a significant elevation in cAMP in these "seemingly" unresponsive cells.
205
5. PGh mechanisms in control and IPAH smooth muscle cells
Control
/  40 //m
B
Figure 5.4 Control HPASM cells 1 (A), 2 (B), 3 (C) and IPAH HPASM cells 1 (D), 2 (E), 3 (F) 
stained with the C1 antibody. Cells were grown in DMEM:F12 + 10% FBS for 48 hours and fixed in 
4% paraformaldehyde prior to staining with the C1 primary antibody. FITC conjugated Alexa fluor 
488 (green) was used as a secondary antibody and TO-PRO-3 (red) was used to stain nuclei. Cells 
were visualised using a confocal microscope with a X60 magnification water immersion lens.
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Figure 5.5 Immunohistochemistry controls. Control (A) and IPAH (B) PASM cells were fixed in 4% 
paraformaldehyde and immuno-stained with FITC conjugated Alexa fluor 488 (green) and TO-PRO- 
3 (Red) in the absence of primary antibody (both 1:300 dilution).
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Figure 5.6 Cyclic AMP was measured in three control distal HPASM cell isolates. Cells were 
stimulated with 10% FBS ± treprostinil (TREP; 100 nM) or IP receptor antagonist (IPRA;1 /xM) or a 
combination. Cells were pretreated with IPRA for 1 hr prior to stimulation with TREP. Cyclic AMP 
was extracted 30 mins after TREP stimulation and measured using an enzyme immunolinked assay. 
Results expressed as mean pmol of cyclic AMP per mg of total protein ± S.E.M. (n=3). ***=p<0.001.
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Figure 5.7 Cyclic AMP measurements in three IPAH distal HPASM cell isolates. Cells were 
stimulated for 30 min with 10% FBS ± either treprostinil (TREP; 100 nM) or IP receptor antagonist 
(IPRA; 1 j*M) or a combination. Cells were pretreated with IPRA for 1 hr prior to stimulation with 
TREP. Cyclic AMP was extracted and measured using an enzyme immunolinked assay. Results 
expressed as mean pmol of cyclic AMP per mg of total protein ± S.E.M. (n=3).* = P<0.05, 
—=P<0.001.
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5.5 Effects of treprostinil on control and IPAH cell proliferation
To further test IP receptor functionality, the effects of treprostinil on cell 
proliferation were assessed in all isolates of both cell types. Cells were 
cultured in DMEM:F12 media containing 10% FBS and cells treated with 1 
pM treprostinil and compared with cells grown in 10% FBS alone. In control 
cells, treprostinil significantly inhibited the proliferation of the two isolates 
that also responded in terms of significant cAMP elevation. After 5 days 
treprostinil caused control-1 and control-3 cell types to proliferate almost 
half as much as they did in FBS alone (n=12-15, P<0.001) (Figure 5.8 A 
and C). However, treprostinil had no anti-proliferative effects on control-2 
cells (n=9, P=0.69). Because of its non-responsiveness in terms of cAMP 
elevation or inhibition of proliferation, the control-2 cell isolate was excluded 
from further proliferation assays.
A somewhat different pattern was seen in the IPAH cells. Despite the fact 
that no significant cAMP elevation was observed in IPAH-3, cell proliferation 
was still inhibited by around 50% after 5 days treatment with treprostinil 
(n=12, P<0.001), with near similar effects observed in the other two 
isolates (Figure 5.9). The results obtained with IPAH-3, contrasts to what 
was observed in control cells where cAMP elevation and proliferation 
inhibition were correlated. Thus the difference in IP receptor signalling 
between control and IPAH cells necessitated further investigation.
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Figure 5.8 Proliferation rates of three normal distal HPASM cell isolates, 1 (A), 2 (B) and 3 (C), 
either left untreated (■) or treated with treprostinil (TREP, •, 1 /iM). Growth arrested cells were 
stimulated with 10% FBS ± TREP and counted at different time points as shown. Data shown as 
mean ± S.E.M. (n=9-15). = P<0.001.
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Figure 5.9 Proliferation rates in response to serum of three IPAH distal HPASM cell isolates, 1 (A), 
2 (B) and 3 (C), either left untreated (■) or treated with treprostinil (TREP, •, 1 /*M). Growth 
arrested cells were stimulated with 10% FBS ± TREP and counted at different time points as shown. 
Data shown as mean ± S.E.M. (n=12).** = P<0.01, *** = P<0.001.
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5.6 PG I2 analogue inhibition of proliferation in control PASM cells: 
role of cAM P.
In HEK-293 cell proliferation assays were performed by counting cells at 48 
hr following stimulation with agonist and/or antagonists (see chapter 3). At 
this tim e-point it was easy to observe a significant and pronounced 
inhibitory effect with treprostinil and other agents. In PASM cells a time 
point of 96 hr (or 4 days) produced a more pronounced effect than at 48 
hours. Thus further proliferation assays were performed at the latter time 
point to elucidate the signalling pathways associated with the anti­
proliferative effects of treprostinil.
Based on evidence presented in this thesis it is likely that the IP receptor 
exclusively mediates the cAMP elevating effects of treprostinil. The receptor 
antagonist was used to further test whether the IP receptor was also 
responsible for mediating the anti-m itogenic effects of this analogue in 
HPASM cells. In control cells, the IPRA (1 pM) alone had no effect on cell 
proliferation induced by 10% FBS at 4 days (n=10, P=0.56) (Figure 5.10). 
When cells were pre-treated for 1 hr with IPRA prior to stimulation with 100 
nM treprostinil for 4 days, the anti-proliferative effects of this agent were 
significantly reversed from 34.5 ± 3.7% to 14.2 ± 5.1% (n = 10, P=0.007) 
(Figure 5.10). This suggests that the IP receptor plays a major role in 
meditating the antiproliferative effects of treprostinil. Likewise, the effects of 
100 nM iloprost, which inhibited proliferation by 31.5 ± 3.0% (n=6, 
P<0.001), were almost totally abolished by pre-treatment with IPRA (Figure
5.11). This suggests that the EPi and EP3 receptors, for which iloprost has 
an equally strong binding affinity (reviewed in Hata and Breyer, 2004), are
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unlikely to play a role in mediating the antiproliferative effects of iloprost in 
control HPASM cells.
To test whether IP receptor-dependent inhibition of proliferation with PGI2 
analogues was driven by increased levels of intracellular cAMP, control cells 
were treated with the adenylyl cyclase inhibitor, 2'5'-DDA. Treatment with 
lOOpM DDA alone had no significant effect on cell proliferation (n=9, 
P=0.37). However, pre-treatment with DDA for 1 hr prior to stimulation with 
100 nM treprostinil, significantly reversed treprostinil-induced inhibition of 
proliferation from 45.9 ± 4.0% to 22.0 ± 7.8% (n=9, P<0.05) (Figure
5.12). Thus, as one would expect, by blocking cAMP production the effects 
of treprostinil on proliferation are dampened suggesting that adenylyl 
cyclase is indeed an important mediator in this pathway.
5.7 Role of IP  receptor and cAMP-dependent pathway in m editating  
PG I2 analogue inhibition of proliferation in IPAH cells
In contrast to the results obtained in control cells, pre-treatment with IPRA 
did not significantly reverse the inhibition of proliferation caused by 
treprostinil in IPAH cells (n=9, P= 0.67) (Figure 5.13). This is surprising 
given the extent to which the IPRA reduced cAMP levels elevated by 
treprostinil in these cells. Similarly, treatm ent with 100 nM iloprost inhibited 
cell proliferation by 33.8% ± 2.7% (n=9, P<0.001) and this inhibition was 
again not sensitive to pre-treatment with IPRA (n=9, P= 0.38) (Figure 5.14). 
Taken together these results suggest that, contrary to what is observed in 
control cells, IPAH cells possess almost an exclusively IP-receptor 
independent mechanism for the inhibition of proliferation by PGI2 analogues.
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Figure 5.10 Growth arrested control distal HPASM cells (2 isolates) were stimulated with 10% FBS 
± TREP (100 nM) or the IP receptor antagonist (IPRA; 1 /xM) or a combination. Cells were 
pretreated with IPRA for 1 hr prior to stimulation with TREP. Cells were counted 96 hrs and data 
expressed as mean % cell proliferation relative to proliferation mediated by 10% FBS alone ± S.E.M. 
(n=9). ** = P<0.01, *** = P<0.001.
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Figure 5.11. Growth arrested control distal HPASM cells (2 isolates) were stimulated with 
DMEM:F12 + 10% FBS and either left untreated or treated with iloprost (ILO, 100 nM) or IPRA (1 
/xM) or a combination as shown. Cells were pretreated with IPRA for 1 hr prior to stimulation with 
ILO. Cells were counted 96 hrs following treatment. Data expressed as mean % proliferative 
response relative to proliferation mediated by 10% FBS alone ± S.E.M. (n=6 ). *** = P<0.001.
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Figure 5.12 Growth arrested control distal HPASM cells (2 isolates) were stimulated with 10% FBS 
±  TREP (100 nM) or the adenylyl cyclase antagonist, DDA (100 /zM) or a combination. Cells were 
pretreated with DDA for 1 hr prior to stimulation with TREP. Cells were counted 96 hrs following 
treatment. Data expressed as % cell proliferation relative to proliferative response mediated by 10% 
FBS alone and shown as mean ± S.E.M. (n=9). * = P<0.05, *** = P<0.001.
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Figure 5.13 Growth arrested IPAH distal HPASM cells (3 isolates) were stimulated with 10% FBS ± 
TREP (100 nM) or IPRA (1 iM )  or a combination as shown. Cells were pretreated with IPRA for 1 hr 
prior to stimulation with TREP. Cells were counted 96 hrs following treatment. Data is expressed as 
% cell proliferation relative to the proliferative response mediated by 10% FBS alone and shown as 
mean ± S.E.M. (n=9). ** = P<0.01, “ * = P<0.001.
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Figure 5.14 Growth arrested IPAH distal HPASM cells (3 isolates) were stimulated with 10% FBS in 
the presence or absence of iloprost (ILO, 100 nM), IPRA (1 /xM) or a combination. Cells were 
pretreated with IPRA for 1 hr prior and counted 96 hrs following treatment. Data are expressed as % 
cell proliferation relative to the proliferatative response mediated by 10% FBS alone and shown as 
mean ± S.E.M. (n=9). *** = F0.001.
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Figure 5.15 Growth arrested IPAH distal HPASM cells (3 isolates) were stimulated with 10% FBS 
and either left untreated or treated with TREP (100 nM), the adenylyl cyclase inhibitor, DDA (100 
/iM) or a combination. Cells were pretreated with DDA for 1 hr prior to stimulation with TREP and 
cells counted 96 hrs later. Data is expressed as % cell proliferation relative to proliferative response 
mediated by 10% FBS alone and shown as mean ± S.E.M. (n=9). * = P<0.05, *** = P<0.001.
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This observation was further strengthened by the fact that the adenylyl 
cyclase inhibitor, DDA was unable to reverse the treprostinil induced 
inhibition of proliferation in IPAH cells (n=9, P=0.53) (Figure 5.15). Hence 
the IP receptor-independent mechanism, preferentially utilised by 
treprostinil in IPAH cells does not seemingly involve cAMP. An interesting 
point to note is that, although isolate 3 was distinct from the other two 
isolates in terms of not being able to elevate cAMP in response to 
treprostinil, it behaved similarly in all proliferation studies; hence all three 
isolates were included experimentally.
5.8  Role of PPARy in the regulation of cell proliferation in control 
and IPAH PASM cells
In the HEK-293-IP stable line, PPARy was found to mediate in part the anti­
proliferative effects of treprostinil, possibly being responsible for the part of 
the response not sensitive to adenylyl cyclase or PKA inhibitors. To assess 
whether control and IPAH cells exhibited distinct proliferative responses 
upon direct activation of PPARy akin to the differences observed between 
HEK-293-IP and HEK-293-Zeo cells, both HPASM cell types were treated 
with varying concentrations of rosiglitazone and counted after 4 days. 
Rosiglitazone had an inhibitory effect on the proliferation of both control and 
IPAH cells with essentially no difference in potency between the two, with 
the control IC50 being 35.1 pM compared to 43.3 pM in IPAH cells (Figure 
5.16). Thus the effects of rosiglitazone are very similar to those seen 
previously with the same drug in HEK-293-IP cells.
To test whether PPARy could contribute, even if only partially, to the 
antiproliferative mechanism of PGI2 analogues, both control and IPAH cells
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were pre-treated for 1 hr with 1 pM GW9662 prior to a 4 day stimulation 
with 100 nM treprostinil. In control cells, GW9662 alone had no effect on 
cell proliferation (n=9, P=0.95; Figure 5.17), although the antagonist was 
able to cause a small but significant reversal of the antiproliferative effects 
of treprostinil (n=12, P<0.05; Figure 5.17). In IPAH cells however, the 
reversal with GW9662 was noticeably greater. The antagonist was able to 
reverse the anti-proliferative effects of treprostinil by more than 50% from a 
33.5 ± 1.8% to a 13.2 ± 3.7% inhibition (n = 15, P<0.001; Figure 5.18). 
This set of results highlights once more the different mechanism used by 
treprostinil in the two cell types to inhibit growth, and fully supports an 
important role for PPARy in IPAH cells.
5.9 Sum m ary
• IPAH PASM cells have a higher proliferative rate compared to 
control PASM cells.
• Both control and IPAH PASM cells express IP receptor mRNA and 
protein, though the expression of this receptor is reduced in IPAH, 
with its localisation, as determined by immunohistochemistry 
appearing to be predominantly cytoplasmic with little evidence of 
the receptor being present at the membrane.
• The PGI2 analogues, treprostinil and iloprost, can inhibit the 
proliferation of both control and IPAH cells but the mechanism by 
which this occurs appears to be markedly different.
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Figure 5.16 Concentration-dependent effect of rosiglitazone (ROSI) on cell proliferation. Growth 
arrested control (2 isolates, ) and IPAH (3 isolates, ?) distal HPASM cells were stimulated with 
10% FBS ± ROSI and counted after 96 hrs. Data are expressed as % cell proliferation relative to 
proliferative response mediated by 10% FBS alone and shown as mean ± S.E.M. (n=9-12). Data 
was fitted using a sigmoidal dose-response formula (see equation 2.1).
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Figure 5.17 Growth arrested control distal HPASM cells (2 isolates) were stimulated with 10% FBS 
and either left untreated or treated with TREP (100 nM), the PPAR7  antagonist, GW9662 (1 fM )  or 
a combination. Cells were pretreated with GW9662 for 1 hr prior to stimulation with TREP and cells 
counted at 96 hrs. Data is expressed as % cell proliferation relative to proliferative response 
mediated by 10% FBS alone and shown as mena ± S.E.M. (n=12), * = P<0.05, *** = P<0.001.
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Figure 5.18 Growth arrested IPAH distal HPASM cells (3 isolates) were stimulated with 10% FBS 
and either left untreated or treated with TREP (100 nM), the PPAR7  antagonist, GW9662 (1 /xM) or 
a combination. Cells were pretreated with GW9662 for 1 hr prior to stimulation with TREP and cells 
counted at 96 hr. Data is expressed as % cell proliferation relative to proliferative responses 
mediated by 10% FBS alone and shown as mean ± S.E.M. (n=15), *** = P<0.001.
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• In responsive control cells the IP receptor elevates cAMP in 
response to treprostinil and mediates the majority of anti­
proliferative effects of PGI2 analogues.
• In IPAH cells treprostinil appears to function through an IP 
receptor and cAMP-independent pathway despite its ability to 
elevate cAMP through the IP receptor in two out of the three 
isolates.
• PPARy is an important mediator of the anti-proliferative effects of 
treprostinil in IPAH cells but appears to only have a minor role in 
control cells.
• More numbers of both normal and IPAH PASMC are needed to 
confirm these results and ensure that these conclusions apply to 
all/m ost children with IPAH.
• The fact that the IPAH patients from which the HPASM cells were 
derived were juvenile and the normal patients were adult is a 
significant lim itation of the study as the physiology of smooth 
muscle cells as well as the functionality and expression of the IP 
receptor and other potentially relevant cellular mechanism may be 
affected by age.
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5.10 Discussion
5.10.1 IP  receptor expression in control and IPAH pulmonary artery  
smooth muscle cells
The present study has shown that PASM cells derived from IPAH patients 
have a significantly faster proliferative rate relative to control PASM cells. A 
sim ilar difference was described between HEK-293 cells with or w ithout the 
receptor (see section 3.5). This initial observation led to the hypothesis that 
IPAH PASM cells may have a lower expression of the IP receptor resulting in 
an altered proliferative phenotype. The present study has confirmed the 
presence of IP receptor mRNA and protein in both control and IPAH PASM 
cells. However, although staining with the C l antibody was observed in both 
cell types, the degree of expression of this receptor and its localisation 
appeared to be different. Expression was noticeably weaker in IPAH cells 
compared to control cells when stained at the same time and under similar 
experimental conditions. This observation is further strengthened by recent 
western blotting data (Sue Hall, UCL unpublished observations). In both cell 
types, our C l antibody picked up a band of 60 kDa, concomitant with a 
glycosylated active form of the IP receptor (Smyth et al., 1998). However, 
the signal was 40% more intense in control pulmonary cells compared to 
IPAH cells. Thus it is possible that down-regulation of the IP receptor in 
IPAH PASM cells could affect the growth characteristics of these cells. 
Reduced expression of the IP receptor in IPAH leading to abnormal growth 
characteristics may be consistent with data from studies in IP receptor 
knockout mice. Mice lacking the receptor displayed essentially normal 
pulmonary arteries, however when exposed to chronic hypobaric hypoxia,
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they developed a greater degree of pulmonary hypertension, right 
ventricular hypertrophy and pulmonary vascular remodelling compared to 
wild type mice (Hoshikawa et al., 2001). This suggests that the IP receptor 
can modulate the response to remodelling stimuli, but that loss of the IP 
receptor per se is not sufficient to trigger the disease.
Down regulation of the receptor might be due to internalisation or 
desensitisation of the receptor. The expression of the receptor was 
essentially confined to the cytosol in IPAH cells, possibly reflecting more 
internalisation of the receptor, maybe as a result of chronic treatm ent of the 
lung with epoprostenol for several years prior to cell culture.
Alternatively, the receptor may be more susceptible to desensitisation in 
IPAH as a result of long-term agonist stimulation. The IPAH patients from 
whom PASM cells originated had all been receiving long term continuous 
epoprostenol infusion prior to transplantation. The prototypical model for 
GPCR regulation involves three key mechanisms (reviewed in Bohm et al.,
1997). The first phase of desensitization occurs rapidly after agonist 
stimulation and is caused by agonist-induced receptor phosphorylation 
mediated by second messenger kinases, such as PKA and PKC, and this 
eventually uncouples the receptor from its G protein. This short-term  
desensitisation is followed by sequestration of the receptor away from the 
membrane. Eventually, more prolonged stimulation causes a net down- 
regulation of the receptor.
The human IP receptor, when overexpressed in HEK293 cells, exhibits rapid 
agonist-induced desensitization occurring within minutes and this has been 
shown to involve phosphorylation of the C-terminal by PKC (Smyth et al.,
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1998). In contrast, native cells naturally expressing the IP receptor reveal a 
much slower time course of desensitization (Krane et a l., 1994; Zucker et 
al., 1998). In fibroblasts, iloprost-induced sequestration was observed but 
no role for PKC phosphorylation was found in the desensitisation mechanism 
(Nilius et al., 2000) whereas in rat PASMC, PKA rather than PKC, appears to 
be the mediator responsible for the uncoupling of the IP receptor and Gs 
leading to desensitisation (Sobolewski et a l., 2004). In light of this it could 
be an attractive hypothesis to suggest that prolonged stimulation with PGI2 
(long-term epoprostenol treatm ent) may have a role in causing 
disfunctionality of the IP receptor by causing excessive sequestration and 
internalisation.
As discussed in chapter 3, there are few commercially available antibodies 
against the IP receptor, and most of these have been developed in the last 
3-4 years. This has meant IP receptor protein expression and localisation in 
smooth muscle cells and indeed in other cell types has been scantily 
investigated. To my knowledge this is the first time expression and cellular 
localisation of the IP receptor protein have been studied in human PASM 
cells in detail. In agreement with our study, data published in an abstract 
form claims to show reduced expression of the IP receptor in remodelled 
vessels obtained from adults with pulmonary hypertension (Mason et al.,
1999).
In our experiments, downregulation of the IP receptor was not concomitant 
with a downregulation of cAMP elevating effects. I f  anything treprostinil- 
mediated cAMP-elevation, in terms of fold increase, was more pronounced in 
IPAH than in control cells. This observation suggests that the number of IP
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receptors present on the cell-surface may not be a measure of how much 
cAMP can be generated; it may be that the re-sensitisation process, 
whereby the re-coupling of the G protein to the receptor occurs after un­
coupling (reviewed in Bohm et al., 1997), is more rapid in the fewer IP 
receptors present in IPAH cells. I t  should be pointed out that the cAMP 
levels and elevation observed in the normal, control SMCs in the present 
study differ significantly from those previously described in the same cell 
type. The basal level of cAMP I measured is significantly higher in our 
experiments than those formerly observed in our laboratory (Clapp et al., 
2002) and the fold increase upon stimulation with a PGI2 analogue is lower 
than that described by Wharton et al (2000), Clapp et al (2002) or Growcott 
et al (2006). The reason for this discrepancy is not immediately obvious but 
may be a result o f differing experimental and assay conditions. For example 
IBMX was not added in our extraction step, we use a different assay to 
measure cAMP which may have a different sensitivity and furthermore we 
did not perform a time course to establish the peak cAMP elevation time. 
However, a time of 30 mins should be very close to maximal cAMP-elevation 
as reported by both Wharton et al (2000) and Clapp et al (2002).
Our studies indicating dysregulation of the prostacyclin pathway in the 
PASMCs of patients with IPAH is supported by the work of other 
investigators showing that PGI2 synthase (PGIS) is decreased in PASM cells 
obtained from adults with IPAH (Tuder et al., 1999). Thus it is tempting to 
speculate that the whole prostacyclin system may be down-regulated in 
pulmonary hypertension and that the level of IP receptor expression may 
dictate the level of PGIS expression or vice versa. Obviously, this will 
require further investigation and could be tested by measuring PGIS mRNA
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levels in our HEK-293-Zeo and HEK-293-IP cell model. Reduction in IP 
receptor expression may explain why short term administration of PGI2 
induces beneficial effects which become less pronounced after more chronic 
use.
S. 10.2 Mechanisms responsible for the anti-proliferative effects o f 
PGI2 analogues in control PASM cells
Data in the present study show clearly that the PGI2 analogues treprostinil 
and iloprost inhibit proliferation in both control and IPAH PASM cells.
However, the mechanism by which they do so is markedly different. In 
control PASM cells PGI2 analogues act through the IP receptor and the 
response follows the classical pathway; by activating adenylyl cyclase via Gs 
and elevating intracellular levels of cAMP to inhibit proliferation. This
mechanism has been described before in these cells (Wharton et a l., 2000; 
Clapp et al., 2002) and is in agreement with the results obtained with HEK- 
293-IP cells, showing strong involvement of cAMP. However, there appears 
to be a small part of the regulatory mechanism which cannot be inhibited by 
DDA, suggesting the presence of cAMP-independent pathways. Although this 
result is consistent with previous studies (Wharton e ta /., 2000; Clapp e ta /., 
2002; Phillips et a/., 2005) and this thesis (see section 3.8), we have not
yet tested whether a combination of both adenylyl cyclase and PKA
antagonists may be required to observe full reversal. Furthermore only one 
adenylyl cyclase antagonist was used which may or may not be able to 
inhibit all isoforms. Clapp et a/ (2002), have previously shown that DDA in 
combination with another adenylyl cyclase inhibitor, SQ22536, did produce
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greater inhibition of iloprost-induced growth suppression than either 
inhibitor given alone.
In the studies presented in chapter 4, it was shown that treprostinil-induced 
PPARy activation was dependent on the presence of the IP receptor, but was 
activated largely independently of cAMP and PKA and that this transcription 
factor was responsible for mediating part of the anti-proliferative effects of 
this PGI2 analogue (see section 4.7). In agreement with published studies 
performed investigating VSMC (Sasaguri et al., 1992; Benson et al., 2000; 
Ward et al., 2004), the present study also shows that activation of PPARy 
inhibits PASM cell proliferation in control cells. Furthermore, as in HEK-293- 
IP cells, this nuclear receptor does seem to have a small but significant 
effect in mediating the inhibition of proliferation caused by treprostinil. 
Thus, as initially hypothesised, we conclude that in control smooth muscle 
cells, the PGI2 analogue-induced signalling pathway is mainly mediated by 
IP-receptor-dependent cAMP elevation with a small role for PPARy. The role 
of the IP receptor in PPARy activation in these cells will need to be 
confirmed by replicating the PPARy reporter gene assays and using siRNA to 
"knockdown" the IP receptor in these cells, a protocol we would like to 
optimise in the near future.
The concentrations of rosiglitazone at which we could observe inhibition of 
cell proliferation in both PASM and HEK-293 cells were relatively high with 
10 pM being the lowest concentration to have significant anti-proliferative 
effects. Although this is in line with what has been previously reported in 
smooth muscle cells with both rosiglitazone (Ward et al., 2004) and 
troglitazone (Benson et al., 2000) it is inconsistent with the binding ability
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of rosiglitazone at the LBD of PPARy (IC50 = 9 nM in human adipocytes) 
(Young et al., 1998) as well as our observation that 1 pM rosiglitazone is 
enough to generate a big increase in PPARy activation in our reporter gene 
assay (see section 4.2). I t  therefore remains to be determined whether the 
anti-proliferative effects of rosiglitazone are exclusively mediated by PPARy 
or may be in part dependent on non-specific effects of the drug. Evidence 
against the latter comes from the observation that the PPARy antagonist, 
GW9662 (1 pM) can fully reverse the inhibitory effect of 10 pM rosiglitazone 
in smooth muscle cells (Ward et al., 2004).
5.10.3  Mechanisms responsible for the anti-proliferative effects o f 
PGI2 analogues in IPAH PASM cells
In the present study we show for the first time the retained effectiveness of 
PGI2 analogues in inhibiting the proliferation of cells from IPAH patients. 
This observation is of great relevance given the widespread clinical use of 
these analogues and our lack of knowledge about their effects on medial 
proliferation in advanced disease. Unexpectedly the signalling mechanism 
observed in control cells does not appear to be responsible for the anti­
proliferative effects of PGI2 analogues in IPAH cells. While treprostinil 
retains its ability to increase cAMP and inhibit proliferation in both control 
and IPAH PASMCs, the former is IP receptor dependent while the latter is 
unaffected by blocking either adenylyl cyclase or the IP receptor. Instead, 
the PPARy antagonist, GW9662, appeared to reverse a large part of the 
anti-proliferative effects. Thus we conclude that although the IP receptor is 
present in IPAH cells, the signalling pathway mediating the anti-proliferative
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effects of PGI2 analogues switches to a mechanism primarily dependent on 
PPARy.
At first glance, this concept contrasts with a study describing decreased 
PPARy gene and protein expression in PAH lungs (Ameshima et al., 2003). 
The authors of this study conclude that PPARy is abundantly expressed in 
control human lung tissue, particularly in endothelial cells, but is reduced or 
absent in the angiogenic plexiform lesions of pulmonary hypertensive lungs, 
suggesting a down-regulation of the PPARy signalling system in this 
disease. However their data was specifically focused on endothelial cells and 
because PPARy was shown to be absent in smooth muscle cells from control 
lungs, they did not assess PPARy expression in PAH smooth muscle cells. In 
fact the authors actually state that the PPARy-negative cells in the plexiform 
lesions analysed are not smooth muscle cells as these lack smooth muscle 
cell actin staining (Ameshima et al., 2003). In contrast, our lab has shown 
that the medial smooth muscle cells of peripheral arteries stain well for 
PPARy in lung sections from IPAH patients with weak or undetectable 
staining in intimal proliferative cells (Falcetti et al., 2005). Consequently an 
attractive hypothesis may be that cellular localisation/expression of PPARy 
alters in disease; it may be predominantly expressed in endothelial cells in 
normal pulmonary arteries, and in smooth muscle cells in IPAH. This shift in 
localisation may be key to the role of PPARy in mediating the inhibition of 
proliferation observed in IPAH PASM by PGI2 analogues. Again, as with 
downregulation of the IP receptor, this shift in PPARy localisation may be a 
result of long-term treatment with PGI2 analogues.
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When the mechanism of treprostinil-mediated PPARy activation was studied 
in chapter 4, we concluded that treprostinil was acting through the IP 
receptor to activate PPARy. This could still be applicable to control cells 
where most of the anti-proliferative properties are mediated by the IP 
receptor; however in IPAH cells this does not appear to be the case given 
the lack of effect with the IP receptor antagonist. One hypothesis is that the 
IP receptor is not exclusive in mediating receptor-dependent activation of 
PPARy; other membrane-bound receptors could activate the same signalling 
cascade upon stimulation. Likely candidates for this role are the EP class of 
receptors due to their known affinity for PGI2 analogues. All analogues have 
some affin ity for EP3 receptors. In addition iloprost and carbacyclin also 
have effects at the EPi receptor. However its ability to bind EPi is species 
specific, only occurring in rat and mice and is largely absent in humans 
(Sharif and Davis, 2002)
Out of the four EP receptor subtypes, EP2 and EP3 are widely expressed in 
smooth muscle, including pulmonary artery SMCs (Jones et a l., 1997) and 
are therefore of most interest to this study. Similar to the IP receptor, the 
EP2 receptor subtype is classified as a "relaxant" receptor given its ability to 
mediate vasodilation by signalling through the Gs protein and causing 
intracellular cAMP elevation (reviewed in Hata and Breyer, 2004). EP3 
receptors classically mediate vascular contraction and aggregation of human 
platelets by signalling through Gj (Sugimoto et al., 1992). Different splice 
variants of EP3 can also couple to Gs and Gq and cause cAMP or IP3 
generation respectively (Irie  et al., 1993; Namba et al., 1993). The broad 
spectrum of signalling options is akin to that observed with the IP receptor 
whereby post-translational modification of the C-terminal is thought to
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modulate its coupling to multiple signalling pathways (Hata and Breyer, 
2004). Interestingly, as discussed earlier, although iloprost treatm ent leads 
to agonist-induced IP receptor-desensitisation this does not occur with PGEi 
a known activator of the EP3 receptor (Zucker et al., 1998). Taking these 
observations together we hypothesise that the EP3 receptor may be an 
alternative target for PGI2 analogues in cells where the IP receptor has lost 
its ability to regulate cell proliferation and warrants further investigation.
Although we observe IP receptor-dependent PPARy activation in HEK-293-IP 
cells (chapter 4), it is possible that in PASM cells a direct ligand binding 
mechanism is responsible for the treprostinil-induced activation of PPARy. 
However, given the complete inability of treprostinil to activate PPARy in 
HEK-293-Zeo cells, this hypothesis seems unlikely.
In conclusion this study has highlighted important differences in the 
signalling mechanisms utilised by PGI2 analogues in IPAH and control PASM 
cells. Although the IP receptor appears to be markedly down-regulated in 
IPAH, PGI2 analogues are still efficacious at inhibiting cell proliferation 
although treprostinil did not reduce the proliferation rate to normal, 
indicating that the PASMCs in IPAH have escaped normal growth regulatory 
mechanisms. The IP-receptor independent signalling mechanism in IPAH 
cells warrants further study to uncover potential novel targets which may 
prove to be beneficial in the treatment of pulmonary hypertension.
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Chapter 6
General Discussion and Conclusion
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6.1 Characterisation of novel tools to analyse IP  receptor expression  
and function
The key objective of this thesis was the study of the IP receptor and its role 
in mediating the anti-proliferative effects of PGI2 analogues. This was of 
interest because, whilst it is assumed that PGI2 analogues work through the 
IP receptor they are also known to have binding affinity at other PG 
receptors (Abramovitz et a\.t 2000), as well as acting as ligands for PPARs 
(Forman et a l., 1997). Due to the lack of experimental tools with which to 
study the role of this receptor, it is not known to what extent other 
pathways may mediate the effects of PGI2 analogues.
At the start of the project, pharmacological antagonists had yet to be 
developed. There were no commercially available siRNA kits for knockdown 
of the receptor and, in any case, there were no IP receptor-specific 
antibodies with which to test the reliability of protein knockdown. An IP 
receptor knockout mouse was generated in 1997 (Murata et al., 1997) and 
smooth muscle cells from IP null mice have subsequently been used to 
demonstrate that the IP receptor mediates the anti-proliferative properties 
of cicaprost (Kothapalli et al., 2003). However, as described previously, 
there are marked differences not only in the affinity of PGI2 analogues for 
human and mouse prostanoid receptors, but also in the nature of G-protein 
coupling of the IP receptor in the two species. Thus the IP knockout mouse 
may not be an ideal model for those of us working on the human receptor, 
studying its role as a target for the PGI2 analogues used in the treatm ent of 
IPAH.
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A major contribution made by this project has been the generation and 
characterisation of a number of novel tools for the study of the human IP 
receptor. HEK-293 cell lines were generated which stably expressed the 
human IP receptor (HEK-293-IP) using the empty zeocin resistance plasmid 
(HEK-293-Zeo) as a control. We also developed a novel antipeptide 
antibody (C l antibody), raised against a portion of the intra-cellular C- 
terminal of the IP receptor. Comparing the staining obtained with this and 
other IP antibodies, such as the commercially available Cayman antibody 
and the antibody raised against the N-terminal sequence described by 
Komhoff et al (1998) (N1 antibody), we concluded that the C l antibody is 
the most specific one available to date, as indicated by the presence of 
strong staining in HEK-293-IP and its virtual absence in HEK-293-Zeo cells. 
The stable transfected HEK-293 line was an invaluable tool with which to 
study the specificity of these receptors, as HEK-293-IP cells could be 
considered strong positive controls while HEK-293-Zeo acted as negative 
controls. The C l antibody was subsequently used to assess localisation and 
protein expression in PASMC from control and IPAH patients. RT-PCR 
performed using custom designed primers further strengthened the validity 
of both the HEK-293-IP cell line and the C l antibody as IP receptor specific 
tools by again highlighting the presence of the functional receptor only in 
HEK-293-IP cells. Currently we are optimising a protocol for use of the C l 
antibody in Western Blotting. Preliminary blots are promising and the 
antibody appears as expected to pick up a band at around 60 kDa in HEK- 
293-IP cells but only a very weak band in HEK-293-Zeo cells. With these 
promising results, in collaboration with Dr. Sue Hall (Institu te of Child
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Health, UCL, London), the antibody is being used to further investigate the 
expression of the IP receptor in PASMC from control and IPAH patients.
The present study is one of the first to utilise the newly developed IP 
receptor antagonist ROl 138452 (IPRA) (Roche, Palo Alto) and we show that 
it is able to fully reverse the anti-proliferative and cAMP-elevating effects of 
treprostinil in HEK-293-IP cells. The investigators responsible for developing 
this agent as an analgesic have demonstrated that it is highly selective for 
the IP receptor over other prostanoid receptor families. This antagonist has 
in fact been shown to have a low binding affinity for EPi, EP3, EP4 and TP 
receptors (Bley et al., 2006) and in various functional systems has been 
shown not to block DPi, EP2/ EP3, EP4 and TP receptors (Jones et a l., 2006). 
For example, at a dose of 1 pM it does not affect PGD2-dependent inhibition 
of platelet aggregation, PGE2-induced relaxation of rabbit mesenteric artery, 
or relaxation of guinea pig trachea induced by the EP2 receptor agonist 
butaprost (Jones et al., 2006). This potent antagonist is therefore an 
extremely useful tool with which to selectively block the IP receptor 
pharmacologically, a feat which would otherwise necessitate using siRNA or 
an IP receptor knockout cell line.
6.2 W hat can w e learn from the IP  receptor HEK-293 stable line?
Results obtained with the HEK-293-IP cell line (see chapter 3) have shown
that the physical presence of the IP receptor is sufficient to slow down cell
proliferation but that this response is unlikely to depend on endogenous
PGI2 generation. The presence of the receptor also alters the proliferative
response to cAMP elevating agents, such as forskolin and IBMX as well as 
PPARy and PPAR6 agonists. In addition it is crucial in mediating the anti­
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proliferative effects of PGI2 analogues. The latter observation was 
demonstrated both by the lack of effect in HEK-293-Zeo control cells as well 
as by the reversal of the anti-proliferative effects of treprostinil with IPRA. 
The IP receptor is therefore crucial in regulating the proliferative responses 
to a wide range of stimuli even in the absence of receptor stimulation.
Using an adenylyl cyclase inhibitor and two structurally dissimilar inhibitors 
of PKA, it was established that the anti-proliferative effects of treprostinil 
were mostly mediated by the cAMP-PKA mechanism in accordance with the 
classical Gs-coupling paradigm of the IP receptor. However, full reversal 
could not be achieved with this set of antagonists, possibly indicating the 
presence of additional IP receptor-dependent but cAMP/PKA-independent 
mechanisms accounting for approximately 25% of total treprostinil effects; 
effects which may be mediated by PPARy. In conclusion, it is becoming 
more apparent that cAMP-independent effects play an important role in the 
response to PGI2 analogues.
The main advantage of using a HEK-293 stable line to dissect IP receptor- 
dependent mechanisms was the fact that we were able to study the 
receptor in relative isolation from prostanoid and other types of receptors. 
However a frequent critique of using this approach, is that HEK-293 cells 
may lack many other cellular components including ion channels and 
scaffold proteins (Thomas and Smart, 2005), potentially altering the 
pathway/mechanism to one which may not be relevant in native cells. 
However PGI2 analogues exhibited a very similar mode of action in HEK- 
293-IP cells and normal, control PASMC, highlighting the validity of using 
this expression system as a tool in this investigation. Expressing the IP
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receptor in HEK-293 cells altered their proliferative rate to one closely 
emulating that presented in control PASMC, which appeared to express 
similar amounts of IP receptor message, immuno-staining and protein 
levels.
Like HEK-293 cells, IPRA was able to reverse treprostinil-induced 
proliferation inhibition while DDA was only able to reverse the effects by 
approximately 75%, a very similar split between cAMP-dependent and 
cAMP-independent effects to that observed in HEK-293-IP cells. This 25% 
magnitude of IP receptor-dependent but cAMP-independent mechanism(s) 
mediating the anti-proliferative properties of PGI2 analogues is reflected in 
other studies in native VSMC (Wharton et al., 2000; Clapp et al., 2002; 
Phillips et al., 2005). Differences in the proliferative response to treprostinil 
between HEK-293-IP and control PASMC were similar in terms of the fold 
increase in treprostinil-induced cAMP-generation. Inhibition of proliferation 
by treprostinil was markedly less pronounced in IPAH PASMCs, possibly 
because the IP receptor was over-expressed in HEK-293-IP cells, resulting 
in a greater-than-physiological amount of receptor at the membrane leading 
to an amplified signal upon ligand stimulation. However, the pattern of C l 
antibody staining as well as relative mRNA expression appeared to be very 
similar between the two cell types. I t  is not unreasonable therefore to 
suggest that in this case the reduced level of sophistication of HEK-293 cells 
may have a role in masking some of the mitogenic processes which may 
still be occurring in PASMC.
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6.3 IP  receptor dependent activation of PPARy
One of our initial hypotheses was that PGI2 analogues could activate PPARy. 
This thesis describes for the first time a novel and unexpected IP receptor- 
dependent activation of PPARy by PGI2 analogues, which appears to be 
distinct from the known ligand binding effects of these analogues to the 
other two PPAR isoforms (Hertz et al., 1996; Forman et al., 1997). Using a 
luciferase-based reporter gene assay, we have shown that the PGI2 
analogues treprostinil, carbacyclin and cicaprost can activate PPARy only in 
HEK-293 cells that express the receptor. Furthermore, this activation was 
fully reversed by the IP receptor antagonist. This regulation may previously 
have been missed due to PPAR function often being studied in cells not 
expressing the receptor.
Surprisingly, pharmacological inhibition of adenylyl cyclase or PKA was 
unable to reverse treprostinil-induced PPARy activation, although it remains 
to be determined whether the concentration at which antagonists were used 
was sufficient to completely block target function. Moreover, treatm ent of 
both HEK-293-IP and control PASMC with a PPARy antagonist reversed the 
anti-proliferative effects of treprostinil by an amount not dissimilar to that 
accounted for by potential cAMP/PKA-independent mechanisms as discussed 
previously. Taken together these results indicate that PPARy does indeed 
have a role in mediating the anti-proliferative effects of treprostinil but that 
it is not downstream of cAMP or PKA and is therefore potentially regulating 
the non-cAMP effects of this agent observed in both HEK-293-IP and control 
PASMC. There are a number of limitations associated with the protocol used 
in this project to investigate PPARy activation. The expression construct
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used in the luciferase assays contains only the LBD portion of PPARy hooked 
up to the GAL4 DBD, which upon stimulation will bind to the GAL4 response 
element on the reporter construct and lead to transcription of the luciferase 
gene (Figure 2.8). This is an important consideration to take into account 
when planning future experiments using a reporter gene assay to study this 
agent. The advantage of this system is that it is totally specific for PPARy 
rather than relying on non-isoform specific activation of a PPRE-luciferase 
construct. However, the fact that it does not represent the full length of the 
protein may mask some effects, especially the ligand independent effects 
we are interested in unravelling, such as phosphorylation mechanisms of 
other regions of the protein. In addition it does not take into account 
endogenous levels of PPARy as only the stimulation of transiently 
transfected expression vector will be picked up by this assay. Optimisation 
of this luciferase assay protocol was lengthy due to the fact that treprostinil 
appears to have non-specific effects on multiple promoters present in many 
commercially available construct plasmids.
The mechanism of PPARy activation beyond IP receptor activation is still 
unclear and will require extensive further investigation both in native cells 
and in the HEK-293 cell model. Data obtained with various pharmacological 
tools ruled out the involvement of cAMP, PKA, PKC and Gj although we still 
hypothesise that the mechanism of IP-receptor-dependent PPARy activation 
is primarily driven by a phosphorylation event, as two relatively broad 
spectrum kinase inhibitors, H-89 and staurosporine could reverse the PPARy 
activating effects at a non PKA/PKC-specific concentration of 10 pM.
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A critique of looking at PPARy activation in HEK-293 cells is that while it is 
an efficient experimental system, as discussed previously, it is also an 
artificial system. Ultimately we would like to be able to replicate the PPARy 
activation results in native PASMC by optimising a method of transfecting 
these cells. I have attempted this a number of times using the 
nucleofector™ method of transfection (Amaxa, Cologne, Germany), but I 
have not yet been able to get more than a 30-40% transfection rate, which 
is not a high enough efficiency for the assay to give strong and reproducible 
luciferase readings in a 96-well-plate format. I f  transfection efficiency is the 
rate lim iting step, the solution may lie in using more cells by scaling up to a 
24- or even a 12-well-plate; this remains to be tested in future studies.
In collaboration with Dr. Vidya Mohammed-Ali at UCL, we are investigating 
whether this IP receptor-dependent mechanism of PPARy activation is 
present in pre-adipocytes and is of relevance in promoting the process of 
adipogenesis. The rationale behind studying this mechanism in these cells is 
that they have been shown to abundantly express PGIS (Negrel and 
Ailhaud, 1981), PPARy and the IP receptor (Borglum et ai.f 1999). In 
addition both prostacyclin and carbacyclin have been shown to promote 
their terminal differentiation into adipocytes (Catalioto et a\.f 1991; Aubert 
et al., 1996). I t  is hypothesised that this response depends in part on the 
presence of the IP receptor (Wise, 2003) and subsequent upregulation of 
C/EBPs, possibly via a CREB dependent mechanism (Aubert e ta /., 2000), in 
addition to direct ligand binding to PPARs, including PPARy (Massiera e t a/.,
2003). Whether PGI2 analogues can cause adipogenesis via PPARy as 
described by our novel IP receptor-dependent pathway therefore warrants 
further investigation.
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PPARy-dependent mechanisms mediating proliferation inhibition necessitate 
further study. A hypothesis we would like to test is whether stimulation of 
the IP receptor by PGI2 may activate PPARy to down-regulate endothelin-1 
thus decreasing proliferation. Endothelin-1 production is known to be 
increased in HPASMC by the mitogenic stimuli present in serum and 
cicaprost has been shown to inhibit the release of this vasoconstrictor in 
these cells (Wort et al., 2001). Further evidence to support this hypothesis 
comes from the fact that rosiglitazone can abrogate the increase in 
endogenous production of endothelin-1 in the mesenteric vasculature of 
hypertensive deoxy-corticosterone acetate (DOCA)-salt rats, which 
overexpress ET-1, and can prevent hypertrophic vascular remodelling and 
progression of hypertension (Iglarz et al., 2003). To test this hypothesis the 
production of ET-1 could be measured before and after PGI2 analogue 
treatm ent in HEK-293-IP cells and compared with HEK-293-Zeo cells. I f  
production of ET-1 was indeed inhibited after PGI2 analogue treatm ent in 
the presence of the IP receptor then the role of PPARy could be tested using 
the antagonist GW9662.
6 .4  Altered PGI2 analogue signalling mechanism in IPAH cells
While PPARy could account for some of treprostinil's anti-proliferative effects 
in HEK-293-IP and control PASMC, its role in IPAH PASMC appeared more 
pronounced. We found that IPAH PASMC had a reduced expression of the IP 
receptor and a faster replication rate, akin to the difference between HEK- 
293-IP and HEK-293-Zeo. Interestingly and importantly the analogues could 
still significantly inhibit proliferation of these cells although they could not 
restore the replication rate of IPAH cells back to that observed in normal
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control cells; indicating that treatm ent with PGI2 analogues alone is possibly 
not sufficient to reverse or impede medial thickening occurring in this 
disease. PGI2 analogue-induced inhibition was not dependent on the IP 
receptor and did not correlate with the analogue induced increase in cAMP 
via the IP receptor. On the other hand, the PPARy antagonist was able to 
reverse the majority of treprostinil effects suggesting that in IPAH PASMC, a 
switch in the signalling mechanism occurs from a classical IP receptor and 
cAMP-driven pathway to a PPARy-dependent but IP receptor and cAMP 
independent mechanism.
As discussed in chapters 4 and 5, we have demonstrated an IP receptor 
dependent mechanism of PPARy activation by PGI2 analogues in our HEK- 
293-IP cell model and we may still be observing a similar receptor-mediated 
mechanism in IPAH cells. The most probable candidate for this role is 
another prostanoid receptor, the most likely being the EP3 receptor given its 
known affinity for PGI2 analogues as well as its ability to couple to multiple 
G proteins (Sugimoto et al., 1992; Irie et al., 1993; Namba et al., 1993) 
and its known expression in the pulmonary artery (Jones et al., 1997). In 
future work we would like to test the involvement of the EP3 receptor in 
mediating the anti-proliferative properties of treprostinil in IPAH cells. This 
hypothesis could be tested by blocking this receptor with the novel highly 
specific antagonist L-798,106 (Merck Frost, Quebec, Canada). In addition 
one could generate HEK-293 cells stably expressing other prostanoid 
receptors and perform luciferase-based reporter assays, and upon 
optimisation of the same assay in PASMC, the same experiments could be 
performed in both control and IPAH PASMC.
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There are a number of lim itations related to our investigation of IPAH 
PASMC. Because lung transplantation is a rare occurrence we were only able 
to obtain PASMCs from 3 children. I t  is obvious that results would be vastly 
strengthened with an increased number of isolates to test the concepts 
explored in this thesis. Furthermore we studied the PASMCs from children 
with IPAH and experimental data should ideally have been compared with 
data obtained from the PASMCs of children with a normal pulmonary 
vasculature.
6.5 Significance of loss or down-regulation of the IP  receptor
Loss or down-regulation of the IP receptor appears to modulate growth and 
alters the response to cAMP-elevating agents. Currently we have very 
preliminary data (n = l)  from a proteomics based screening assay 
(Kinetworks™, Kinexus, Vancouver, Canada) to establish semi- 
quantitatively if there are differences in cell-cycle protein expression as a 
consequence of the presence of the IP receptor. Of note is the up-regulation 
of both the tumour-suppressor p53 and the cyclin dependent kinase 
inhibitor p27Kipl in HEK-293-IP versus HEK-293-Zeo, both proteins are 
usually up-regulated during cell-cycle arrest. Although still premature and in 
need of confirmation, these results add some credence to the importance of 
this receptor in terms of growth modulation.
Loss of the IP receptor does not cause pulmonary hypertension per se as 
demonstrated in IP receptor knockout mice. I t  does, however, hasten the 
development of pulmonary hypertension under hypoxic conditions 
(Hoshikawa et al., 2001). In addition IP receptor mRNA expression is 
reduced in spontaneously hypertensive rats (SHR) compared to control
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W istar-Kyoto rats (WKY). Specifically it was suppressed at the pre­
hypertensive state (Numaguchi et al., 1999). Whether an early loss or 
down-regulation of the IP receptor contributes to increased cell proliferation 
in the pre-symptomatic patient leading to medial thickening of the 
pulmonary arteries, or conversely is a consequence of other initiating 
factors, remains to be determined.
Loss or down regulation of the IP receptor could lead to a mere loss of 
receptor function, but could lead to upregulation/downregulation of other 
mechanisms, some of which may have deleterious rather than having 
beneficial compensatory effects. Recently, the importance of the physical 
presence of the IP receptor to lim it the deleterious effects of the 
thromboxane (TP) receptor was demonstrated both in vitro and in vivo. 
Deletion of the IP receptor exacerbated TP receptor-dependent smooth 
muscle cell proliferation following arterial injury in mice (Cheng et al., 
2002). In contrast, the presence of the IP receptor significantly enhanced 
cAMP generation in response to TPa receptor isoform activation in both 
transfected HEK-293 cells and aortic smooth muscle cells (Wilson et al.,
2004). I t  would appear that the presence of the IP receptor facilitates this 
effect via the formation of an IP/TPa heterodimer rather than by activating 
the cAMP-PKA cascade (Wilson et al., 2004). The presence of the IP receptor 
therefore has a specific role in promoting a "PGI2-like" cellular response to 
TXA2 and the isoprostanes. Thus it is possible that in IPAH, where the IP 
receptor appears to be down-regulated, PASMCs could be more responsive 
to the pro-proliferative responses mediated by TP receptors, thereby 
increasing the replication rate.
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Lack of the IP receptor may provide an additional pro-proliferative pathway 
in the form of direct PPARS activation. PGI2 analogues can bind to and 
activate PPARS (Hertz et al., 1996; Forman et at., 1997). Although the role 
of this nuclear isoform in controlling cell proliferation is the subject of much 
debate, PPARS has been reproducibly identified as a biological target for 
PGI2 during angiogenesis, a process requiring smooth muscle cell 
proliferation (Lim et al., 1999; Lim and Dey, 2000; Pola et al., 2004). I t  
may be possible therefore that loss of the IP receptor may enhance this 
angiogenic pathway for PGI2 analogues.
An important consideration in the present study is that IPAH PASMC were 
derived from patients who had previously undergone long-term 
epoprostenol treatment. The observed down-regulation of the IP receptor 
therefore may not be associated with the disease itself but rather a 
consequence of desensitisation caused by long-term agonist stimulation. It  
is known that internalisation and reduced GPCR expression can occur 
following long-term agonist stimulation (reviewed in Bohm et al., 1997). In 
future studies we would like to test whether the reduced expression of the 
IP receptor in IPAH cells is a result of long-term treatment and whether this 
course of events could contribute to the switch in the signalling pathway 
which we have demonstrated. A model of long-term treatment might be 
established in an in vivo model of pulmonary hypertension and PASMC from 
these animals could be compared in terms of IP receptor expression and 
PGI2 signalling mechanisms. I t  is however notoriously difficult, if not 
impossible to produce an animal model of human obliterative pulmonary 
vascular disease. The role of the IP receptor could be further investigated 
by knocking down the IP receptor (using siRNA) in normal PASMC, to test
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whether this would lead to the same switch in mechanism and increase in 
cell proliferation that was observed in IPAH cells. Conversely we could over­
express functional IP receptor in IPAH PASMC and test whether this could 
rescue some of the "normal" characteristics observed in the control PASMC 
we studied.
6.6  Conclusion
To conclude, this thesis has developed novel tools for the study of the 
prostacyclin receptor and has established that this receptor is important for 
the control of cell proliferation and the response to cAMP-elevating agents. 
In "norm al" cells, IP receptor stimulation by PGI2 analogues leads to 
inhibition of cell proliferation via a predicted elevation of cAMP although a 
fraction of the anti-proliferative effects of PGI2 analogues appear to be 
mediated by PPARy in a potentially PKA-independent manner. In IPAH cells 
a downregulation of the IP receptor was observed in Dr. Sue Hall's western 
blot, but PGI2 analogues are still efficacious at inhibiting cell proliferation. 
However, the regulation of growth control switches to an IP receptor- and 
cAMP-independent pathway and PPARy becomes an important mediator, 
further establishing the importance of PPARs as regulators of cell 
proliferation. A limitation of the present thesis, which will need to be 
addressed in future studies, is the absence of data on the contribution of 
apoptosis and cell death to the effects of IP-receptor and PPARy activation.
Further work will be necessary to elucidate the receptor and signalling 
pathways involved in regulating the anti-proliferative effects of PGI2 
analogues in IPAH cells, remembering that the replication rate still remains 
significantly greater than normal. The data obtained in the present studies,
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particularly those showing PGI2 analogue dependent activation of PPARy in a 
reporter gene assay justifies exploring PPARy as a potential therapeutic 
target for the treatment of IPAH, probably in combination with existing 
therapies including prostacyclin analogues, endothelin receptor antagonists 
and phosphodiesterase inhibitors.
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